impact medicines feel better live longer annual report wwwgskcommission global quest improve quality human life enabling people feel better live longer spirit undertake quest enthusiasm entrepreneurs excited constant search innovation value performance achieved integrity attain success world class global leader every one people contributing passion unmatched sense urgency strategic intent want become indisputable leader industry glaxosmithkline plc english public limited company shares listed london stock exchange new york stock exchange glaxosmithkline plc acquired glaxo wellcome plc smithkline beecham plc th december way scheme arrangement merger two companies became effective th december report annual report glaxosmithkline plc year ended st december comprises single document annual report company accordance united kingdom requirements annual report formf securities exchange commission united states america summary report year annual review intended investor needing full detail annual report produced separate document annual review includes joint statement chairman chief executive officer summary review operations summary financial statements summary remuneration report annual review issued shareholders annual report issued shareholders elected receive documents available glaxosmithklines corporate website wwwgskcom website glaxosmithklines website wwwgskcom gives additional information group information made available website constitute part annual reportglaxosmithkline glaxosmithkline plc annual report year ended st december contents report directors financial summary joint statement chairman chief executive officer description business corporate governance remuneration report operating financial review prospects financial statements directors statements responsibility independent auditors report consolidated statement profit loss consolidated statement total recognised gains losses consolidated statement cash flow consolidated balance sheet reconciliation movements equity shareholders funds company balance sheet notes financial statements financial record investor information shareholder return shareholder information share capital taxation information shareholders cross reference form f glossary terms annual report approved board index directors th march published th march contact details glaxosmithkline financial summary restated increase statutory results cer sales trading profit profit taxation earningsnet income basic earnings per share p p dividends per share p p merger restructuring disposal subsidiaries trading profit profit taxation earningsnet income business performance sales trading profit profit taxation adjusted earningsnet income adjusted earnings per share p p business performance primary performance measure used management presented excluding merger items integration restructuring costs disposal businesses management believes exclusion nonrecurring items provides better comparison business performance periods presented statutory results include nonrecurring items information provided supplement included consolidated statement profit loss pages prepared accordance ukgaap group multinational business operates many countries earns revenues incurs costs many currencies results group reported sterling therefore affected movements exchange rates sterling overseas currencies group uses average exchange rates prevailing year translate results overseas companies sterling currencies influence translations us dollar euro japanese yen average sterling exchange rates stronger usdollar japanese yen four per cent seven per cent respectively weaker euro one per cent compared order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used previous year discussion report therefore terms cer unless otherwise stated represents growth actual exchange rates cer represents growth constant exchange rates frs deferred tax implemented group frs requires deferred tax accounted full provision basis rather partial provision basis earlier years change accounted prior year adjustment comparative information restated necessary cautionary statement regarding forwardlooking statements group 's reports filed us securities exchange commission sec including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give group 's current expectations forecasts future events investor identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future operating financial performance particular include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings financial results group undertakes obligation update forwardlooking statements whether result new information future events otherwise forwardlooking statements involve inherent risks uncertainties group cautions investors number important factors including document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pages annual reportglaxosmithkline joint statement chairman chief executive officer new product growth drives commercial strength success new products providing fuel future growth new products representing per cent total pharmaceutical sales per cent sales seretideadvairfor asthma second largest product continued grow impressively per cent billion recently launched avandametfor type diabetes avodartfor benign prostatic hyperplasia well important line extensions augmentinand paxil look forward launching new compounds line extensions include levitra new treatment erectile dysfunction co promoting bayer wellbutrin xl new improved version successful antidepressant creating productive rd organisation outset merger rethought way rd carried glaxosmithkline aim creating purpose glaxosmithkline deliver productive rd organisation industry established six medicines positive impact quality therapeutically focused centres excellence drug discovery human life chosen fundamental cedds cedds nimble entrepreneurial range challenging objective theme years skills scale resources required drive midstage annual review development projects key decision point proof concept largescale phase iii clinical trials pleased report year significant two years activity new rd organisation progress establishing glaxosmithkline one worlds seeing significant progress advance promising early stage leading pharmaceutical companies achieved strong financial pipeline pharmaceutical products clinical development results despite entry generic competition glaxosmithkline projects clinical development usa augmentin one major products new chemical entities number therapy areas progress stems groups key strengths broadly new vaccines number new chemical entities starting phase based product portfolio strong financial capability promising ii clinical trials doubled since merger early stage pipeline products built confident phase pipeline move core attributes confident help development build best late stage pharmaceutical glaxosmithkline continue deliver success future pipeline industry plan provide detailed update progress rd towards end achieving business success essential demonstrate stakeholders around world success partner choice conduct business integrity continue make size quality global rd organisation together positive contribution society strength sales marketing teams enabled glaxosmithkline become partner choice industry good financial performance signed unprecedented major external collaborations delivered solid financial performance last two years helped boost product challenging operating environment global pharmaceutical sales portfolio also provided exciting new opportunities grew eight per cent nearly billion us pharmaceutical number areas unmet medical need erectile sales grew per cent despite generic competition augmentin dysfunction obesity hiv group demonstrated continued financial strength total sales seven per cent business performance trading profit patent challenges per cent strong performances key therapy last year number developments areas including central nervous system respiratory antivirals involving patents key products vaccines july usa first generic version augmentinwas business performance earnings per share grew per cent launched followed ruling federal judge delivering guidance demonstrating continuing augmentinpatents invalid appealing financial strength provide group sound decision firm belief patents valid meanwhile platform future already offset impact generics recent glaxosmithkline made good progress merger successful launches new improved versions augmentin manufacturing restructuring plans remain track es xr formulations deliver forecast total annual merger manufacturing glaxosmithkline also involved litigation patents restructuring savings least billion wellbutrin srand zybanin usa awaiting outcome stopping continuous improvement programme appeal judgement last year favour andrx operational excellence delivering additional savings corporation applied market generic versions continue productsglaxosmithkline description business description business discusses activities resourcesandthe operating environment business identifies developments achievements following headings business history development company products operating environment competition regulation operating activities marketing distribution manufacture supply research development operating resources intellectual property information technology glaxosmithkline people property plant equipment business community corporate social responsibility responsibility environment health safety access healthcare developing world global community partnerships discussion groups management structures corporate governance procedures set corporate governance pagesto remuneration report gives details groups policies directors remuneration amounts earned directors senior management pages discussion groups operating financial performance financial resources given operating financial review andprospects pages report glaxosmithkline group means glaxosmithkline plc subsidiary undertakings thecompany means glaxosmithkline plcglaxosmithkline share means ordinary share ofglaxosmithkline plc p american depositary shares ads represent two glaxosmithkline shares throughout report figures quoted market size market share market growth rates relate months ended th september orlater available glaxosmithkline estimates based onthe recent data independent external sources valued sterling relevant exchange rates figures quoted product market share reflect sales glaxosmithkline licensees brand names appearing italics throughout report trade marks glaxosmithkline associated companies theexception baycol levitratrade marks bayer ag bexxar trade mark corixa corporation inc hepseraa trademark gilead services inc natrecora trade mark scios inc navelbine trade mark pierre fabre mdicament nicoderm trade mark aventis sa pritor trade mark boehringer ingelheim international gmbh used licence group glaxosmithklinejoint statement chairman chief executive officer seroxatpaxil continues subject threat generic positive action international programme hivaids competition particularly usa education care support established ten years backing international programmes countries federal judge chicago recently ruled glaxosmithklines patent usa covering hemihydrate form paxilwas valid glaxosmithkline key partner global effort eliminate infringed generics company apotexs product lymphatic filariasis disabling disfiguring disease currently believe patent infringed apotexs product affects million people threatens one billion appeal ruling also continue pursue poorest nations world date litigation infringement patents relating paxilagainst glaxosmithkline donated million tablets part apotex generics companies usa year commitment eradicate disease result pending matters possible timing generic guardian newspapers giving list recently recognised competition paxilin usa unclear consequently glaxosmithklines total global community expenditure glaxosmithklines published earnings guidance remains greater british company increased previously stated guidance high single digit percentage comprehensive programme social investment investing growth business performance earnings per share constant million support global community programmes product exchange rates assuming generic competition paxil donations charitable contributions usa generic launch paroxetine hydrochloride became imminent glaxosmithkline would reassess guidance corporate governance corporate governance continues high profile issue uptake paxil cr enhanced form antidepressant publication higgs review role effectiveness launched excellent represents nonexecutive directors sir robert smiths report audit per cent paxils new prescriptions usa also committees usa sarbanesoxley act became law patent challenges number products zofran july impact glaxosmithkline relation lamictal cases illustrate industrywide trend certification annual report form f disclosure generics companies filing patent challenges earlier processes relationship external auditors internal controls obviously defend intellectual property vigorously number governance issues glaxosmithkline regularly undertakes thorough reviews groups internal control contribution society systems committed remaining leader governance responsible behaviour types organisations including processes structure multinational companies governments charities high public agenda last year first report corporate social acknowledgements responsibility set commitment reflecting ethical business discover effective medicines healthcare social environmental concerns business decisions products people throughout world result create second report updating activities published shareholder value great position build time annual report covers issues success last year build best pipeline industry generated significant interest stakeholders launch new products extend thanks corporate social responsibility report also includes employees committed making happen indicators show progress addressing issues bob ingram chief operating officer president pharmaceutical corporate responsibility integral part business operations retired end december continue inherent mission glaxosmithkline makes significant work parttime vice chairman pharmaceuticals special positive contribution society around world advisor group would like express appreciation medicines vaccines healthcare products research contribution company particular develop manufacture sell significant role making merger success products must improve peoples lives ensure profitable behalf board corporate executive team also sustainable future business also understand thank shareholders support hope stakeholders including employees want know make share enthusiasm company look forward profit need reassured sound ethical basis continued success business focus making contribution improving healthcare alleviating suffering developing world never greater significant progress made towards tackling enormous challenge hivaids end secured arrangements supply preferentiallypriced hivaids medicines worlds poorest countries shipments medicines developing world continue grow significantly year year september reduced preferential prices hivaids medicines per cent sir christopher hogg j p garnier chairman chief executive officer glaxosmithkline description business business history development company glaxosmithkline plc subsidiary associated undertakings constitute major global healthcare group engaged creation discovery development manufacture marketing pharmaceutical consumer healthrelated products glaxosmithkline corporate head office london area great west road brentford middlesex tw gs england tel glaxosmithkline also operational headquarters philadelphia pa research triangle park nc usa operations countries products sold countries principal research development rd facilities uk usa japan italy belgium products currently manufactured countries major markets groups products usa japan france germany theuk italy glaxosmithkline plc public limited company incorporated thdecember english law th december company acquired glaxo wellcome plc smithkline beecham plc english public limited companies way scheme arrangement merger two companies glaxo wellcome smithkline beecham major global healthcare businesses st october glaxo wellcome plc changed name glaxosmithkline services plc th march became glaxosmithkline services unlimited historical references glaxo wellcome plc document changed business segments glaxosmithkline operates principally two industry segments pharmaceuticals prescription pharmaceuticals vaccines consumer healthcare overthecounter medicines oral care nutritional healthcaredescription businessglaxosmithkline products pharmaceuticals therapeutic area trade mark compound mechanism indication may vary country central nervous seroxatpaxil paroxetine selective serotonin reuptake depression panic anxiety system inhibitor wellbutrin bupropion noradrenaline reuptake inhibitor depression imigranimitrex sumatriptan ht agonist migraine cluster headache naramigamerge naratriptan ht agonist migraine lamictal lamotrigine sodium channel modulator epilepsy requip ropinirole dopamine agonist parkinsons disease zyban bupropion sr noradrenaline reuptake inhibitor smoking addiction respiratory flixotideflovent fluticasone propionate inhaled antiinflammatory asthma bronchial conditions serevent salmeterol xinafoate bronchodilator bronchial asthma bronchitis seretideadvair salmeterol fluticasone bronchodilatorantiinflammatory asthma propionate flixonaseflonase fluticasone propionate intranasal antiinflammatory hayfever perennial rhinitis ventolin salbutamolalbuterol bronchodilator bronchial asthma bronchitis becotidebeclovent beclomethasone dipropionate inhaled antiinflammatory bronchial asthma bronchitis beconase beclomethasone dipropionate intranasal antiinflammatory hayfever perennial rhinitis antivirals trizivir lamivudine zidovudine reverse transcriptase inhibitor hivaids abacavir combivirbiovir lamivudine zidovudine reverse transcriptase inhibitor hivaids epivirtc lamivudine reverse transcriptase inhibitor hivaids retrovirazt zidovudine reverse transcriptase inhibitor hivaids ziagen abacavir reverse transcriptase inhibitor hivaids agenerase amprenavir protease inhibitor hivaids valtrexzelitrex valaciclovir dna polymerase inhibitor shingles genital herpes zovirax aciclovir dna polymerase inhibitor herpes infections shingles chicken pox cold sores zeffixheptavir lamivudine reverse transcriptase inhibitor chronic hepatitis b infection heptodinepivir hbv antibacterials augmentin amoxicillin broad spectrum oralinjectable common infections antimalarials clavulanate potassium antibiotic zinnatceftin cefuroxime axetil oral antibiotic common infections fortumfortaz ceftazidime injectable antibiotic severe life threatening infections bactroban mupirocin topical antibiotic skin infections amoxil amoxicillin broad spectrum oralinjectable common infections antibiotic malarone atovaquoneproguanil electron transport system treatment prophylaxis malaria metabolic avandia rosiglitazone ppargamma agonist type diabetes gastrointestinal avandamet rosiglitazone metformin ppargamma agonist type diabetes hydrochloride antihyperglycemic agent metformin zantac ranitidine hydrochloride antisecretory duodenal ulcers stomach ulcers reflux dyspepsia avodart dutasteride selective inhibitor type ii benign prostatic hyperplasia isoforms ar vaccines havrix hepatitis engerixb hepatitis b twinrix hepatitis b infanrix diphtheria tetanus acellular pertussis oncology zofran ondansetron ht receptor antagonist nausea vomiting cancer emesis therapy hycamtin topotecan topoisomerase inhibitor ovarian cancer small cell lung cancer navelbine vinorelbine cytotoxic nonsmall cell lung cancer breast cancer cardiovascular coreg carvedilol alphabeta blocker congestive heart failure lanoxin digoxin cardiac antiarrhythmic congestive heart failure cardiac arrhythmia flolan epoprostenol inhibitor blood clotting primary pulmonary hypertension lacipil lacidipine calcium channel blocker hypertension pritor telmisartan angiotensin ii antagonist hypertension arthritis relafen nabumetone non steroidal antiinflammatory osteoarthritis rheumatoid arthritis glaxosmithkline description business products pharmaceuticals therapeutic area antivirals combivir combination retrovirand epivir consolidated glaxosmithklines principal pharmaceutical products presently position two reverse transcriptase inhibitors directed therapeutic areas analysis salesby cornerstone many multiple antihiv product regimens physician therapeutic areas description principal products acceptance clearly demonstrated value placed setout minimising pill burden faced patients sales therapeutic area ziagenis reverse transcriptase inhibitor products potency central nervous system ease use resistance profile allow play significant role respiratory variety highly active well tolerated andsimplified hiv antivirals treatment regimens antibacterialsantimalarials triziviris combination combivirand ziagen combining three metabolic gastrointestinal antihiv therapies one tablet twice daily administration vaccines oncology emesis ageneraseis protease inhibitor treatment hiv cardiovascular first medicine class brought market arthritis glaxosmithkline agenerasehas twice daily dosing regimen others significant food drink restrictions divested products zeffixhas approved marketing usa europe china markets treatment chronic hepatitis b valtrexis treatment chicken pox zoster shingles cold sores central nervous system cns episodic genital herpes well long term suppression seroxatpaxilis selective serotonin reuptake inhibitor ssri genital herpes valtrex supersedes zovirax also widely approved depression panic obsessive compulsive disorder used treat herpes infections post traumatic stress disorder social anxiety disorder general anxiety disorder paxil cr controlled release version antibacterials antimalarials launched usa augmentinis broadspectrum antibiotic suitable treatment wide range common bacterial infections wellbutrinis antidepressant available usa normal particularly effective respiratory tract infections augmentin orsustained release tablet formulations esis extra strength suspension specifically designed treat imigranimitrexis ht receptor agonist used treatment children recurrent persistent middle ear infections ofsevere frequent migraine cluster headache augmentin xris extra strength tablet form adults combat become reference product sector naramigamergeis growing problem bacterial resistance community newer migraine product zinnatis oral antibiotic used primarily communityacquired lamictalis treatment epilepsy used alone combination infections lower respiratory tract fortumis used products achieved penetration mature hospitalbased injectable antibiotics market market successful treatment severe cases malaroneis oral antimalarial used treatment requipis specific dopamine dlike receptor agonist prophylaxis malaria caused plasmodium falciparum treatment ofparkinsons disease metabolic gastrointestinal zybanis nicotinefree prescription medicine available avandiais potent insulin sensitising agent acts asasustainedrelease tablet treating problem underlying pathophysiology type diabetes avandametis smokingaddiction combination avandiaand metformin hci first medicine targets insulin resistance decreases glucose production respiratory one convenient pill seretideadvair combination sereventand flixotide offers alongacting bronchodilator antiinflammatory single zantac treatment peptic ulcer disease range inhaler ofgastric acid related disorders continues play major role number markets even patent protection lost sereventis longacting bronchodilator ventolinis selective shortacting bronchodilator vaccines flixotidefloventand becotidebecloventare inhaled steroids glaxosmithkline markets range hepatitis vaccines havrix treatment inflammation associated bronchial asthma protects hepatitis engerixbagainst hepatitis b chronic bronchitis twinrixis combined hepatitis b vaccine protecting diseases one vaccine available adult flixonaseflonaseand beconaseare intranasal preparations paediatric strengths treatment perennial seasonal rhinitis infanrixis range paediatric vaccine combinations infanrix provides protection diphtheria tetanus pertussis whooping cough infanrix pentapediarix provides additional protection hepatitis b polio andinfanrix hexafurther adds protection haemophilus influenzae type b causesmeningitisdescription businessglaxosmithkline additionally glaxosmithkline markets priorixa measles major products mumps rubella vaccine typherix vaccine protection category product typhoid fever varilrix vaccine varicella chicken pox overthecounter medicines analgesics panadol oncology emesis dermatologicals oxy zofranis used prevent nausea vomiting associated zovirax chemotherapy radiotherapy cancer available abreva bothoral injectable forms also approved use gastrointestinal tums prevention treatment postoperative nausea vomiting citrucel respiratory tract contac hycamtinis second line treatment ovarian cancer beechams forsmall cell lung cancer smoking control commit navelbine approved first line treatment nonsmall cell lung nicorette cancer combination cisplatin single agent nicoderm cq niquitin cq cardiovascular nicabate cq coregis alphabeta blocker proven natural wellness support abtei effective intreating mild moderate severe heart failure oral care aquafresh glaxosmithkline sole marketing rights usa corega drbest arthritis macleans relafenis nonsteroidal antiinflammatory drug treatment odol arthritis polident poligrip sensodyne category includes groups principal dermatological nutritional healthcare horlicks products betnovate thehigher potency dermovateand newer lucozade cutivateare antiinflammatory steroid products used treat skin ribena diseases suchas eczema psoriasis divested products overthecounter medicines accordance agreements regulatory approvals leading products panadol widely available merger glaxo wellcome smithkline beecham paracetamolacetominophen analgesic nicorettegum products kytril treatment chemotherapy nicodermniquitincqand nicabaterange smoking control radiotherapyinduced nausea vomiting famvir patches tums calcium based antacid citrucellaxative contac antiviral treatment shingles herpes divested treatment colds influenza abtei natural indecember medicines vitamin range oxyacne treatment zovirax abreva treatment cold sores products consumer healthcare glaxosmithkline consumer healthcare introduced two glaxosmithklines principal consumer healthcare products new prescription overthecounter switches presently directedto three major areas analysis sales areas isset eumovate cream clearing skin flareup dermatitis eczema uk beconase allergy hoursfor hayfever australia overthecounter medicines oral care oral care leading oral care products toothpastes mouthwashes nutritional healthcare aquafresh sensodyne macleansand odolbrand divested products names range toothbrushes sold aquafresh sensodyneand dr bestnames addition denture care products available principally polident poligripand corega constant exchange rates sales two per cent higher brand names nutritional healthcare leading products category lucozadeglucose energy sports drinks ribenablackcurrantbased juice drink rich vitamin c horlicks range milkbased malted food chocolate drinks glaxosmithkline description business operating environment competition pharmaceuticals respiratory glaxosmithklines respiratory franchise driven growth pharmaceutical industry highly competitive seretideadvair gaining patients competitor products glaxosmithklines principal competitors large international cannibalisation sereventand flixotide ventolinand becotide pharmaceutical companies substantial resources faced generic competition years companies major products mentioned maintained significant sales pharmaceuticals may subject competition major respiratory competitors singulair merck especially products period patent protection usa symbicort astrazeneca primarily european patent generic versions manufacturers generic union spiriva pfizerboehringer ingelheim primarily products typically donot bear significant research development europe costs consequently areable offer products considerably lower prices thebranded competitors research antivirals development based pharmaceutical company normally major competitors hiv market bristol myers squibb seek achieve sufficiently high profit margin sales volume merck pfizer amongst others period patent protection repay original investment fund research forthe future competition glaxosmithkline pioneering role hiv market generic products generally occurs patents major markets retrovirand epiviracting cornerstone combination expire increasingly patent challenges made prior patent therapy available combivirin single tablet launches expiry ziagen ageneraseand trizivirhave broadened thegroups glaxosmithkline undertakes range activities maximise portfolio hiv products valtrexhas helped strengthen value intellectual property including introducing innovative groups position antiherpes area although zoviraxfaces products many markets possible accelerating process competition generic aciclovir valtrexand zovirax bring new products tomarket increasing brand recognition compete novartis famvir zeffixwas first antiviral among customers market treat hepatitis b gileads hepsera second approved usfood drug administration fda glaxosmithkline believes competitive position dependent september upon discovery development new products together effective marketing existing products within antibacterials antimalarials pharmaceutical industry introduction new products generic versions augmentinand ceftinzinnat processes competitors may affect pricing levels result introduced usa following successful legal challenges product replacement assurance products may generic manufacturers see note financial statements become outmoded notwithstanding patent trade mark legal proceedings augmentinhas already lost patent protection protection addition increasing government pressure various countries europe recently launched augmentin physicians patients use generic pharmaceuticals rather xr augmentin escompete broad range brandname medicines may increase competition branded generic antibiotics malarones safety profile products longer protected patent convenient dosing regimen helped put product strong position versus mefloquine following recent launch cns disorders malaria prophylaxis major competitors paxilin usa selective serotonin reuptake inhibitor ssri market fluoxetine generic form eli lillys metabolic gastrointestinal prozac zoloft pfizer forest laboratories celexa lexapro major competitor avandiais takeda chemicals actos principal competitors usa wellbutrinare ssris copromoted eli lilly usa effexor xr wyeth product success seroxatpaxiland wellbutrin made target generic manufacturers vaccines glaxosmithkline continues respond appropriately glaxosmithklines major competitors vaccine market include see note financial statements legal proceedings aventis pasteur ap merck wyeth engerixband havrix imigranhas grown one glaxosmithklines leading products compete vaccines produced ap merck comvax addressing previously unmet needs migraine recombivax hb hepatitis b vaqta avaxim hepatitis sufferers although companies launched competing infanrixsmajor competitor aps range dtpabased products newer formulations imigransuch nasal spray combination vaccines introduction naramighave helped group retain lead competitors migraine market maintain growthdescription businessglaxosmithkline competition consumer healthcare grant marketing authorisation affords group protection period competitor rely confidential data main competitors groups consumer healthcare markets regulatory file basis marketing authorisation include major international companies colgatepalmolive data protection period begins thedate authorisation johnson johnson pfizer procter gamble unilever wyeth first granted european union andexpires ten years addition many companies compete authorisations granted via centralised procedure ten six glaxosmithkline selected markets years authorisations grantedvia mutual recognition major competitor products overthecounter otc procedure depending onthecountry concerned medicines usa drug price competition patent term usametamucil laxative clearasil acne treatment restoration act hatchwaxman established current pepcid indigestion private label smoking control framework approval generic drugs including related patent products data protection provisions hatchwaxman sponsor uk lemsip cold remedy nurofen anadin abbreviated new drug application anda receive analgesics nicorette nicotinell smoking control marketing approval without submitting safety efficacy data remedies rely pioneer companys extensive preclinical clinical development data provided proposed generic drug nutritional healthcare major competitors horlicksare demonstrated bioequivalent pioneer product ovaltine milo malted food chocolate drinks however generic drug approvals subject data protection competitors ribenaare primarily local fruit juice products periods five years new chemical entities three years lucozadecompetes energy drinks modifications supported new clinical studies moreover glaxosmithkline holds leading global positions key provisions hatchwaxman filing andacan consumer product areas worldwide second largest oral trigger procedures may allow patent holders initiate patent care third largest otc medicines nutritional infringement litigation significant procedural advantage healthcare holds leading position uk india assured fdas approval proposed generic ireland product stayed months pending resolution litigation procedures generated litigation regulation pharmaceuticals controversy particularly currently applied resulted multiple nonconcurrent month stays international pharmaceutical industry highly regulated proposed generic products fdahas proposed changes national regulatory authorities administer panoply laws regulations address certain aspects procedures andregulations governing testing approval manufacturing generated litigation controversy reform legislation labelling marketing drugs also review safety also proposed us congress andefficacy pharmaceutical products regulatory requirements major factor determining whether usa second reauthorisation prescription drug substance developed marketable product user fee act came effect st october pdufa iii amount time expense associated development recent general accounting office report senate particular importance requirement many countries committee health education labor pensions noted products authorised registered prior marketing gradual increase median time gain approval drugs authorisation registration maintained subsequently standard review designation since approval time priority review drugs judged fda represent national regulatory authorities many jurisdictions including significant therapeutic advance remained constant usa european union japan australia high median time approval six months standards technical appraisal consequently introduction new pharmaceutical products generally entails lengthy increasing gap approval times approvalprocess priority standard applications approval time drugs designated standard review reached low european union two procedures obtaining months rising months marketing authorisations medicinal products centralised procedure applications made direct remains seen substantial additional resources funded theeuropean medicines evaluation agency leading pdufa iii result reduction overall approval times authorisation valid member states compulsory drugs biologics review times certain biologics products derived biotechnology optional new vaccines may substantially impacted recently activesubstances innovative medicinal products announced consolidation review activities center mutual recognition procedure applicable drug evaluation research activities previously majority conventional medicinal products operates mutual carried center biologics evaluation research recognition national marketing authorisations agreement reached resolved procedure binding arbitration glaxosmithkline description business last decade regulatory authorities focused value money significant attention measures manage risk associated becoming increasingly necessary demonstrate value use prescription products particularly noticeable money new products particular impact upon drug usa fda pharmaceutical industry budget expenditure burden disease subjected intense public scrutiny adequacy treated measures taken protect public health substantial funding markets need satisfy healthcare purchasers fda strengthen post market surveillance activities value money becoming additional hurdle product included pdufa iii performance goals associated acceptance regulatory tests ofsafety efficacy legislation drug manufacturers encouraged submit quality delay bringing effective improved voluntarily proposed risk management plans part applications medicines market reduce effective patent marketing new drugs recent developments represent protection time additional challenge market registration process usa many markets becoming increasingly difficult th june fda announced approval supplemental significantly improved therapy obtain premium price new drug application snda allows restricted marketing existing medication philosophies founded valuebased pricing lotronexalosetron hydrochloride treat women severe difficult follow circumstances although usa diarrhoeapredominant irritable bowel syndrome ibs still possible price products reflect value november reintroduction followed advisory committee review implementation fdaglaxosmithkline agreed risk possible predict whether extent management programme intended ensure patients groupsbusiness may affected future legislative physicians fully informed possible risks benefits regulatory developments relating specific pharmaceutical lotronex products price across international markets countries outside usa regulation consumer healthcare europe regulatory environment continues extremely varied challenging glaxosmithkline anticipates consumer healthcare industry subject national regulation introduction new products continue require substantial testing approval manufacturing labelling marketing effort time expense comply regulatory requirements products many countries high standards technical appraisal entail lengthy approval process new product price controls launched manycountries prices pharmaceutical products national regulatory authorisation also required approve controlled law governments may also influence prices switch products prescription otc requirements control national healthcare organisations may bear include longterm experience quality safety efficacy large part cost supplying products consumers oftheproduct wide patient population data confirm usa debate reform healthcare system thatthe relevant condition selflimiting easily increased focus pricing currently government diagnosed bythe consumer price controls private sector purchases federal legislation requires pharmaceutical manufacturers pay prescribed rebates certain drugs order eligible reimbursement medicaid federal healthcare programmes europe historically affected government regulation pricing reimbursement pharmaceutical industry continues experience pressure prices range measures including acrosstheboard cuts linking lowcost countries price referencing delays agreeing reimbursement increasing pressure generic substitution crossborder imports fromlowpriced markets may exert commercial pressure incountrypricing japan discussions ongoing new price reimbursement controls government introduce worldwide pharmaceutical market continued experience increasing pressure pricing reimbursement governments healthcare providers though nonprice factors new products higher volumes principally driving growth pharmaceutical expendituredescription businessglaxosmithkline operating activities marketing distribution directtoconsumer dtc advertising major component product marketing usa dtc advertisements glaxosmithkline sells products worldwide primary source information patients requesting specific extensivenetwork subsidiaries licensees distributors brand name products physicians usa gross profit margins earned sales pharmaceutical outside usa dtc either prohibited limited products generally higher earned sales rolein informing patients european union dtc consumer products reflecting many risks uncertainties prescriptiononly products currently prohibited australia inherent developing marketing pharmaceuticals risks government allows dtc advertising pharmacyonly products include high level research development expenditure subject certain safeguards new zealand dtc allowed required discover test obtain patent protection new selfregulated industry collaboration advertising products competition new generic products standards agency markets allow dtc date glaxosmithklines worldwide operation subject number impact limited risks inherent conducting business certain countries including addition direct marketing products subsidiaries possible nationalisation expropriation restrictive glaxosmithkline entered agreements withother government actions capital regulation addition currency pharmaceutical companies comarketing copromotion fluctuations changes economic conditions may occur products many markets example levitra bayer either favourable unfavourable effect trading income group regard factors marketing distribution consumer healthcare deterrents expansion international operations however closely reviews methods operation particularly principal markets consumer healthcares otc medicines developing countries develops strategies respond usa uk germany australia argentina italy mexico changing economic political conditions japan canada france principal markets oral care products usa germany uk nutritional drinks marketing distribution pharmaceuticals business particularly strong uk ireland india although range products available markets analysis total pharmaceutical sales including divested products geographic region set otc oral care products primarily distributed pharmacy mass market outlets either directly sales geographic region wholesalers nutritional healthcare products distributed similar extensive retail wholesale network usa europe international manufacture supply asia pacific glaxosmithkline large portfolio products ranging japan tablets toothpaste inhalers complex capsules latin america different pack sizes presentations middle east africa canada manufacture medicines begins development therapeutic active ingredient bulk active selected formulation global manufacture supply gms develops manufacturing processes full scale volume production active compounds glaxosmithkline sells prescription medicines primarily 'primary ' manufacturing sites converting active compounds wholesale drug distributors independent chain retail finished dosage formulation responsibility 'secondary ' pharmacies physicians hospitals clinics government entities manufacturing sites institutions products ordinarily dispensed public pharmacies prescriptions written doctors gms operates single global network sites hospitals doctors surgeries countries year gms produces around tonnes bulk actives four billion packs packaged usa worlds largest pharmaceutical market delivered sale countries throughout world pressureto contain healthcare costs encouraged growth also supports approximately new product line extension managed care organisations pharmacy benefit managers launches year intermediaries use range methods lower costs including substitution generic products cheaper gms focused delivering therapies branded products prescribed doctors secure source supply high quality products increasing importance supplier healthcare compliance regulatory requirements customer community glaxosmithkline contracts managed care expectations sector small number wholesalers best class cost market glaxosmithkline deploys salesforces leading edge practices performance sites representatives supporting medical staff promote procurement global functions prescription products medical prescribers healthcare purchasers personal visits organisation gms operations structured supply chains regions promotion glaxosmithklines products supplemented scientific seminars advertising medical journals television advertising provision samples direct mailing information contained groups website glaxosmithkline description business primary supply chain vaccines supply chain global organisation sites spread across vaccine production located principally rixensart belgium countries broad range active ingredients antibiotic six sites worldwide managing vaccine supply chain nonantibiotic products manufactured packaged involves anticipating market needs using flexible approach sites located australia india ireland singapore uk able meet fluctuations demand based usa majority active ingredients manufactured forecasts different markets firm orders health primary supply chain supplied secondary authorities mass vaccination campaigns bulk filling pharmaceutical sites europe north america international packaging carefully balanced stocking vaccines helps manage shortterm increases demand increases secondary supply chain prompted disease outbreaks increased demand european region public owing disease awareness campaigns sites european region spread across eight countries european sites manufacture nearly consumer healthcare supply chain major pharmaceutical products marketed globally consumer healthcare manufacturing sites spread glaxosmithkline wide variety finished dosage forms across countries consumer healthcare supply chain diverse includes manufacturing supply otc north america region medicines oral care nutritional healthcare smoking control six pharmaceutical sites north america region products well internal facilities contract suppliers located puerto rico canada usa used worldwide international region research development pharmaceuticals international region comprises manufacturing sites global biological pharmaceutical research countries spread across six distinct areas five sites development rd function glaxosmithkline responsible middle eastafrica sites spread across asia pacific area discovering developing registering commercialising four sites china one japan five latin america supporting effective marketing innovative prescription medicines vaccines delivery systems treatment glaxosmithkline integration prevention human disease longterm integrated change programme implemented time merger called global supply network gsn fundamental goal thorough understanding structured deliver benefits five major streams diseases investigation involving pioneering work ingenetics activity predictive medicine well traditional research disciplines addition work create new medicines reduction abovesite infrastructure costs vaccines extensive efforts made gain clear understanding procurement initiatives unmet needs patientsand healthcare providers continued network rationalisation payers guide overall direction rd logistics improvements operational excellence lean sigma improvements glaxosmithkline invested billion pharmaceuticals rd rd organisation benefits part network rationalisation plan production ceased insights top scientists around world employs sites countries included argentina india staff biological pharmaceutical rd activities japan kenya mexico south africa taiwan venezuela sites worldwide including usa disposal closure sites announced uk beckenham brentford cambridge dartford year greenford harlow stevenage tonbridge ware welwyn external suppliers usa bristol tennessee philadelphia upper merion procurement global function supporting functions areas upper providence pennsylvania research triangle glaxosmithkline business manufacturing one park north carolina largest areas billion spent many external belgium rixensart suppliers every year including purchase active ingredients canada mississauga chemical intermediates partfinished finished products gms france les ulis evreux taken appropriate steps protect supply chains italy verona disruption resulting interrupted external supply japan tsukuba science city takasaki appropriate stock levels contracting alternative registered spain tres cantos madrid suppliers rd continued deliver range products market accelerated progress early stages development extensive inlicensing activity begun continued latestage earlier pipeline significantly enhanced practical prioritisation management portfolio compounds development also focus ensuring glaxosmithkline rd invests resource achieve optimum value deliver new medicines patientsdescription businessglaxosmithkline product development pipeline product development pipeline set shows considerable breadth depth end glaxosmithkline pharmaceutical vaccine projects development clinic key v vaccine phase evaluation clinical pharmacology usually conducted p pharmaccine volunteers compounds shionogiglaxosmithkline pharmaceuticals llc joint venture phase ii determination dose initial evaluation inlicense alliance relationship third party efficacy conducted small number patients date first submission date first regulatory approval maa first phase iii large comparative study compound versus placebo eu approval letter andor established treatment patients al approvable letter establish clinical benefit safety maa marketing authorisation application europe nda new drug application usa compound type indication phase maa nda cardiovascular urogenital metabolic antifactor ix monoclonal antibody stroke beta adrenergic agonist type diabetes thrombin inhibitor prevention thrombotic complications cardiovascular disease peroxisome proliferatoractivator dyslipidaemia receptor pparagonist ppar agonist dyslipidaemia ppar agonist type diabetes nin oral insulin analogue type diabetes ccka agonist obesity ii indirect thrombin inhibitor prevention thrombotic complications ii cardiovascular disease lppla inhibitor atherosclerosis ii bvt htc agonist obesity ii piboserod ht antagonist atrial fibrillation ii avandia sulphonylurea ppar gamma agonist plus sulphonylurea type diabetes iii avodart alpha reductase inhibitor prostate cancer prevention iii nesiritide recombinant betatype natriuretic peptide acute heart failure submitted ssep na levitravardenafil pdev inhibitor erectile dysfunction submitted sjan aljul avandia ppar gamma agonist type diabetes combination insulin submitted alfeb avandamet ppar gamma agonist plus metformin type diabetes approved soct aoct avandia metformin combination tablet infectious diseases topical pleuromutilin bacterial skin infections lapdap artesunate antifolate artemisinin treatment uncomplicated malaria na phospholipid antiendotoxin emulsion sepsis ii augmentingranules beta lactam antibiotic respiratory tract infections incl penicillinresistant ii na pneumoniae modified release granule formulation augmentin es chewable beta lactam antibiotic acute otitis media incl penicillinresistant iii na pneumoniae highdose chewable tablet augmentinxr beta lactam antibiotic treatment acute exacerbation chronic bronchitis iii aecb including complicated aecb oxibendazole polymerase inhibitor treatment adult paediatric helminth iii na intestinal infections sitamaquine unknown treatment visceral leishmaniasis iii na tafenoquine aminoquinoline malaria prophylaxis adults iii lapdap antifolate treatment uncomplicated malaria submitted soct na antivirals aspartyl protease inhibitor hiv infections nonnucleoside reverse transcriptase inhibitor hiv infections hiv integrase inhibitor hiv infections ii ziagenepivir reverse transcriptase inhibitors hiv infection combination tablet iii protease inhibitor amprenavir prodrug hiv infection submitted sdec sdec valtrex nucleoside analogue hsv suppression immunocompromised patients submitted na ssep valtrexzelitrex nucleoside analogue prevention herpes simplex virus hsv transmission submitted snov soct glaxosmithkline description business compound type indication phase maa nda neurology gastrointestinal endothelin antagonist stroke ht antagonist alzheimers disease schizophrenia dual alpha integrin antagonist vla multiple sclerosis ms inflammatory bowel disease ibd also asthma rheumatoid arthritis ra corticotropin releasing factor crfr irritable bowel syndrome ibs also anxiety antagonist depression cox inhibitor second generation pain ii adenosine agonist neuropathic pain ii endothelin antagonist stroke ii benzodiazepine inverse agonist alzheimers disease vascular dementia ii carabersat benzopyran migraine prophylaxis epilepsy ii imigranimitrex ht agonist migraine needlefree injection ii talnetant tachykinin nk antagonist ibs also schizophrenia ii alvimopan adl peripheral muopioid antagonist post operative ileus iii imigranimitrex ht agonist migraine fast dissolving tablet iii lamictal sodium channel inhibitor neuropathic pain iii na requip nonergot dopamine agonist parkinsons disease controlled release formulation iii requip nonergot dopamine agonist restless leg syndrome iii imigranimitrex ht agonist adolescent migraine nasal formulation submitted ssep aldec oncology musculoskeletal inflammation grot cxc chemokine prevention chemotherapyinduced cytopaenias cathepsin k inhibitor osteoporosis osteoarthritis recombinant human interleukin immunologicallysensitive cancers melanoma immunomodulator renal cell thrombopoietin agonist chemoprotection p alpha kinase inhibitor rheumatoid arthritis also chronic obstructive pulmonary disease kinesin inhibitor breast ovarian cancers vascular epidermal growth factor tyrosine solid tumours kinase inhibitor topotecan topoisomerase l inhibitor bioenhancer cancer erbb egfr dual kinase inhibitor solid tumours breast colorectal cancers ii ethynylcytidine selective rna polymerase inhibitor solid tumours ii hycamtin topoisomerase inhibitor small cell lung cancer first line therapy ii repifermin keratinocyte growth factor mucositis also wound care inflammatory ii bowel disease hycamtin topoisomerase inhibitor nonsmall cell lung cancer second line therapy iii na hycamtin topoisomerase inhibitor small cell lung cancer second line therapy iii oral formulation hycamtin topoisomerase inhibitor ovarian cancer first line therapy iii ibandronate bisphosphonate treatment prevention postmenopausal iii osteoporosis monthly oral dosing ibandronate bisphosphonate treatment prevention postmenopausal iii osteoporosis quarterly iv dosing navelbine vinca alkaloid nonsmall cell lung cancer oral therapy iii na bexxar radiolabelled antib monoclonal nonhodgkin 's lymphoma submitted na ssep antibody hycamtin topoisomerase inhibitor small cell lung cancer second line therapy submitted snov na ibandronate bisphosphonate treatment prevention postmenopausal submitted sjun sjul osteoporosis daily oral regimen psychiatry ht antagonist schizophrenia alzheimers disease noradrenalinedopamine reuptake inhibitor depression bipolar disorder glycine antagonist smoking cessation nk antagonist depression anxiety corticotropin releasing factor crfr anxiety depression also ibs antagonist nk antagonist depression anxiety ii talnetant tachykinin nk antagonist schizophrenia also ibs ii vilazodone selective serotonin reuptake inhibitor ssri depression ii emd hta partial agonist lamictal sodium channel inhibitor bipolar disorder acute treatment iii na paxil cr ssri premenstrual dysphoric disorder pmdd intermittent iii na treatment controlled release formulation lamictal sodium channel inhibitor bipolar disorder longterm prophylaxis submitted saug sjun paxil cr ssri pmdd continuous treatment controlled submitted na sjun release formulation paxil cr ssri social anxiety disorder submitted na sdec wellbutrin xl noradrenalinedopamine reuptake inhibitor depression controlled release formulation submitted saug daily dosingdescription businessglaxosmithkline compound type indication phase maa nda respiratory td beta agonist asthma chronic obstructive pulmonary disease copd selective inos inhibitor asthma copd allergic rhinitis beta agonist asthma copd p alpha kinase inhibitor copd also ra dual alpha integrin antagonist vla asthma ra also ms ibd chemokine receptor antagonist asthma allergic rhinitis alpha integrin antagonist asthma allergic rhinitis ii glucocorticoid receptor agonist asthma copd allergic rhinitis ii awd pde iv inhibitor asthma copd allergic rhinitis ii mepolizumab antiil monoclonal antibody asthma atopic dermatitis ii ariflo pde iv inhibitor copd submitted sdec noncfc metered dose inhaler propellants serevent beta agonist asthma copd iii na flixotideflovent inhaled corticosteroid asthma copd approved aapr aldec seretideadvair beta agonistinhaled corticosteroid asthma approved ajun aloct oct diskusaccuhaler dry powder inhaler seretideadvair beta agonistinhaled corticosteroid adult paediatric asthma daily dosing iii seretideadvair beta agonistinhaled corticosteroid copd submitted ssep almar dec serevent beta agonist copd approved amar hepatitis vaccines hepatitis e recombinant hepatitis e prophylaxis ii extra strength hepatitis b recombinant extra strength hepatitis b prophylaxis iii tbd twinrix doses recombinant combined hepatitis b prophylaxis approved asep childadolescent paediatric vaccines rotarix live attenuated oral rotavirus prophylaxis ii n meningitidis conjugated meningitis prophylaxis ii meningitis b cuba subunit meningitis b prophylaxis ii tbd pneumoniae paediatric conjugated pneumoniae disease prophylaxis children iii mmrvaricella live attenuated measles mumps rubella varicella prophylaxis iii infanrixpediarixpenta recombinant diphtheria tetanus pertussis hepatitis b approved aoct adec hepbipv inactivated polio prophylaxis infanrixhexahep b ipvhib conjugatedrecombinant diphtheria tetanus pertussis hepatitis b approved aoct tbd inactivated polio prophylaxis haemophilus influenzae type b prophylaxis vaccines dengue fever attenuated tetravalent vaccine prophylactic use hiv recombinant hiv prophylaxis new influenza subunit influenza prophylaxis new delivery pneumoniae elderly conjugated pneumoniae disease prophylaxis staphylococcal antibodies monoclonal antibody prevention staphylococcal infections epsteinbarr virus ebv recombinant ebv prophylaxis ii human papillomavirus hpv recombinant prophylaxis hpv infections ii malaria recombinant malaria prophylaxis ii boostrix subunit adolescentadult booster diphtheria tetanus approved aoct pertussis boostrix ipv subunit adolescentadult booster diphtheria tetanus iii pertussis inactivated polio simplirix recombinant genital herpes prophylaxis iii pharmaccines gskpowderject recombinant hepatitis b treatment recombinant treatment lung cancermelanoma ii content portfolio change time new compounds progress research development development market owing nature drug development process unusual compounds especially early stage investigation terminated progress development competitive reasons new projects preclinical development disclosed project types may identified glaxosmithkline description business compounds progressed phase clinical development several discovery projects listed table progressed nonclinical safety testing early phase clinical development compounds continuing rigorous nonclinical clinical commercial assessments leading proof concept decisions next months compound mechanism indication topotecan multidrug resistance inhibitor topoisomerase inhibitor cancer endothelin antagonist stroke inos inhibitor asthma topical pleuromutilin bacterial skin infections norepinephrinedopamine reuptake inhibitor depression cathepsin k inhibitor osteoporosis glycine antagonist smoking cessation interleukin cancer thrombopoietin agonist chemoprotection alphaintegrin antagonist allergic rhinitis inhaled beta adrenergic receptor agonist asthma aspartyl protease inhibitor hiv ppar pan agonist diabetes neurokine antagonist depression p alpha kinase inhibitor rheumatoid arthritis dual alphaintegrin antagonist multiple sclerosisirritable bowel syndrome inhaled corticosteroid asthmaallergic rhinitis nonnucleoside reverse transcriptase inhibitor hiv kinesin inhibitor cancer chemokine receptor antagonist asthma vegfr tyrosine kinase inhibitor solid tumours lapdap artesunate chlorproguanildapsone combination artesunate malaria hiv prophylactic vaccine hiv dengue fever vaccine vaccine dengue fever significant regulatory submissions product countryregion description advair usa labelling corticosteroid sparing effect combination salmeterol longacting betablocker fluticasone corticosteroid dry powder diskusdevice ariflo usa cilomilast pde iv inhibitor treatment chronic obstructive pulmonary disease avandamet europe combination rosiglitazone metformin type diabetes coreg usa carvedilol alphabetablocker inlicensed roche cardiac dysfunction following heart attack flixotide europe lower age limit fluticasone inhaled corticosteroid asthma flovent usa cfcfree metered dose inhaler fluticasone ibandronate europe usa bisphosphonate treatment osteoporosis inlicensed roche lamictal europe usa lamotrigine sodium channel blocker longterm prophylaxisprevention bipolar disorder lamictal japan lamotrigine epilepsy levitra europe pde v inhibitor treatment erectile dysfunction inlicensed bayer nesiritide europe natriuretic peptide inlicensed scios inc acute heart failure paxil cr usa controlled release cr paroxetine selective serotonin reuptake inhibitor treatment premenstrual dysphoric disorder paxil cr usa paroxetine treatment social anxiety disorder europe usa protease inhibitor hiv valtrex usa europe valaciclovir dna polymerase inhibitor suppression transmission herpes simplex virus wellbutrin sr usa additional sustained release sr strength bupropion noradrenalinedopamine reuptake inhibitor treatment depression wellbutrin xl usa extended release xl formulation bupropion treatment depressiondescription businessglaxosmithkline product approvals approvals received number new products including several significant new indications formulations existing products summarised table countryregion product approval date description augmentin xr usa october extended release formulation amoxicillin betalactam antibiotic clavulanate beta lactamase inhibitor adult respiratory tract infections avandamet usa october fixed dose combination avandia metformin type diabetes avodart usa october year data dutasteride alpha reductase inhibitor treatment benign prostatic hypertrophy bph avodart europe july dutasteride treatment bph epivir usa october daily dosing lamivudine reverse transcriptase inhibitor hiv flixotide europe october lower age limit fluticasone inhaled corticosteroid asthma flonase usa may intranasal fluticasone nasal symptoms flutide japan october fluticasone cfcfree inhaler lotronex usa june reintroduction alosetron irritable bowel syndrome ibs paxil cr usa february paroxetine selective serotonin reuptake inhibitor panic disorder pediarix usa december combined diphtheria tetanus pertussis hepatitis b polio vaccine children serevent diskus usa march dry powder formulation salmeterol longacting beta blocker copd serevent mdi diskus japan april salmeterol metered dose dry powder inhalers asthma sultanol diskus japan march shortacting beta blocker salbutamol dry powder device asthma twinrix dose europe september combined vaccine hepatitis b valtrex usa september valaciclovir dna polymerase inhibitor treatment cold sores wellbutrin sr usa june additional strength bupropion depression zovirax cream usadecember aciclovir dna polymerase inhibitor treatment cold sores zylorictablets japan march allopurinol xanthineoxidase inhibitor treatment gout rd processes discovery commercialisation delivery rd measures productivity number innovation products creates also commercial value product 's ability address unmet needs healthcare customers including patients healthcare professionals budget holders regulators centres perspective constitutes valuable new product genetics preclinical research excellence development new rd positioned ensure generates right medicines safety efficacy quality information respond drug discovery proven different perspectives data demonstrating overall discovery new product value research development social benefits new medicine increased length quality cedds life increased workplace productivity one historical contradictions pharmaceutical industry need lever advantages large organisation without losing creative spirit research environment glaxosmithkline rd structured balance areas benefit large scale take advantage small enhance productivity intellectual property key areas benefit large validated targets drugs products leads capital intensive high throughput activities compound screening require scarce skills rd processes highly regulated mainly later end line glaxosmithkline 's strategic intent become development chain areas flourish best indisputable leader industry rd set goal advantage structural unit remains small units becoming industrys productive rd organisation steps respond quickly changing environment opportunity achieve included initiatives reduce time scientists interact optimised need return taken phases discovery development chain investment focussed fostering also gain earlier understanding candidate molecules entrepreneurial accountable culture increasing probability making new medicine available treat patients soon possible glaxosmithkline description business rd power smaller units manifest centres discovery research excellence drug discovery cedd ensure purpose discovery research dr identify lead efficient rapid validation lead candidates preclinical compounds may form basis drug discovery efforts testing proof concept criteria handing cedds investment dr focused improving productivity compound new product development organisation large quality quantity rd completed construction scale clinical trials new automation facilities tres cantos spain continued work facilities upper providence harlow new product development function integrates clinical regulatory commercial activities necessary bring new parallel development ability generate medicine marketplace similarly new product supply efficiently large numbers high quality new compounds organisation bridges traditional divide development substantial progress implementing methods evaluate manufacturing ensuring robust manufacturing processes using high throughput biology discipline developed integration knowledge animal human biology starting deliver highly predictive models forecast efficacy significant progress also made integration compounds extend understanding human disease groups rd japan global development commercialisation processes order eliminate duplication centres excellence drug discovery speed regulatory filings discovery two crucial steps converting lead compounds drug development portfolio japan reviewed prioritised candidates optimising lead potency efficacy safety context global rd pipeline intrinsic characteristics molecule ii crucial success rd capacity embrace demonstrating validity therapeutic hypothesis develop new technologies streamline drug discovery process early clinical trials resulting candidate cedds technology development organisation keeps abreast focused specific disease areas designed nimble emerging technologies may advance creation new entrepreneurial range skills resources required medicines evaluates provides investment drive midstage development projects lead optimisation knowledge required develop selected technologies appropriately key decisionpoint demonstration proof rd generates modifies technologies focus concept major investments made fund largescale groups internal goals also maximise return clinical trials rd assets sales spinouts outlicensing six cedds three based usa three europe early research role genetics cardiovascular urogenital diseases centred upper early stages finding new medicines requires essentially two merion components targets shown affect mechanisms metabolic viral diseases centred research triangle park important pathological processes human disease microbial musculoskeletal proliferative diseases including compounds typically small molecules also including cancer centred upper providence macromolecules protein therapeutics vaccines able neurology centred harlow uk modulate behaviour specific targets psychiatry centred verona italy respiratory inflammation centred stevenage uk part target validation process glaxosmithkline aims identify genes relevant common diseases large cedd responsible identifying optimal drug unmet medical needs asthma noninsulin dependent candidate desired biological effect assessing diabetes osteoarthritis chronic obstructive pulmonary disease safety development characteristics preclinical screens early onset heart disease alzheimers disease many diseases achieved cedds responsible proving arise complex interactions number gene compound safe efficacious patients smallscale variants environmental factors challenge involved clinical trials proof concept decision point significant identifying genes predispose patients decision made whether information available particular disease understanding role progression date justifies compounds progression latestage drug lead finding new ways intervene diseases development necessary largescale clinical trials programme identify tractable targets conducted register commercialise product genetically associated human diseases interest cedds progressed significantly compounds initiated enables validation targets associated first dosing humans initial evaluation diseases prior extensive investigation efficacy patients see table compounds practical application genetics moved forward progressed phase order progress highly year several opportunities identified promising medicines yet rapidly without compromising safety knowledge specific markers efficacy susceptibility selected projects currently piloting process involves adverse events enhancing ability focus development running activities parallel rather sequentially new medicines patients likely benefit ultimately providing reassurance prescriber patientdescription businessglaxosmithkline part glaxosmithklines major response challenges matrix teams responsible maximising worldwide diseases affecting developing world microbial development opportunities product within remit musculoskeletal proliferative diseases cedd responsibility ensure early stage regional marketing needs drug discovery unit based tres cantos dedicated fully integrated development plans information finding new medicines diseases research projects needed support registration safety programmes pricing tres cantos focus malaria tb together work formulary negotiations available careful prioritisation across elsewhere group hivaids vaccines address phases development ensures high potential prevention treatment three world health integrated portfolio achieved organizations top priority diseases group also works teams collaborate early stage cedds define numerous external partners worldwide search new target product profiles new molecules integrated treatment diseases developing world ddw technical development manufacturing functions ensure rapid effective launch delivery product innovative preclinical development clinical programmes lead molecules cedds preclinical development pcdparticipates wide range developed using crossfunctional project teams activities within drug development process optimising selection compounds potential development launch new group translational medicine technology marketplace enhancement existing products established within npd optimise use variety devising convenient formulations early development technologies reduce risk cost across development process metabolic fate safety compounds evaluated crossfunctional input extends focused lifecycle management laboratory animals prior testing humans testing products deliver new indications new presentations required animals humans mandated highly initial regulatory approval commercial launch examples regulated governmental agencies lifecycle management include extended release formulation pcd researchers investigate dosage form eg tablet inhaled augmentin xr development programmes designed deliver develop formulations enhance drugs effectiveness pcd new indications use seretideadvairfor chronic also responsible development drug formulations used obstructive pulmonary disease copd clinical trials processes supporting analytical methods new initiative gold pass implemented drug synthesis product formulation delivery scaled designation agreed rd regional markets meet increasing supply requirements ultimately leading manufacturing key component portfolio resource technical transfer processes methods manufacturing prioritisation management process ensure new product supply process partnership rd resources placed behind key emerging assets yield optimum global manufacturing supply ensures robust product commercial benefit well maximum medical benefit developed large scale commercial manufacturing launch patients gold pass assets high value strategic pcd pursuing novel technologies enhance rd productivity importance glaxosmithkline require specific organisational lowering rate project failure reducing cycle time visibility urgency meet patients needs consequently enhancing product value predictive toxicology integrated multi small number assets receive gold passstatus one time disciplinary collaboration pcd dr genetics research enabling full focus organisation aligned established improve quality candidate selections reduce latestage attrition due toxicity inlicensing research collaborations glaxosmithkline continued identify compounds would key technology areas provide ways improve rds enhance portfolio create innovative collaborations productivity include drug delivery systems predictive technologies ensure group regarded partner choice particle engineering process innovation use particle large small companies compounds subject engineering process innovations enhances ability inlicensing copromotion deals january manufacture efficiently consistently highquality products new product development alvimopan adl oral muopoid antagonist provide focus development commercialisation phase iii postoperative ileus codeveloped process must proceed unison major functional copromoted adolor components clinical medical biomedical data regulatory safety bvt htc receptor agonist compounds commercial strategy integrated single advanced phase ii obesity inlicensed management organisation new product development npd biovitrum biovitrum retains exclusive six crossfunctional therapeutic area strategy teams commercialisation rights five nordic countries covering one following groups diseases glaxosmithkline exclusive rights elsewhere awd backup compounds cardiovascular urogenital metabolic diseases advanced phase ii intranasal delivery infectious diseases including ddw allergic rhinitis phase inhaled asthma copd neurology gastrointestinal diseases inlicensed elbion ag oncology musculoskeletal diseases inflammation preclinical development programme ppargamma psychiatry modulators advanced bay respiratory development osteoporosis inlicensed bayer ag bayer retains right claim certain compounds use fields cardiovascular disease oncology glaxosmithkline description business novel selective inhibitors sodiumdependent renal latestage projects terminated glucose transporter type sglt compounds preclinical development cardiac arrhythmia development oral antidiabetic agents inlicensed hypertension phase ii oncedaily formulation excluding japan china korea taiwan kissei augmentin oral formulation analogue parathyroid hormone preclinical development treatment osteoporosis vaccines rd inlicensed unigene laboratories inc part pharmaceuticals sector worldwide vaccines rd novel medicines containing longacting beta agonists conducted glaxosmithklines centre rixensart belgium laba treatment respiratory diseases licenced together activities related vaccines including clinical theravance inc phase clinical studies already development regulatory scaling production packaging started support functions research scientists employed cellular chemokine receptor ccr antagonist currently devoted discovering new vaccines developing development treatment hiv infection well costeffective convenient combination products prevent backup followup compounds licenced ono infections cause serious medical problems worldwide glaxosmithkline plans initiate phase clinical studies discovery work new vaccines performed potential usa first half candidate vaccines expressed yeast bacteria mammalian cells purified high level followed strategic alliance formed nobex corporation formulation vaccine involves mixing antigens development commercialisation orally administered insulin selected adjuvants stimulate good immune response products first product developed collaboratively humans next step evaluate safety efficacy nin novel modified oral insulin phase candidate vaccine invivo models preclinical proof type diabetes concept established next stage test alliance also formed exelixis inc development candidate vaccine clinical trials healthy individuals evaluate exelixis small molecule compounds using genetodrug safety effective vaccine inducing immune discovery technology platform delivered phase ii response protect body disease encountered later full development exclusive global commercialisation natural setting largescale field trials healthy individuals follow manufacturing rights exelixis retains copromotion rights north establish safety efficacy cross section population america results obtained clinical trials development quality production process facilities combined existing collaborative agreement tanabe seiyaku co ltd regulatory file submitted authorities various extended facilitate acceleration candidate selection countries group intends launch vaccine tanabe glaxosmithkline hits screening addition glaxosmithkline already entered number animals research agreements third parties codevelop comarket ethical regulatory scientific reasons research using animals certain compounds arrangements range milestone remains vital part research development new payments third parties acquire rights intellectual medicines vaccines animals used property joint ventures develop commercialise specified alternative available glaxosmithkline constantly aims compounds many agreements group reduce numbers used group strives exceed industry obligations make payments future specified milestones standards care welfare animals uses laboratory achieved financial commitments summarised animals usually bred specifically research well cared note financial statements commitments throughout lives qualified trained staff animals used research unnecessary pain suffering discontinuations isscrupulously avoided glaxosmithkline actively engaged research development carries risk failure research develop validate experimental methods commensurate extension scientific knowledge provide better alternatives use animals compound effects lead compounds research identified possess positive activity validated target prove safe enough introduce humans feasible glaxosmithkline acknowledges use animals research manufacture commercial scale glaxosmithkline rd purposes subject rightly commands high level public endeavours ensure far possible risks interest full glaxosmithkline public policyposition 'the care ameliorated extensive predictive testing early possible ethical use animals research ' isavailable website development process despite efforts ultimate test wwwgskcom secretariat product remains point administered large numbers patients disease research development consumer healthcare glaxosmithkline korean company lg chem principal centres consumer healthcare rd uk investments lgci reviewed status joint development usa focus rd identification programme quinolone antibiotic factive gemifloxacin rapid development novel products bring benefits result companies agreed factives value could consumers otc oral care nutritional healthcare better realised within lgcis portfolio lgci taken full markets consumer healthcare liaises closely pharmaceuticals worldwide responsibility future commercialisation maximise groups assets prescription products product including regulatory activities following transition also find application otc marketplace perioddescription businessglaxosmithkline operating resources intellectual property paxilseroxat patent protecting commercial form paxilseroxatis due expire major markets glaxosmithkline regards intellectual property key business glaxosmithkline initiated patent infringement litigation asset effective legal protection intellectual property usa europe several markets number critical ensuring effective return investment rd generic manufacturers attempting launch intellectual property protected patents trade marks versions product prior patent expiry registered designs copyrights domain name registrations patent trade mark rights regarded particularly valuable retrovirthere patents active ingredient zidovudine patents covering pharmaceutical formulations containing patents zidovudine medical use due expire glaxosmithklines policy obtain patent protection usa europe significant products discovered developed rd seretideadvairthe patents specific combination active activities patent protection new active ingredients available ingredients salmeterol fluticasone propionate due significant markets protection also obtained new expire usa bin europe patent pharmaceutical formulations manufacturing processes challenge made combination patent uk new medical uses special devices administering products serevent patents active ingredient salmeterol xinafoate patent position respect significant products due expire bin europe b france follows c italy usa augmentinin usa patents key active ingredient valtrex patents active ingredient valaciclovir potassium clavulanate extending held invalid due expire usa bin europe decisions federal court decisions appeal markets patents potassium wellbutrin sr andzybanpatents basic active ingredient clavulanate expired except italy c expired various formulation patents protect currently marketed srsustained release formulations latest avandia avandametthe basic patent active ingredient due expire usa patents rosiglitazone products due expire legal challenge uscourts europe regulatory data usa europe patents commercial form exclusivity provides protection least active ingredient rosiglitazone maleate due expire countries usa bin europe ziagen patents active ingredient abacavir due avodart patents active ingredient dutasteride expire usa bin europe normal expiry usa europe requests extension term patents pending expected zofran patents active ingredient ondansetron extend terms patents usa due expire usa bin europe bin europe c italy patents use treating emesis expire glaxosmithkline initiated legal action patents combivirthe patents specific combination lamivudine generic manufacturers usa zidovudine due expire usa bin europe trade marks coreg glaxosmithkline exclusive licensee us patent glaxosmithklines pharmaceutical products protected active ingredient carvedilol due expire registered trade marks major markets general mark used product market around world epivirthe patents active ingredient lamivudine due may local variations example usa trade mark expire usa bin europe paxilis used instead seroxatand advairis used instead seretide flixotidefloventand flixonaseflonasein usa patent active ingredient fluticasone propionate expires trade mark protection may generally extended long protection expected extended virtue paediatric trade mark used renewing necessary exclusivity may european countries protection glaxosmithklines trade marks pharmaceutical products due expire generally assume increasing importance patent product expired particular country generic imigranimitrex patents active ingredient sumatriptan versions product become available due expire usa bin europe c italy consumer healthcare business trade marks particularly important business brand orientated many lamictal patents active ingredient lamotrigine products patent protection due expire usa virtue paediatric exclusivity bin europe glaxosmithkline initiated glaxosmithkline routinely engaged legal disputes defence legal action usa generic manufacturer intellectual property rights many products see note attempting launch version product prior financial statements legal proceedings patent expiry levitrad glaxosmithkline copromotion rights us including extension term patent active ingredient vardenafil due b including extension term supplementary protection certificates expire usa c including extension term national supplementary protection certificate notified following recent change italian law subject legal challenges registered trademark bayer ag glaxosmithkline description business information technology access information regulatory agencies clinical opinion leaders healthcare professionals patients public information technology plays three strategic roles enhanced number markets steps taken glaxosmithkline reduce reliance paper based processes clinical trials supporting key business processes local regional registration new medicines use wireless handheld functional global levels technologies well internet enabling transformation extension key business activities collaborating assessing information facilitating collaboration access information importance glaxosmithkline internet internal global basis intranet continues grow internal websites allow information shared across group global basis supported addition computer infrastructure hardware software search engines analogous used externally internet organisation responsible voice video technologies ability provide shared access information enabled monitoring business technology trends could growing use virtual teams work collaboratively spanning impact glaxosmithkline preparing group risks multiple geographies time zones glaxosmithkline associated modern information technology adopted strategy enables employees choose integrating business systems two legacy companies receive information need remained top priority achieved glaxosmithkline project teams departments using avoiding significant disruption critical business systems computers collaborate effectively standard collaboration groups function strong focus improving business product suite deployed across group included processes adopted new rapid cost effective methods new specialist tool permits information shared external colleagues securely quickly enhancing business performance part overall internet technologies initiative significant virtually glaxosmithklines major business processes rely heavily savings achieved example via global learning use information technology major programmes management information exchanged electronically broad capture source key information electronic form make array suppliers customers partners protection available wherever required unauthorised access information assets growing risks improving quality potential value molecules posed computer viruses major issue addressed move discovery development key aim rd rigorous security management processes developed web based tools provide scientists telephone video conferences familiar aspect information need candidate medicines way early business life complemented computerbased phase rd teams draw shortlists molecules collaborative working screensharing tools help teams consideration possible treatments specific diseases faster respond practical challenges posed operating global confidence qualities organisation enabling glaxosmithklines knowledge workers shortlist areas rd playing important role productive key goal standard desktop highthroughput biology laboratory automation imaging adopted globally assist supporting employees use electronic data capture document knowledge clinical data software efficiently management work continued extend manufacturing enterprise glaxosmithkline people resources planning solution ensure compliant glaxosmithkline people fundamental success systems common processes place standard transactions business skills intellect key components middleware used enable efficient movement successful implementation sound business strategy across supply chain whilst time allowing human capital maximises potential groups independent optimisation commercial units regional scientific commercial financial assets outcome effective functional level well manufacturing human resources policy glaxosmithklinessolid reputation ability consolidate critical operations reflects growing international employer choice availability reliability global data networks employees achieve group initiated candidate care us sales representatives benefiting ability commitment seeking acquiring best employment connect systems via virtual private network away candidates reflect diversity background experience office perspective contribute success glaxosmithkline transforming extending business activities insights gained genomics proteomics transforming performance reward way disease targets identified validated importance people must translate employment information obtained variety external sources needs practices demonstrate value individual integrated internally generated information rapid compensation benefit packages glaxosmithklines total flexible manner relies heavily information technology reward aim competitive innovative either global support analysis databases also requires significant local orientation depending best drives business amounts processing power taking full advantage advances performance rewards individual contribution computer technology new technological approaches grid computing whereby computers linked use processing power fully investigateddescription businessglaxosmithkline compensation philosophy programme development comprehensive leadership development opportunities available underscore glaxosmithklines commitment performance managers levels opportunities targeted help culture performance based pay base variable share leaders meet challenges face global organisation awards share options performance development planning ensure leadership motivates enables teams evaluation contribute retention key talent superior individuals best work development opportunities performance accomplishment business targets innovative based peer interaction idea exchange contribute strategy deployment commitment flexible working flexitime teleconferencing remote working flexible work schedules human resources services information systems recognises employees work best environment helps glaxosmithklines human resource delivery strategy designed integrate work personal lives make technology human resources services information delivered low cost highly effective communication involvement channels make easy job candidates employees extensive programme open twoway communications retirees access information employment compensation stimulates employee engagement glaxosmithklines strategy benefits policies programmes include intuitive daytoday operations includes publication regular personalised webbased tools available employees many summary reports corporate executive team meetings locations chief executive officers home featuring presentations qa area groupwide magazine town hall meetings video property plant equipment conferences satellite broadcast involving sites countries watched employee audience glaxosmithkline operating establishments around live video streaming video demand options countries geographical spread groups activities developed additional means ensuring employees indicated note financial statements principal group access senior levels management companies glaxosmithkline conducts research development powerful tools building culture driving alignment across sites manufactures product common goals sites countries refer research development pharmaceuticals manufacture supply share ownership schemes encourage participation owners business increasing awareness short long term business objectives global local employee opinion surveys allow glaxosmithkline invested billion property employees opportunity express views perspectives acarrying value financial statements almost billion important group issues billion carrying value invested plant equipment assets construction glaxosmithkline diversity invested billion new andrenewal property plant glaxosmithkline diversity strategy focuses creating equipment mainly related large number projects inclusive work environment approach aims enhance improvement expansion facilities various worldwide employee innovation productivity valuing drawing sites property mainly heldfreehold new investment financed differing knowledge perspectives experiences styles group liquid resources st december group resident global community corporate executive team capital contractual commitments future expenditure leads diversity initiative key objective create million operating lease commitments implement diversity strategies measurably improve employee million attraction development retention tailored initiatives glaxosmithklines business sciencebased technologyintensive progress embed inclusive behaviours glaxosmithklines highly regulated governmental authorities allocates culture practices significant financial resources renewal maintenance glaxosmithkline committed employment policies free property plant equipment minimise risks interruption discrimination potential existing staff grounds production achieve compliance regulatory age race ethnic national origin gender sexual orientation standards research development manufacture faith disability active pharmaceutical ingredients require use ofchemicals hazardous materials glaxosmithkline observes stringent particular glaxosmithkline committed offering people procedures uses specialist skills manage environmental risks disabilities access full range recruitment career activities environmental issues sometimes dating opportunities every effort made retain support staff operations modified discontinued referenced become disabled working group responsibility environment health safety note financial statements legal proceedings talent management leadership development glaxosmithkline believes facilities adequate development planning key element performance planning current needs integration glaxo wellcome smithkline employees year reviews conducted beecham operations involved series announcements business function ensure diverse talent pool fully rationalisation potential disposal number sites developed meet future business needs successors properties considered changes identified key positions glaxosmithkline description business business community corporate social responsibility objectives targets objectives focused progressing toward full year glaxosmithkline produced separate report implementation ehs management systems systems social environmental issues covers issues meant ensure ongoing compliance legislation primary concern stakeholders include medicines regulations well internal standards sites analysed well developing world community investment rd environment programmes met requirements ehs standards health safety metrics environmental developed plans achieve requirements performance reported many years currently met full assistance corporate ehsgroup group developed indicators issues enable provided form information materials intranet system show progress addressing report available support ehs programmes awards programme secretariat website wwwgskcom encourage innovative solutions responsibility environment health safety targets ehs improvements set accomplished five years health safety target environment health safety ehsis key issue group reduction lost time injury illness rate per cent per year high priority responsibility ehs highest environmental targets include reductions energy usage level corporate group reporting general counsel associated greenhouse gas emissions reductions waste overall responsibility providing governance services wastewater disposed increase waste recycled ehs issues within operations line managers responsible ehs supported ehs medical performance improvement measures professionals glaxosmithkline measures impact health safety people work sites impact environment environment health safety management measure impact people lost time injury illness glaxosmithkline takes systematic approach managing ehs rate number injuries illnesses serious enough risks impacts framework information programmes result lost time per hours worked impacts air based set universal ehsstandards guides management water land measured metric tonnes material emitted issues throughout organisation waste disposed impact natural resources measured cubic metres water used gigajoules energy consumed environment health safety audits part governance responsibility glaxosmithkline conducts glaxosmithkline selects measures performance improvement ehs audits sites contract manufacturers key suppliers based risk risks determined part evaluation audit protocols developed introduced impacts impacts considered potential derived ehs standards new scoring system tested adverse impact people environment business year fully implemented continuity business reputation measures selected similar reported companies pilot process begun global manufacturing supply recommended global reporting initiative longterm investigate obtaining group wide certification multistakeholder international undertaking develop international standards ehs involves review third disseminate globally applicable sustainability reporting guidelines party registrar glaxosmithklines ehs standards auditing procedures completion number certification audits product stewardship group sites aim registrar gain confidence glaxosmithkline global standard product stewardship corporate auditing process well performance establishes requirements responsible ethical representative sites international standards proceed management ehs aspects products throughout full certification based sample sites remaining lifecycles product stewardship provides systematic way sites subject audits third party registrar part identify product process risks early may obtaining certification mitigated managed integrating product stewardship sites audited seven followup reviews business activities protects people environment enhances performed part continuous improvement process compliance local regulatory requirements avoids progress monitored actions arising issues raised interruption product supply audits web based tool assist process developed launched environmental sustainability concept sustainable development central groups part commitment corporate social responsibility environmental programmes work started towards eventual proactive management glaxosmithkline manufacturing environmental sustainability mitigating environmental impacts supply base key contract manufacturers looking ways improve production efficiency use suppliers also assessed process evaluated renewable raw materials overall balance management ehs risks impacts based groups ehs consumption resources generation waste requirements contract manufacturers good performance investigated future group standard sustainable identified recommendations made improvements development defines approach discovery needed manufacturing sales environmental sustainability starts rd part support rd toolkit developed assist selection green chemistries processesdescription businessglaxosmithkline access healthcare developing world evidence uncovered companys arvs sold africa notforprofit prices access healthcare developing countries presents unique illegally reimported european union sale challenge global community problem rooted higher price victims trade hivaids patients poverty demands significant mobilisation resources africa beneficiaries illegal importers unprecedented sense urgency new spirit partnership diversion threatens glaxosmithklines ability provide preferential must tackled shared responsibility sectors global prices developing world offer notforprofit prices society group mandate expertise requires sustainable framework combining groups resources address underlying problems exist however commitment preferential pricing commitments others glaxosmithkline playing vital role three key areas put place ways prevent product diversion avoid makes innovative responsible sustainable price referencing preferentially priced medicines contributions improving healthcare developing world glaxosmithkline taken steps address problem regulatory perspective able supply countries investing rd targets diseases particularly affect combivirin special trilingual access pack provide barrier developing world diversion however alone fully deter illegal traders preferential pricing antiretrovirals arvs antimalarials experts repackaging medicines stricter vaccines regulations enforcement counter illegal trade community investment activities partnerships required foster effective health care success partnership rd diseases developing world glaxosmithkline continued engage continued investment rd new drugs vaccines stakeholders working improving access healthcare diseases affect developing world essential longterm developing world group long history supporting improvement health people regions least community investment programmes wide range challenges development resistance partnerships support delivery better health education current treatments poor patient adherence complex underserved communities around world group also treatment regimens consulted worked governments developed group believes glaxosmithkline industrys developing world united nations ngos extensive portfolio products rd projects diseases investment community continue constructive developing world group undertaking rd dialogue organisations share aim trying improve prevention treatment three world health access healthcare developing world organisations priority diseases developing world glaxosmithkline making vital contribution improving hivaids tuberculosis malaria group currently healthcare developing world group continue rd projects programmes relevance developing efforts improving initiatives applying lessons learned world ten aimed producing vaccines looking opportunities example september medicines diseases disproportionally affect developing group reduced preferential prices arvs countries glaxosmithkline increasingly involved publicprivate per cent looks stakeholders also go partnerships enable wider range projects undertaken play part embracing partnership addition rd hivaids rd group dedicated showing political committing significant new diseases developing world created ensure funding critical improvement healthcare quality focus diseases projects prioritised primarily life across developing world achieved socioeconomic public health benefits rather commercial returns global community partnerships preferential pricing arrangements glaxosmithklines community investment totalled glaxosmithkline offered vaccines public health million million related groups programmes significant discounts years group patient assistance programmes usa equivalent sets single sustainable preferential price arvs per cent group profit tax many programmes antimalarials wide range customers least longterm commitments help bring sustainable developed countries subsaharan africa total change groups community investment activities focused countries glaxosmithkline committed contributing health health education include improvements sustainable manner preferential prices arvs antimalarials therefore set levels patient assistance programmes profit made cover direct costs supply patient assistance programmes provide access sustained long required notable progress glaxosmithklines medicines needy uspatients expanding access preferential pricing group prescription drug insurance arrangements covering worlds poorest patients received medicines groups patient assistance countries supply arvs preferential prices customers include programmes value million governments nongovernmental organisations ngos hospitals academic institutions private employers glaxosmithkline description business public health programmes glaxosmithkline gave unrestricted gift million imperial college london gift used support biomedical global alliance eliminate lymphatic filariasis research effort identify develop new treatments glaxosmithkline active involved member global disease alliance eliminate lymphatic filariasis lf unique partnership group announced renewed support science education includes ministries health endemic investing million four years inspire innovative scheme countries nongovernmental organisations community based postdocs research education partnership organisations academic institutions international organisations department education skills imperial college london private sector committed eliminating one specialist schools trust worlds disabling diseases education programmes included science glaxosmithkline committed much antiparasitic drug across world international educational programme albendazole required eliminate lf anticipated encouraging communication shared learning across different year life programme fourth year cultures sponsorship royal institution christmas programme million tablets worth million wholesale lectures provide opportunity young people learn acquisition cost donated countries numbers eminent scientists expand programme extends one billion people risk countries addition group gave grants support international impact awards uk recognise excellence global alliance eliminate lf totalling work voluntary community healthcare organisations across uk years ten winners received unrestricted award positive action hivaids donated royal national institute positive action groups international programme blind support new low vision unit london hiv education care community support marked tenth group also supporting shaw trusts pain management anniversary programme glaxosmithkline works project wales donation partnership networks people living hivaids group sponsored exhibition art making community groups international agencies ngos governments underdrawings renaissance paintings national gallery intensify community responses hivaids london supporting earthwatch institutes environmental positive action supported international awards primary school teachers three years donation programmes countries programmes included grant three years international center research women investigate underlying factors cause europe hivaidsrelated stigma discrimination develop programmes europe focused childrens health interventions minimise barriers limiting access healthcare total funding million supporting range longterm project conducted ethiopia tanzania zambia programmes including zippys friends programme run partnership children teach coping skills children following consultation conference community committee denmark lithuania positive action contributed support attendance participation community representatives barretstown gang ireland lenvol france resourced regions th international aids conference held provide therapeutic recreation seriously ill children across barcelona july europe received respectively working charity healthprom azerbaijan health african malaria partnership ministry glaxosmithkline invested part april glaxosmithkline launched african malaria four year programme benefit nearly refugees partnership fund three behavioural development programmes azerbaijan new safe childbirth initiative africa help combat disease kills million people every year north america november announced three programmes programmes north america focused improving access selected share grants totalling million three years better healthcare funding million allocated programmes benefit nearly two million people seven north america community partnerships team countries million donated regional community activities share awards foster healthy ageing across cultures regional community initiatives recognising communitybased programmes meet needs united kingdom older people racially ethnically culturally diverse glaxosmithkline made corporate contributions million backgrounds past four years glaxosmithklines grants uk charities projects science education million supported shareawards organisations medical research healthcare arts environment enabling improve healthcare access delivery funded addition glaxosmithkline companies uk provided international impact awards usa acknowledge reward million community investment purposes giving excellence nonprofit healthcare community greater combined total million support projects uk philadelphia area ten winners received almost total provided medical research unrestricted award foundation study infant deaths multiple sclerosis society action research primary immunodeficiency association stroke associationdescription businessglaxosmithkline glaxosmithkline gave unrestricted gifts million product donations university pennsylvania million duke university glaxosmithkline donates essential products humanitarian relief gifts used support discovery research efforts efforts donations made request governments identify develop new treatments disease major charitable organisations generally manufactured specifically meet requests ngos complete needs science summer librarybased science education assessment order product needed programme philadelphia area offering handson courses international communities ensures right product taught certified teachers glaxosmithkline grant reaches right person right time american association advancement science supports programme total value groups international product donations excluding lymphatic filariasis programme north carolina duke university medical center received million wholesale acquisition cost grant two years expand adult diabetes glaxosmithklines wholesale list price including discounts education programmes outreach minority underserved standard industry method valuing product donations populations contribution five years rescue missions employee involvement ministry set glaxosmithkline educational scholarship glaxosmithkline employees encouraged contribute endowment formerly homeless people local communities employee volunteering schemes support varies around world includes employee university north carolina chapel hill received time donations charities employees completed part overall million grant travelling science voluntary work matching gifts programme technology bus help improve science teaching encourage usa group matched employee gifts advance science careers underserved ethnic value million minority students glaxosmithkline also matched contributions employees international united way campaigns value million glaxosmithklines international community partnerships supplemented glaxosmithklines three year grant programmes addressed health education mobilisation united way southeastern pennsylvania provides providing partnership funding million programmes specific capacity building grants creates effective included healthcare delivery united ways member agencies support phase initiative personal hygiene glaxosmithklines investment volunteer excellence give sanitation education kenya uganda nicaragua provided grants qualifying usnonprofit organisations peru phase targets school children aims reduce based employee partner volunteer time give grants diarrhoearelated disease death totalled reflect employee volunteer hours part threeyear commitment fund hivaids clinic masoyi tribal area mpumalanga foundations south africa group operate single charitable foundation group extended rural nursing excellence programme corporate programmes numberof countrybased thailand sponsors female high school graduates rural foundations including areas complete fouryear nursing degrees glaxosmithkline glaxosmithkline france foundation supports programmes donated another train nurses improve hivaids prevention education training care ethiopia glaxosmithkline provided integrated primarily africa result people expected management childhood illnesses imci partnership access care support services end unicef goal contribute global reduction north carolina glaxosmithkline foundation endowed mortality morbidity children age five selffunding organisation operates separate entity pneumonia diarrhoea malaria measles malnutrition foundation publishes annual report available china glaxosmithkline funding supporting request uses asset base support math science development communitybased hivaids programme health education north carolina foundation made collaboration red cross movement china british red donations totalling million figure included cross australian red cross groups total community investment figure glaxosmithklineglaxosmithkline corporate governance section discusses glaxosmithklines management structures governance procedures board corporate executive team governance policy dialogue shareholders annual general meeting accountability audit internal control framework combined code glaxosmithkline corporate governance deh board donald mchenry aged nonexecutive director mr mchenry formerly non directors listed appointed rd may executive director smithkline beecham plc served since date distinguished professor practice diplomacy school bdfh foreign service georgetown university president sir christopher hogg aged irc group llc nonexecutive directorships include nonexecutive chairman sir christopher formerly cocacola company fleetboston financial corporation nonexecutive director smithkline beecham plc non international paper company att corporation executive chairman reuters group plc amember previously served ambassador us permanent supervisory board air liquide sa chairman royal representative united nations national theatre bdg dhj sir ian prosser aged sir roger hurn aged nonexecutive director sir ian formerly nonexecutive nonexecutive deputy chairman sir roger appointed director smithkline beecham plc executive chairman nonexecutive director glaxo wellcome plc deputy six continents plc world travel tourism council chairman nonexecutive director cazenove nonexecutive deputy chairman bp plc member group plc also chairman court governors cbi presidents committee henley college ad dr ronaldo schmitz aged dr jeanpierre garnier aged nonexecutive director dr schmitz formerly nonexecutive chief executive officer dr garnier appointed executive director glaxo wellcome plc nonexecutive director director smithkline beecham plc became chief legal general group plc member board directors executive officer april nonexecutive director rohm haas company cabot corporation united technologies corporation member board df trustees eisenhower exchange fellowships holds phd dr lucy shapiro aged pharmacology university louis pasteur france nonexecutive director dr shapiro formerly nonexecutive mba stanford university usa director smithkline beecham plc ludwig professor cancer research department developmental biology john coombe aged director beckman center molecular genetic chief financial officer mr coombe formerly executive medicine stanford university school medicine director glaxo wellcome plc responsible holds phd molecular biology albert einstein college finance investor relations member supervisory medicine board siemens ag uk accounting standards board code committee uk takeover panel membership board committees indicated following di paul allaire aged symbols nonexecutive director mr allaire formerly nonexecutive chairman member director smithkline beecham plc nonexecutive director audit b lucent technologies inc pricelinecom inc chairman corporate administration ford foundation transactions dr michle barzachdfj aged corporate social responsibility e f nonexecutive director dr barzach formerly nonexecutive financial results director glaxo wellcome plc member nominations g h international cooperation high council chairman board remuneration j equilibres et populations director board project hope international consultant health strategy formerly french details terms reference board committees may minister health family found bdj sir peter job aged directors nonexecutive director sir peter formerly nonexecutive director glaxo wellcome plc nonexecutive director sir richard sykes nonexecutive chairman sir peter walters schroders plc shell transport trading company plc tibco nonexecutive deputy chairman mr john young nonexecutive software inc instinet group inc multexcom inc also director retired board th may member supervisory boards deutsche bank agand bertelsmann ag dhj john mcarthur aged nonexecutive director mr mcarthur formerly nonexecutive director glaxo wellcome plc nonexecutive director bce inc bceemergis inc cabot corporation hcacorporation koc holdings rohm haas company telsat canada aes corporation also senior advisor president world bankcorporate governanceglaxosmithkline corporate executive team cet david stout president jp garnier pharmaceutical operations chief executive officer mr stout president uspharmaceuticals chief executive officer dr garnier link board appointed current position january responsible staff oversees operational aspects including establishing global pharmaceuticals business well global policies objectives initiatives directing longterm strategy vaccines business joined smithkline beecham head dr garnier formerly chief executive officer smithkline us sales marketing function became beecham joined group president pharmaceuticals north america rupert bondy chris viehbacher senior vice president general counsel president mr bondy responsible legal matters across group uspharmaceuticals together environmental health safety issues insurance responsible european pharmaceuticals operations security lawyer private practice joining end mr viehbacher took us pharmaceuticals smithkline beecham senior counsel operations january joined wellcome became director continental europe glaxo wellcome ford calhoun chief information officer andrew witty dr calhoun responsible information technology global president function enables key business processes across parts pharmaceuticals europe group doctoral postdoctoral training microbiology mr witty responsible groups pharmaceuticals genetics biomathematics computer science dr calhoun operations europe post took january joined smith kline french appointed cet mr witty joined glaxo glaxosmithkline senior vice president asia pacific john coombe current post chief financial officer head finance function mr coombe responsible tachi yamada activities financial reporting control tax treasury chairman investor relations finance systems internal audit real estate research development joined glaxo group financial controller dr yamada leads groups complex business drug discovery appointed group finance director development creating new medicines research joined smithkline beecham nonexecutive member dan phelan board became chairman rd pharmaceuticals senior vice president human resources mr phelan responsible benefits compensation recruitment jennie younger organisation development leadership development succession senior vice president planning human resource information systems employee corporate communications community partnerships health management joined smith kline french mrs younger responsible groups internal external appointed senior vice president director communications image partnerships communities human resources smithkline beecham world joined glaxo wellcome director investor relations howard pien president jack ziegler pharmaceuticals international president mr pien leads pharmaceutical operations outside usa consumer healthcare europe covering countries account mr ziegler head global consumer healthcare business per cent worlds population joined produces oral healthcare overthecounter medicines smithkline beecham appointed nutritional healthcare products joined smithkline beecham president pharmaceuticals appointed president consumer healthcare business david pulman president members global manufacturing supply dr palmer mr tyson left group st december appointed post december dr pulman pursue roles pharmaceutical industry mr ingram responsible global manufacturing supply chain retired st december continue work network joined glaxo prior recent parttime vice chairman pharmaceuticals acting posting responsible north american supply network special advisor group attend cet meetings manufacturing strategy logistics capacity glaxosmithkline corporate governance governance policy remuneration committee remuneration committee determines terms service board executive remuneration executive directors corporate executives directors listed board assistance external independent advisors board glaxosmithkline plc responsible groups evaluates makes recommendations board system corporate governance ultimately accountable remuneration nonexecutive directors group 's activities strategy financial performance committee consists entirely nonexecutive directors board comprises executive nonexecutive directors meets four times year otherwise necessary chairman role nonexecutive directors bring independent judgement ceo attend meetings except remuneration board deliberations decisions board considers considered senior vice president human resources nonexecutive directors independent also attends meeting sir christopher hogg appointed nonexecutive chairman following retirement sir richard sykes th may nominations committee dr jeanpierre garnier chief executive officer sir roger hurn nominations committee reviews structure size nonexecutive deputy chairman senior independent director composition board appointment corporate executives new board members makes recommendations board process board appropriate committee also review board meets least sixtimes year formal schedule managements succession plan ensure adequacy matters reserved decision otherwise delegates committee consists entirely nonexecutive directors meets specific responsibilities board committees described least year consider succession planning otherwise board works agreed agenda reviewing key necessary activities business receives papers presentations enable effectively board considers reviews corporate administration transactions committee work undertaken committees corporate administration transactions committee reviews approves matters connection administration board recognises may occasions one groups business certain corporate transactions directors feel necessary take independent committee consists directors corporate executive team legal andor financial advice agreed procedure members company secretary committee meets enable necessary company secretary responsible board available individual directors respect board procedures company corporate social responsibility committee secretary simon bicknell appointed may corporate social responsibility committee consists entirely barrister joined group secretary nonexecutive directors provides board level forum board committees regular review external issues potential serious impact upon groups business reputation committee board committees also responsible annual governance oversight groups board established following committees worldwide donations community support committee written terms reference meets formally twice year meetings consultations required audit committee audit committee reviews financial internal reporting corporate executive team process system internal control management risks executive management group responsibility external internal audit process committee also ceo senior managers form corporate proposes shareholders appointment external executive team cetwhich meets times per year auditors directly responsible remuneration members responsibilities listed 'corporate oversight work committee consists entirely executive team ' nonexecutive directors meets least four times year chief executive officer ceo chief financial officer cfo remuneration directors general counsel heads global internal audit information remuneration directors given corporate compliance representatives external auditors remuneration report pages attendance dialogue shareholders financial results committee financial results announced quarterly financial results committee reviews approves behalf board annual report form f annual review company reports formally shareholders twice year convening annual general meeting together halfyear fullyear results announced ceo cfo preliminary quarterly statements trading results give presentations final year end results institutional director member committee quorum investors analysts media london new york meeting three members quorate meeting must addition teleconferences release first include chairman chairman audit committee second third quarter results institutional investors analysts ceo cfo meets necessary media presentations may also accessed via wwwgskcom websitecorporate governanceglaxosmithkline annual general meeting takes place london formal remuneration report notification sent shareholders least one month advance remuneration report pages sets meeting business presentation made shareholders remuneration policies operated glaxosmithkline disclosures directors able attend available formally directors remuneration including required meeting informally afterwards questions details companies act schedule directors remuneration annual general meeting set section 'annual report regulations resolution proposed approve general meeting ' remuneration report ceo cfo maintain dialogue institutional auditors shareholders plans objectives programme following transfer pricewaterhousecoopers business regular meetings speak regularly external conferences limited liability partnership pricewaterhousecoopers llp presentations st january pricewaterhousecoopers resigned auditors groups investor relations department offices london company audit committee proposed board philadelphia acts focal point contact investors subsequently appointed pricewaterhousecoopers llp auditors throughout year company fill casual vacancy created resignation website wwwgskcom gives access current financial resolutions proposed reappoint pricewaterhousecoopers business information group llp auditors authorise audit committee determine remuneration share buyback programme october following completion billion share special business buyback programme announced company announced company seek renew authority plans new billion share buyback programme make donations eu political organisations incur programme covers purchases company shares eu political expenditure cancellation accordance authority given shareholders give directors authority disapply preemption rights annual general meetings allotting new shares certain circumstances maximum five per cent current issued share capital total billion spent may obtain authority purchase ordinary shares company authorised purchase maximum million maximum ten per cent current issued shares million shares may million shares share capital purchased cancellation details given note financial statements share capital share accountability audit internal control framework premium account exact amount timing future purchases determined company dependent board recognises responsibility present balanced market conditions factors understandable assessment groups position prospects structure accountability audit operated donations political organisations eupolitical glaxosmithkline follows expenditure annual general meetings may audit committee board shareholders authorised company make donations eu audit committee board responsibility reviewing political organisations incur eu political expenditure behalf board effectiveness system internal provisions political parties elections control management risks external internal audit referendums act year group process process monitoring compliance laws made donations noneu political organisations totalling regulations ethical codes practice internal control donations made eupolitical framework operation whole year organisations review continues operate date approval report annual general meeting audit committee receives regular reports areas significant annual general meeting held pm monday risk group related internal controls following th may queen elizabeth ii conference centre consideration reports committee reports annually broad sanctuary westminster london swp ee board effectiveness controls controls may mitigate eliminate risks addition areas directors groups business necessary take risks achieve sir christopher hogg dr garnier sir roger hurn mr coombe satisfactory return shareholders cases sir peter job mr mcarthur mr mchenry sir ian prosser dr schmitz companys objective apply expertise prudent dr shapiro retire offer reelection management rather elimination risk directors review board article company 's articles relates company subsidiaries extend association biographical details given material associated undertakings joint ventures 'the board ' investments glaxosmithkline corporate governance considered audit committee reports risk oversight compliance council rocc effectiveness controls board believes system rocc council senior executives authorised board internal controls provides reasonable although absolute oversee risk management internal control activities assurance material misstatement loss process group ensure business units designated accords guidance internal control issued managers manage significant risks membership comprises turnbull committee several members cet heads departments internal control risk management audit compliance audit committee also keeps review scope responsibilities roccs responsibilities also include ensuring results external audit independence objectivity regular analysis carried identify gaps internal external auditors committee reviewed nature controls providing reports cet audit committee extent nonaudit services external auditors provided addition separate reports provided individual internal ensure services significant call control audit compliance departments direct reporting line question auditors independence group audit committee provides mechanism bypassing effect st january committee preapprove executive management irregularities ever identified nonaudit services provided external auditors internal control framework relies rocc well corporate social responsibility committee board sector business unit risk management compliance reviews amongst matters external issues boards rmcbs help identify risks provide guidance potential serious impact upon groups business risk management compliance initiatives corporate reputation forms part internal control business unit levels rocc meets regularly review framework assess significant risks mitigation plans directed risks rocc developed corporate policy referred management structure provided business units framework risk board overall responsibility ensuring group management reporting risks management appropriately managed achieves strategic objectives agreed rocc mitigation planning identification manager board enable exercise responsibility board overall responsibility management given risk requires management information concerning business requirement rocc oversees many risks deemed including relevant information risk exposures internal controls significant glaxosmithkline rmcb oversees risks important external developments ceo reports board business function thus increasing number risks responsible management group assist actively managed across group rocc supported task ceo established cet committee corporate ethics compliance department board key functional activities management sectors represented cet corporate ethics compliance internal control framework includes central direction resource corporate ethics compliance department responsible allocation risk management key activities research supporting development implementation practices development manufacturing marketing sales legal facilitate employees compliance laws group policy human resources information systems financial practice thrust groups compliance effort due diligence part framework comprehensive planning system preventing detecting misconduct noncompliance annual budget approved board results law regulation promoting ethical behaviour compliance operating units reported monthly compared laws regulations corporate responsibility levels budget forecasts prepared regularly year extensive effective compliance systems compliance officers support financial controls procedures selfassessment exercises risk groups main operating sectors rd manufacturing mitigation activities reviewed groups internal auditors pharmaceuticals consumer healthcare corporate commercial financial responsibility however clearly compliance officer chairs rocc coordinates delegated local business units supported regional risk management activities among various compliance management structure principles designed provide audit functions across group provides summary reports environment central leadership coupled local operating roccs activities groups significant risks autonomy framework exercise accountability audit committee regular basis control within group areas potentially significant risks group also attaches importance clear principles areas potentially significant risk subject regular procedures designed achieve appropriate accountability reporting rocc include following control corporate policy risk management legal details risks affecting group may found note compliance mandates business units establish processes financial statements legal proceedings managing risks significant businesses group risk factors pages number risk areas specific standards meet exceed requirements applicable law established human resources specialist audit compliance groups example corporate legal requirements regarding discrimination harassment environment health safety worldwide regulatory integrity workforce including preemployment screening compliance assist dissemination implementation control use contractors temporary staff carry audits standards risks inherent group employeescorporate governanceglaxosmithkline research development information technology safety marketed products potentially significant risk protecting information technology assets increasing risk matter great concern glaxosmithkline conduct businesses extend networks systems data third parties laboratory clinical practices rd must dependency internet communications increases accordance applicable laws regulations well ensuring proper systems validation electronic records corporate standards may exceed requirements signatures key regulatory issues matters potential risk pharmaceutical products bring benefits risks group web systems accessible public must comply including potential side effects preclinical clinical trials legal regulatory requirements represent potential conducted development potential products risks potential risks include use personally identifiable determine safety efficacy products use humans information electronic record retention outsourced business following approval regulatory bodies spite efforts applications susceptibility viruses outside incursions drugs introduced marketplace unanticipated much groups business dependent upon electronic side effects may become evident group views use means disaster recovery also poses potential risk animals human tissue testing required develop new products another risk security environment safety threats security well employees property marketing sales environment present significant risks appropriate group operates globally complex legal regulatory safeguards precautions continually reviewed upgraded environments often vary among jurisdictions groups employee injury changes health due occupational conditions policy conduct marketing accordance applicable laws plant management potential impact plants regulations well corporate standards may environment potential risks group addresses exceed requirements failure observe applicable process sets targets provides guidance results marketing codes rules regarding government pricing management may achieved samples legal restrictions sale marketing practices may create significant risks commercial sectors combined code group failure comply may result legal proceedings company seeks uphold report compliance best practice corporate governance board reviewing legal intellectual property recommendations derek higgs review role product liability intellectual property antitrust government effectiveness nonexecutive directors sir robert smiths investigations related private litigation potential risks report audit committees combined code guidance glaxosmithkline group involved various legal intends ensure group continue comply administrative proceedings areas outcome listing rule requirement relation combined code proceedings predicted level certainty principles good governance code best practice also potential risk third parties may allege combined code issued uk listing authority marketing groups products infringe combined code comprises recommendations best practice intellectual property rights third parties terms control reporting functions board company combined code sets principles finance headings potential risks surrounding groups ability forecast future thus uncertainty ability meet financial directors targets set budgeting process group invests new directors remuneration products ventures based assumptions success relations shareholders efforts may prove inaccurate addition accountability audit prescribes detailed potential risks around groups treasury operations including provisions respect principle tax liabilities transfer pricing possibility trading losses specifically provisions require directors report counterparty fraud compliance evolving financial annual report disclosures legal reporting requirements constitute risks groups pension liabilities represent area potential directors remuneration risk discussion may found note financial directors responsibility financial statements statements employee costs going concern internal control manufacturing maintaining supply key glaxosmithkline products potentially compliance significant risk groups policy take reasonable measures directors report compliance combined code ensure uninterrupted supply product including manufacturing corporate governance requirements reports accordance applicable laws regulations well accordance provisions combined code set corporate standards may exceed requirements directors statements responsibility group takes efforts minimise single sourcing key products rationalising supply chain balancing manufacturing capacity present risks could potentially disrupt supply important products glaxosmithkline corporate governance sarbanesoxley act evaluation disclosure controls procedures within days prior date report group following number corporate accounting scandals carried evaluation supervision usa congress passed sarbanesoxley act sarbanes participation groups management including ceo oxley took effect th july sarbanesoxley cfo effectiveness design operation establishes new enhanced standards corporate accountability groups disclosure controls procedures inherent usa number provisions sarbanesoxley apply limitations effectiveness system disclosure controls glaxosmithkline company quoted new york procedures including possibility human error stock exchange form adss although companys circumvention overriding controls procedures corporate governance structure believed robust accordingly even effective disclosure controls procedures line best practice certain changes necessary ensure provide reasonable assurance achieving control compliance sarbanesoxley objectives based upon date groups recommended securities exchange commission evaluation ceoand cfo concluded disclosure sec glaxosmithkline established disclosure committee controls procedures effective material respects committee reports ceo cfo audit ensure information required disclosed reports committee chaired company secretary group files submits ussecurities exchange act members consist senior managers finance legal amended recorded processed summarised compliance public investor relations responsibility reported required considering materiality information timely basis determination disclosure treatment material related party transactions information committee also responsibility timely glaxosmithkline held per cent interest quest diagnostics filing reports sec formal review inc throughout holding reduced per cent contents glaxosmithklines annual report form f february following quests acquisition unilab corporation december glaxosmithkline quest ceocfo certifications amended terms global trials agreement sarbanesoxley introduced requirement ceo longterm contractual relationship quest cfo must complete formal certifications require primary provider clinical laboratory testing support confirmation groups clinical trials testing requirements worldwide reviewed annual report form f contains material misstatements omissions february mr ingram member cet financial statements financial information fairly purchased portion land part residential property presents material aspects financial condition results owned group adjacent mr ingrams operations cash flows period report residence total sale price based responsible establishing maintaining disclosure independent valuation land group subsequently controls procedures ensure material information determined retention residential property longer made known evaluated served business needs listed property sale effectiveness controls procedures within past independent valuation property rd june valued days results evaluation contained property offered sale report estate agent mr ingram made highest offer disclosed auditors audit committee property purchased group total significant deficiencies material weaknesses design consideration operation internal controls fraud regardless materiality involving persons significant role documents display internal controls glaxosmithkline documents referred annual report available indicated report whether inspection registered office company significant changes internal controls including corrective actions ceo cfo completed certifications filed sec usa part groups form fglaxosmithkline remuneration report remuneration report sets remuneration policies operated glaxosmithkline disclosures directors remuneration including required schedule companies act directors remuneration report regulations regulations accordance regulations following sections remuneration report subject audit annual remuneration nonexecutive directors share arrangements share options incentive plans pensions remaining sections subject audit remuneration introduction describes processes policies programmes effect directors remuneration sets remuneration earned directors glaxosmithkline together interests share options share incentive plans directors senior management sets interests directors glaxosmithkline shares glaxosmithkline plc contracts information also provided aggregate remuneration interests directors senior management glaxosmithkline glaxosmithkline remuneration report directors remuneration report report submitted shareholders board approval remuneration committee engaged deloitte touche annual general meeting referenced chairmans conduct additional independent review glaxosmithklines letter notice annual general meeting sent current remuneration policy including competitiveness shareholders advise committee shaping development future remuneration policy context glaxosmithklines corporate report describes background outlines groups base uk competitive needs business remuneration policy also gives required information global point view earnings directors senior management well directors interests shares glaxosmithkline background contracts glaxosmithkline one worlds leading researchbased references glaxosmithkline shares adss mean respectively pharmaceutical healthcare companies ordinary shares glaxosmithkline plc p american global outlook operations group employs depositary shares glaxosmithkline plc ads represents people countries per cent two glaxosmithkline shares sales generated outside uk usa largest pharmaceutical market world remuneration committee fundamental glaxosmithklines success profitability reviewing governance arrangements board decided per cent pharmaceutical sales usa year separate roles former remuneration chief executive officer based along another eight nominations rn committee order give separate individual thirteen person corporate executive team cet cet board focus functions accordingly remuneration considerable global experience half group committee terms reference revised take account worked outside home country latest governance standards assumed remuneration responsibilities previous rn committee october quality motivation management matter enormously members remuneration committee previously large complex company like glaxosmithkline rn committee times matters considerable corporate effort required recruit develop relating directors remuneration motivate talented people ensure managers considered mr allaire chairman dr barzach sir roger hurn level necessary breadth experience knowledge mr mcarthur mr mchenry mr young retirement leadership skills mr allaire succeeded mr young chairman rn committee pharmaceutical industry international highly specialised th may sir peter job appointed member characterised handful global companies compete committee th february chairman chief intensely talent business industrys top executive officer ceo invited attend committees managers scientists much demand widely known meetings except remuneration considered industry internationally corporately mobile board review current terms reference way managers scientists glaxosmithkline rewarded committees light higgs review role developed therefore industrycompetitive crucial effectiveness nonexecutive directors consequent changes retention effectiveness key market data regard combined code material changes remuneration remuneration senior management science based positions committees terms reference reported next years sales provided survey covers following group report global pharmaceutical companies competitor panel remit remuneration committee market cap remuneration committee considers regularly reviews constituents competitor panel location groups policy executive remuneration approval board determines individual remuneration packages abbott laboratories usa members corporate executive team astrazeneca uk aventis france policy set remuneration committee shapes bristolmyers squibb usa remuneration levels within group affecting eli lilly usa arrangements management population whole johnson johnson usa approximately individuals representing per cent merck usa employee population novartis switzerland towers perrin leading firm remuneration benefits pfizer usa consultants provides strategic advice glaxosmithkline general pharmacia usa remuneration benefits planning also provides market data roche switzerland towers perrin also advises remuneration committee scheringplough usa separate mandate regard remuneration senior wyeth usa executive management nonexecutive directors changes st december market capitalisation remuneration nonexecutive directors determined glaxosmithkline million compared average glaxosmithkline board advice market capitalisation group million remuneration committeeremuneration reportglaxosmithkline majority competitor panel us based companies relating total remuneration opportunity available operate globally companies competing comparable roles within competitor panel committees talent perceived shortfall glaxosmithklines policy provide opportunity earn total remuneration competitive position could lead loss key talent within range targeted median th percentile available among comparable roles glaxosmithklines remuneration policy set time opportunities crystallise individual team corporate merger endorsed shareholders made performance met strategic financial related business major contribution success merger objectives provide appropriate incentives exceptional performance committees policy provide market remuneration policy referenced opportunities beyond truly outstanding glaxosmithklines remuneration policy pay industry performance competitive levels heavy emphasis pay performance risk remuneration policy designed however committee aware current levels long term incentives deliver policy independent market data focus longterm sustained success demonstrates glaxosmithklines top management focus shareholder value strong emphasis share remuneration currently uncompetitive regard longterm plans incentives result total remuneration opportunity set high levels minimum achievement well industry median ensure integrated performance assessment throughout management team deliver concerted action towards success remuneration committee continue monitor closely provide opportunities earn globally competitive rewards quantum trend competitor panels awards performance delivered consider done best interests company shareholders remuneration committee believe individual team performance directly linked organisational success salary therefore critical glaxosmithklines future base salaries established reference median global job evaluation management level employees monitored relevant market cases competitor panel centrally ensure consistency interlinking performance vary based executives experience responsibility objectives top bottom management chain market value adjustments base salaries following appointment throughout group position based performance salaries typically reviewed annual basis glaxosmithklines executive remuneration consists four components performance bonus salary based formal review annual performance business performance bonus teams demanding financial targets detailed longterm incentives assessment individual accomplishments objectives benefits bonuses subject upper limits derived practice across competitor panel highest limits per cent relative importance fixed variable elements pay base salary target business performance brings total annual executive directors illustrated table cash remuneration line competitor panel annual cash remuneration rises target performance exceeded fixed performancerelated falls well level competitors targets shortterm incentives longterm incentives achieved executives may invest bonus glaxosmithkline shares case bonus enhanced ten per cent base pay performance bonus share option performance plan share plan shares must held minimum three years measures longterm incentives operating financial eps growth tsr vs ftse comprise share options participation performance measures percentage points greater retail eps growth share plan links reward shareholder value long performance prices index rpi percentage points medium term respectively individual objectives years greater rpi years performance conditions relevant measurement periods different plans designed provide competitive remuneration package whole focuses executive directors meeting groups business objectives components subject regular review make sure design plans reviewed ensure evolve meet remuneration remains competitive challenging following needs changing competitive environment terms sections provide greater detail performance conditions maintaining competitive position global market ensuring focus current business issues glaxosmithkline remuneration report share options benefits share options allow holder buy shares future date executive directors participate glaxosmithklines senior price determined reference open market price shares executive pension plans see details mr coombe time grant share options granted participates defined benefit plan uk dr garnier managers glaxosmithkline including executive cash balance plans usa benefits payable age directors vesting options granted executive directors executive directors participate legacy glaxo wellcome subject performance condition business performance smithkline beecham employee share plans either uk earnings per share growth excluding currency exceptional usa glaxosmithkline plans replaced items least nine percentage points us retirement savings plan dr garnier received increase uk retail prices index threeyear four per cent basic salary form glaxosmithkline measurement period respect future grants shares remuneration committee reviews performance conditions annually light market conditions however currently uk arrangements mr coombe member considers performance condition achieves balance sharesave plan contributes per month option expectations uk institutional investor guidelines buy shares end three year savings period pressures responding market practice within per cent discount market price ruling start competitor panel savings period mr coombe also member sharereward plan contributing per month buy shares number performance share plan shares bought month matched company participations performance share plan granted sharesave plan sharereward plan inland revenue approved approximately top executives group including plans open uk employees terms executive directors designating target number shares executive directors also receive following benefits cash participant vesting awards plan subject value shown two performance conditions apply three year measurement period provision retesting operates healthcare medical dental event performance conditions satisfied personal financial advice period life assurance contributions personalfamily travel first condition applies half award compares glaxosmithklines total shareholder return tsr period share ownership guidelines tsr companies uk ftse index align executive interest shareholders executives period glaxosmithkline delivers returns would rank required hold shares company chief executive officer top ftse based tsr performance required hold shares value four times basic salary shares part award vest executive directors required hold shares value th position ftse per cent shares vest three times basic salary members cet required glaxosmithkline ranked th position none hold shares value two times basic salary shares subject part award vest executives participate performance share plan th th positions vesting occur sliding scale one times salary purposes requirements shares second condition applies balance award adss held glaxosmithkline annual investment plan requires glaxosmithkline business performance earnings per share smithkline beecham bonus deferral plans vested growth excluding currency exceptional items least deferred awards smithkline beecham midterm nine percentage points increase uk retail incentive plan included year end dr garniers total prices index threeyear performance period shareholding basis adss mr coombes condition met shares subject performance shares result directors exceeded share condition vest condition met none ownership guidelines shares subject part performance condition vest extent awards vest reported upon performance graph completion performance period new regulations covering directors remuneration require graph presented showing companys total shareholder combination earnings based measure one based return tsr tsr performance broad equity market shareholder return compared ftse index decided index following graph shows glaxosmithklines tsr time merger following consultation time performance ftse chosen number shareholders uk equity mandate requested principal index companys shares quoted performance measure tied ukequity index competitor panel set even performance conditions met vesting indicates glaxosmithklines relative performance peers performance share plan awards cet subject final approval remuneration committee consider whether final vesting consistent underlying financial performance groupremuneration reportglaxosmithkline performance graph remuneration committee believes current termination payments due executive directors contracts justified represent fair reasonable compensation event contracts terminated given market practice associated restrictions arising need protect intellectual property dr j p garnier dr garnier service agreement smithkline beecham corporation dated nd december agreement expires glaxosmithkline total return index ftse total return index st october last day month glaxosmithkline pharma peers return index dr garnier reaches th birthday dr garniers contract specifies notes compensation paid termination employment tsr graph starts beginning first accounting year dr garniers current basic salary us following formation glaxosmithkline uses base share increased us st april price st december calculations graph based spot dr garnier may terminate agreement giving calendar prices beginning end year required directors remuneration report regulations whereas glaxosmithklines months written notice following credited performance conditions performance share plan psp use average extra three years pension contributions treated prices period year therefore graph three years older actual age taken indication likely vesting awards granted psp smithkline beecham corporation may terminate agreement average price method selected psp smoothes volatility reduces impact particularly large temporary price giving calendar months notice termination smithkline movements either beginning end performance period beecham corporation cause dr garnier entitled receive within days lump sum representing salary past performance taken guide future performance bonus notice period bonus calculated basis target performance gives bonus payout executive directors terms conditions per cent basic salary following section sets date unexpired term addition first months notice period dr garnier executive directors contract details provisions entitled receive share entitlements stock share necessary enable shareholders estimate liability incentive plans available senior executives usa except company event early termination extent part period would fall beyond determining overall policy respect service contracts retirement date awarded one annual share committee aims balance costs associated early option grant performance share plan grant date termination provisions need protect glaxosmithklines termination notice intellectual property rights committee maintains close watch pension purposes provided pension benefits advisors trends contractual terms amongst treated way additional pension contributions companies competitor panel wider market place otherwise employment ended three years committed ensuring achieving balance actual termination date three years expiry service processes fair limiting far possible scope agreement event dr garniers employment continues rewarding failure committee considered recent expiry service agreement addition dr garnier guidance produced association british insurers spouse treated three years older national association pension funds uk take actual ages termination cause account alongside market practice reviewing expiry service agreement applicable purpose contractual terms calculating annuity rates pension based executive directors employed service contracts would also receive outplacement counselling financial employing company required give calendar months planning advice two years following termination notice termination executive directors required shall limited per year choose give calendar months notice life assurance cover provide benefit two times executive directors service contracts contain garden leave salary th birthday noncompetition nonsolicitation confidentiality clauses dr garnier continue receive benefits cash value remuneration committee currently believes one year notice period dr garniers agreement terminated contracts would best interest glaxosmithkline reason disability treated still employed regard offering globally competitive overall remuneration purposes pension benefits retirement date package securing maximum protection intellectual addition payment distribution benefit property rights dr garnier would subject excise tax interest penalties incurred dr garnier entitled receive additional cash payment aftertax position additional tax imposed glaxosmithkline remuneration report event retirement expiry service agreement addition mr coombe leaves employment incapacity event termination employment smithkline age pension already accrued becomes beecham corporation cause event payable date incapacity may augmented dr garnier elected retained director trustees pension plan amount would glaxosmithkline merged company result entitled employed full service change control glaxosmithkline provided event notice termination given resignation occurs within days first anniversary case redundancy mr coombe required mitigate loss change control share option grants vest earnings resulting thereafter immediately remain exercisable expiry option period dr garnier still employed smithkline event mr coombes early retirement result beecham corporation performance time conditions termination glaxosmithkline services unlimited shall deemed satisfied b final awards cause redundancy outstanding options granted performance share plan determined end glaxosmithkline share option plan must exercised within full performance period originally specified relevant months date grant outstanding options granted participation without proportionate reduction glaxo wellcome share option plans must exercised retirement termination resignation respect dr garniers within months cessation employment end participation smithkline beecham senior executive bonus option period earlier options investment plan provided agreement terminated three years old outstanding options less three years old cause deferred amount income gains must exercised within months date grant losses automatically distributed soon administratively case remuneration committee may use discretion practicable termination dr garnier resigns retires allow longer period exercise termination cause deferred amount case awards performance share plan distributed end minimum three year deferral period mr coombes employment contract terminated redundancy retirement employing company ceases member mr j coombe glaxosmithkline group remuneration committee mr coombe service agreement glaxo wellcome plc determine percentage award vest glaxosmithkline services unlimited dated th february plan rules end financial year agreement expires st march last cessation employment occurred ordinarily calculated day month mr coombe reaches th birthday reference performance period elapsed mr coombes current basic salary increased extent performance condition satisfied st april period employment ceases reason end awards performance period awards lapse mr coombe may terminate agreement giving calendar unless committee determines otherwise months written notice respect mr coombes participation glaxo wellcome glaxosmithkline services unlimited may terminate agreement long term incentive plan ltip special rules apply calendar months written notice without notice participants employment ends however awards made event mr coombes gross misconduct wilful neglect dishonesty mr coombe ltip vested completion bankruptcy conviction criminal offence affecting position measurement period senior executive mr coombes agreement specifies compensation cash entitlements paid event redundancy follows addition contractual provisions outlined event dr garnier mr coombes service agreements amount equal twice annual rate salary terminated employing company would entitled amount account bonus equal per cent special deferred bonus awarded member annual rate salary cet respect payable th february amount equal value two years benefit unless terminated cause prior date details circumstances mr coombes pension entitlement also bonus given augmented amount equal value pension case awards glaxosmithkline annual would accrued period months investment plan provided agreement terminated commencing date termination employment cause deferred amount income period consecutive months incapacity gains losses automatically distributed soon mr coombe becomes entitled disablement pension administratively practicable termination resign entitled amount equivalent amount would retire termination cause deferred received worked period months first amount distributed end minimum day absence less amounts actually received three year deferral period periodremuneration reportglaxosmithkline nonexecutive directors sir peter walters mr john young nonexecutive directors glaxosmithkline service sir peter walters retired deputy chairman contracts instead letters appointment company nonexecutive director mr young retired nonexecutive aims provide nonexecutive directors fees director effect th may sir peters competitive companies equivalent size complexity mr youngs letters appointment dated th june nonexecutive directors entitled compensation cases agreed serve company appointment terminated nonexecutive directors conclusion annual general meeting following third anniversary appointment enhance link directors shareholders cases could extended term set table glaxosmithkline requires nonexecutive three years mutual agreement sir peter received fees directors receive significant part fees form per annum together allocation ordinary shares allocated share account offers opportunity shares nonexecutive directors share arrangements invest part balance fees share account mr young received fees per annum together shares paid directors retirement allocation american depositary shares made board later date basis dividends reinvested nonexecutive directors share arrangements interim chairman deputy chairman chairmen sir roger hurn mr paul allaire dr michle barzach sir peter board committees receive higher fees job mr john mcarthur mr donald mchenry sir ian prosser dr ronaldo schmitz dr lucy shapiro terms conditions letters appointment directors sir richard sykes dated th june cases agreed sir richard sykes retired chairman nonexecutive serve company nonexecutive directors conclusion director th may sir richards letter appointment annual general meeting following third anniversary board dated th june agreed appointment cases could extended serve company nonexecutive director term three years mutual agreement fees payable conclusion annual general meeting following third share allocations nonexecutive directors share anniversary appointment could extended arrangements directors follows term three years mutual agreement sir richard received fees per annum together allocation shares nonexecutive directors nonexecutive annual shares allocated directors fees annually share arrangements sir roger hurn ordinary shares following retirement board recognition paul allaire adss services company board decided make michle barzach ordinary shares augmentation payment pension plan respect sir peter job ordinary shares sir richard also agreed period two years john mcarthur adss st june sir richard appointed senior advisor donald mchenry adss company salary per annum sir ian prosser ordinary shares ronaldo schmitz ordinary shares company agreed procure sir richard sykes pension lucy shapiro adss age calculated basis salary st december remained fulltime employment th birthday mr allaire succeeded mr young chairman rn committee th may fees increased sir christopher hogg per annum date mr mchenry succeeded sir christopher hoggs letter appointment board sir christopher hogg chairman corporate social dated th june agreed serve responsibility committee th february fees company nonexecutive director conclusion increased per annum date sir ian prosser annual general meeting following third anniversary succeeded sir christopher hogg chairman nominations appointment extended term three committee th february fees increased years mutual agreement per annum date sir christophers letter appointment amended st september record appointment nonexecutive directors senior management remuneration chairman effect th may becoming following tables set directors glaxosmithkline plc chairman sir christophers fees increased remuneration earned interest shares per annum plus allocation shares per annum glaxosmithkline plc interests share options incentive nonexecutive directors share arrangements plans pension benefits members corporate per annum plus allocation shares per annum executive team cet company secretary known senior management also participate remuneration plans executive directors aggregate remuneration interests directors senior management also provided glaxosmithkline remuneration report annual remuneration total annual total fees annual annual fees deferred annual salary benefits bonus remuneration salary benefits bonus remuneration footnote executive directors dr j p garnier ac mr j coombe bc total nonexecutive directors sir richard sykes de sir christopher hogg sir roger hurn sir peter walters e mr p allaire dr barzach f mr c bonham g sir peter job mr j h mcarthur f mr f mchenry sir ian prosser dr r schmitz dr l shapiro h mr j young e total total remuneration previous years dr garniers salary fees included glaxosmithklines match compensation deferred included within contributions money purchase schemes dr garniers salary fees restated representing glaxosmithklines match order provide consistent presentation b mr coombes bonus includes glaxosmithklines match deferred bonus addition bonus shown mr coombe received awarded respect second half executive director glaxo wellcome plc c bonus dr jpgarnier mr coombe includes special deferred bonus awarded members cet amount awarded equivalent salary st december notionally invested glaxosmithkline shares adss th february bonus paid th february amount equivalent value shares adss notionally acquired february plus dividends reinvested period st december value shares adss notionally acquired respect dr jpgarnier decrease per cent year includes dividends reinvested year shares notionally acquired respect mr coombe valued st december decrease per cent year includes dividends reinvested year addition sir richard sykes received relating appointment senior advisor st june sir richard received bonus awarded respect second half executive chairman glaxo wellcome plc e th may sir richard sykes sir peter walters mr young retired board following retirement received value shares adss awarded nonexecutive directors share arrangements equivalent smithkline beecham arrangements th may awarded shares adss total value date award indicated sir richard sykes sir peter walters mr young th may value shares adss paid sir richard sykes sir peter walters mr young change value attributable dividends reinvested change share price dates awards th may mr young elected receive value shares th may three equal annual instalments accordingly received f dr barzach received fees euro euro gskfrance healthcare consultancy provided included within fees salary mr mcarthur received fees director glaxo wellcome inc mr mcarthur longer receives fees shown emoluments restated fees salary accordance requirements schedule companies act directors remuneration report regulations schedule g mr bonham resigned nonexecutive director stmay mr bonham received respect value shares st may allocated nonexecutive directors share arrangements st may awarded shares valued date award st may shares worth change value attributable dividends reinvested change share price date award st may h dr shapiro member glaxosmithklines scientific advisory board received fees addition shown form adss directors received part remuneration currencies sterling average rates exchange year used none directors received expenses year requiring separate disclosure required schedule aremuneration reportglaxosmithkline nonexecutive directors share arrangements nonexecutive directors required receive part fees form shares adss detailed together value dates award may also elect receive part balance fees form shares adss shares allocated accounts transferred retirement also included directors interests total value holdings allocated elected allocated elected shares adss shares adss sir richard sykes sir christopher hogg sir roger hurn sir peter walters mr paallaire dr barzach mr dcbonham sir peter job mr jhmcarthur mr f mchenry sir ian prosser dr r schmitz dr l shapiro mr j young total value holdings st december represents value shares adss awarded prior years together value dividends reinvested upon retirement nonexecutive directors receive either shares adss cash amount equal value shares adss date retirement directors interests following beneficial interests directors company shown register maintained company accordance companies act shares adss rd marchst december st december rd marchst december st december footnote dr j p garnier mr j coombe ab sir christopher hogg sir roger hurn mr p allaire dr barzach sir peter job mr j h mcarthur mr f mchenry cd sir ian prosser dr r schmitz dr l shapiro one glaxosmithkline ads represents two glaxosmithkline shares includes shares purchased glaxosmithkline sharereward plan totalling shares st december shares rd march b includes nonbeneficial interest trusts hold shares st december nil shares rd march c addition interests shown mr mchenry interests deferred fees plan relating period mrmchenry director smithkline beckman priorto merger beecham group deferred fees indexed total return glaxosmithkline shares payable seven years following mr mchenrys retirement nonexecutive director glaxosmithkline total accumulated value deferred fees st december restated reflect merger fully provided equivalent glaxosmithkline adss includes shares adss received part fees described nonexecutive directors share arrangements dividends received shares adss converted shares adss st december also included directors interests interests abovementioned directors rdmarch reflect changes end financial year rdmarch glaxosmithkline remuneration report share options granted weighted average options adss grant price number dr j p garnier granted weighted average options shares grant price number mr jdcoombe sir richard sykes dr jpgarnier granted options adss granted rd december grant price mr jdcoombe granted options shares rd december grant price also granted options shares glaxosmithkline sharesave scheme st december grant price options outstanding st december earliest latest vesting lapse dates market price glaxosmithkline share year end given table vesting date lapse date weighted average grant price number earliest latest earliest latest dr jpgarnier market price year end market price year end mr jdcoombe market price year end market price year end options held sir richard sykes grant price market price glaxosmithkline share year end glaxosmithkline grants share options executive directors senior managers annual basis around november initial grant made following completion merger march measurement period options granted march commenced st january measurement period options granted november commenced st january respectively directors hold options various share option plans referred note financial statements employee share schemes none directors interest option companys shares following merger directors elected exchange outstanding options legacy share option plans options glaxosmithkline shares directors participants legacy schemes made election receive additional benefit cash sum equal ten per cent grant price original option additional benefit given new option exercised lapses provided exercise lapse second anniversary effective date merger case sir richard sykes cessation executive employment earlier highest lowest closing prices year ended st december glaxosmithkline shares respectively highest lowest prices glaxosmithkline adss year st december respectively market price glaxosmithkline share st december st december glaxosmithkline ads st december share price rd march per glaxosmithkline share per glaxosmithkline ads options exercised adss gain gain dr j p garnier options exercised shares gain gain mr jdcoombe sir richard sykes remuneration reportglaxosmithkline incentive plans granted adss market adss performance share plan adss number price dr j p garnier award award award granted shares market shares performance share plan shares number price mr j coombe award award award performance share plan psp mediumterm incentive scheme introduced psp replaces longterm incentive plan midterm incentive plan operated respectively glaxo wellcome smithkline beecham terms psp number shares actually vesting determined following end relevant three year measurement period dependent glaxosmithklines performance period described share awards granted annually november december measurement period commences following st january ends three years st december following completion merger initial grant made march measurement period awards commenced st january end st december shares exercised market average money price market price value shares award exercise exercise longterm incentive plan shares number mr j coombe longterm incentive plan ltip share award scheme operated glaxo wellcome plan closed new entrants upon completion merger grants made awards made mr coombe march february vested march february respectively completion measurement periods connection merger performance conditions respect grants made march february waived awards made ltip lapse exercised within months vesting shares ltip awarded atnominal cost recipient vested vested unvested participations unvested deferred participations dividends deferred participations vesting participations participations vested reinvested participations midterm incentive plan adss dr j p garnier midterm incentive plan mtip share award scheme operated smithkline beecham plan closed new entrants upon completion merger participations granted connection merger performance conditions respect grants made waived measurement period ended st december participations vested awarded dr garnier th october theads price ads price time vesting final award ads made receipt award may deferred director dr garnier deferred receipt full amount awarded deferred awards together additional adss subsequently received dividend reinvestment arenot included directors interests table since technically retained mtip paid average stock appreciation rights sars adss grant price dr l shapiro sars held dr l shapiro grant price market price glaxosmithkline ads year end dr shapiro member glaxosmithklines scientific advisory board sab dr shapiro member smithkline beechams sab completion merger glaxo wellcome along members sab received annual grants smithkline beecham sars general vested three years date grant expire years date grant grants sars sab members ceased sars entitle holder cash sum future date based share price growth date grant date exercise full provision made financial statements accrued gains sars date grant connection merger previously granted sars became immediately exercisable glaxosmithkline remuneration report pensions pension benefits accruing following directors defined benefit schemes accrued annual benefits transfer values individual directors retirement set schedule requires disclosure accrued benefit end year change accrued benefit year transfer value beginning end year change transfer value year listing rules require additional disclosure change accrued benefit net inflation transfer value change change change change accrued transfer value accrued accrued transfer transfer year benefit change benefit benefit value value transfer year net accrued year value inflation benefit dr j p garnier mr j coombe sir richard sykes change transfer value shown net contributions made individual dr garnier also member money purchase scheme contributions paid scheme followingsir richard sykes retirement board recognition services company board decided make augmentation payment pension plan sir richard director full year change accrued benefit revalued effects inflation transfer value change accrued benefit calculated date leaving sir richards transfer value st december calculated basis pensions payment includes additional benefits granted retirement transfer values calculated basis actuarial advice accordance actuarial guidance note gn transfer values represent present value future payments plans rather remuneration currently due individual meaningfully aggregated annual remuneration directors senior management us reporting purposes necessary provide information compensation interests directors senior management asagroup group purposes disclosure group defined directors members cet company secretary respect financial year total compensation paid members group periods served capacity aggregate increase accrued pension benefits aggregate payment defined contribution schemes members group granted options shares adss awarded shares adss performance share plan rdmarch thencurrent members group comprised persons owned shares adss constituting less one per cent issued share capital company group also held date options purchase shares adss shares adss awarded performance share plan shares legacy glaxo wellcome longterm incentive plan shares adss legacy smithkline beecham midterm incentive plan including shares adss vested deferred adss awarded legacy smithkline beecham stock appreciation rights holdings issued pursuant various executive share option plans described note financial statements employee share schemes directors interest contracts except described related party transactions end financial year director connected person material interest contract significance relation groups business group company see note financial statements related party transactions directors remuneration report approved board directors agreed behalf mr paul allaire chairman remuneration committee th march glaxosmithkline operating financial review prospects operating financial review prospects discusses operating financial performance group financial outlook financial resources group following headings financial trends ratios year results year st december compared year st december financial position resources st december outlook risk factors additionally accordance us requirements year results year st december compared year st december selected financial data ukus gaap results us accounting principles results year compared primarily results preceding year reference made also quarterly halfyearly trends within results exchange group multinational business operates many countriesand earns revenues incurs costs many currencies results group reported sterling therefore affected bymovements exchange rates sterling overseascurrencies group uses average exchange rates prevailing period translate results cash flows overseas group subsidiary associated undertakings joint ventures sterling period end rates translate net assets undertakings currencies influence translations usdollar euro japanese yen average sterling exchange rates stronger us dollar japanese yen four per cent seven per cent respectively weaker euro one per cent compared business performance constant exchange rates business performance primary performance measure used management presented excluding merger items integration restructuring costs disposal businesses management believes exclusion nonrecurring items provides better comparison business performance periods presented statutoryresults include nonrecurring items order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used todetermine results overseas companies sterling remained unchanged used previous year discussion review therefore terms cer unless otherwise stated glaxosmithkline operating financial review prospects financial trends ratios statutory results restated restated cer cer sales pharmaceuticals consumer healthcare total cost sales selling general administration research development trading profit profit taxation earnings basic earnings per share pence p p p merger restructuring disposal subsidiaries cost sales selling general administration research development trading profit profit taxation earnings business performance results sales cost sales selling general administration research development trading profit profit taxation adjusted earnings adjusted earnings per share pence p p p research development business performance pharmaceuticals consumer healthcare total business performance primary performance measure used management presented excluding merger items integration restructuring costs disposal businesses management believes exclusion nonrecurring items provides better comparison business performance periods presented accordingly information provided supplement included consolidated statement profit loss pages prepared accordance ukgaap statutory results include nonrecurring items frs deferred tax implemented group frs requires deferred tax accounted full provision basis rather partial provision basis earlier years change basis accounted prior year adjustment comparative information restated necessary interest net interest payable interest cover times times times interest cover calculated statutory profit interest divided net interest payable tax rate business performance statutory results borrowings net debt gearing gearing ratio calculated net debt percentage shareholders funds net debt minority interestsoperating financial review prospects glaxosmithkline year world economy world market pharmaceuticals worlds economy began upbeat fashion global pharmaceutical sales increased per cent expectation recent interest rate cuts sides billion atlantic would revive consumer confidence provide relief corporate sector still feeling effects september world market value growth geographic region bn total tragedy usa general optimism proved misplaced combination europe weaker anticipated economic growth corporate scandals germany bankruptcies profit warnings dividend cuts forced selling france equities soaring stock market volatility fears deflation uk conflict middle east took toll share prices across italy developed world plunged third year running japan strong start us economy cooled stimulus asia pacific interest rate cuts failed counterbalance negative factors latin america november federal reserve cut us interest rate middle east africa per cent reached lowest level years canada total european economy fared better countries experiencing little growth germany particularly badly affected suffering stagnant economy rise us market remained buoyant represents per cent unemployment per cent european central bank global prescription pharmaceutical market compared responded per cent cut interest rates per cent per cent decade ago december glaxosmithkline holds second position world pharmaceutical japanese stock market outperformed major stock market market share per cent behind pfizer markets first half fell ending market share per cent year low glaxosmithkline eight products worlds top products outlook may summarised uncertain whilst augmentin avandia flixotideimigran seretideadvair never four consecutive years declines majority seroxatpaxil wellbutrinand zofran western stock markets market commentators anticipating reasonable level economic growth world market value growth top five therapeutic classes bn total likely occur second half year sluggish cardiovascular start billion economic package designed boost us central nervous system economy announced president bush january alimentary tract metabolic hopefully accelerate however number risks antiinfectives bacterial timing economic recovery viral fungal excluding vaccines respiratory exchange currencies influence groups results us note data based months th september dollar euro japanese yen pharmaceutical sales euro us jpy jun total pharmaceutical sales million compared million increase eight per cent less one per cent overall growth came price increases growth sterling terms five per cent significantly impacted weakness us dollar currencies within groups portfolio sales new products launched major market within last five years accounted per cent total sales grew per cent million sales established franchise products amounted million representing per cent total sales grew six per cent compared last year sales older products less actively promoted million decline per cent representing per cent total sales pound hit highest level dollar twoandahalf years climbing euro gained global pharmaceutical sales fourth quarter grew per cent dollar first year sevenper cent twoper cent sterling terms reflecting us sales dollar fallen value euro investors weighed growth per cent million whereas europe sales impact possible war iraq tensions north korea growth weaker one per cent sales million fears us economy international sales flat million nuj ced nuj ced nuj ced nuj ced nuj ced nuj ced nuj ced glaxosmithkline operating financial review prospects us sales growth benefited quarter increases antivirals wholesaler stocks products normal operating hiv medicines grew across regions totalled billion levels year end review customer discount rebate sales per cent sales trizivir glaxosmithklines new triple provisions result underlying growth quarter excluding combination therapy grew per cent million items estimated management high single valtrexfor herpes continued benefit convenient digit range spite generic competition augmentin oncedaily dosing suppressive therapy achieved strong sales growth per cent worldwide per cent pharmaceutical sales therapeutic area usa october glaxosmithkline filed sndafor valtrex across groups portfolio products six major therapeutic areas seeking firstever indication reduce risk transmission experienced doubledigit percentage growth year including genital herpes december glaxosmithkline filed fast growing franchises cns billion per cent ndafor protease inhibitor treatment hiv respiratory billion per cent antivirals billion decline zoviraxsales reflected transfers newer valtrex per cent vaccines billion per cent generic competition central nervous system antibacterials sales seroxatpaxil glaxosmithklines leading product antibacterial sales declined per cent worldwide per cent depression anxiety disorders driver growth usa augmentinsussales per cent cns therapy area sales billion per cent globally year result generic competition began third per cent usa international sales paxilgrew quarter four generic versions augmentinhave introduced per cent million led continued strong growth usa following decision usdistrict court japan product launched two years ago eastern virginia held invalid glaxosmithklines patents launched april paxil crcontinues gain acceptance augmentinexpiring hearing due strong tolerability profile represents glaxosmithklines appeal courts decisions per cent new us prescriptions paxilin months scheduled th march us sales ceftindeclined per cent due generic competition began sales wellbutrin depression grew per cent first quarter million reflecting increased physician awareness products outstanding efficacy favourable side effect profile usa glaxosmithklines two new antibiotics augmentin es application approval oncedaily formulation children augmentin xrfor adults performing well wellbutrin xl submitted fda esformulation launched fourth quarter represents per cent branded generic augmentin glaxosmithklines medicine epilepsy lamictal continued paediatric prescriptions based recent weekly data xr grow across regions achieving sales million formulation launched october represents per cent per cent group filed sndafor lamictalseeking branded generic augmentinadult prescriptions firstever indication longterm management depressive episodes bipolar disorder january fda approved metabolic gastrointestinal use lamictalfor treatment partial seizures worldwide sales metabolic gastrointestinal category paediatric patients aged two years billion one per cent avandiafranchise avandiaand avandamet grew per cent year us respiratory sales per cent million glaxosmithkline continues global leader respiratory pharmaceuticals sales three key products avandamet combination avandiaand metformin hci seretideadvair flixotideflovent serevent amounting expanded avandiametabolic franchise us launch nearly billion per cent fourth quarter avandametfor treatment type diabetes first medicine targets insulin resistance sales seretideadvair glaxosmithklines second largest product decreases glucose production one convenient pill since grew per cent billion although contributed approval fda may avandiahas used declines sereventand flixotide constituent products advair four million patients worldwide us asthma market leader new prescriptions less two years market seretidealso continued perform zantacsales million per cent declines strongly europe per cent international markets markets per cent january glaxosmithkline received positive opinion european committee proprietary vaccines medicinal products cpmp use seretideas new sales vaccines grew per cent billion supported treatment chronic obstructive pulmonary disease copd hepatitis franchise per cent million group expects european marketing authorisation within next total sales europe growing per cent us sales grew months followed launches across europe first per cent launch twinrixand continued growth half december glaxosmithkline filed nda havrix driven new state mandates requiring hepatitis ariflofor copd vaccination school age children infanrixglaxosmithklines dtpa range combination vaccines grew eight per cent older respiratory products ventolinand becotidecontinued million priorix tritanrixgrew per cent per cent decline patients converted newer products respectively usa glaxosmithklines new pediarixvaccine launched january pediarixadds protection hepatitis b poliomyelitis infanrixcombination results six fewer injections infantsoperating financial review prospects glaxosmithkline pharmaceutical sales therapeutic area total usa europe international therapeutic area cer cer cer cer major products total growth growth growth growth cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antivirals hiv trizivir combivir epivir retrovir ziagen agenerase herpes valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic gastrointestinal avandia zantac vaccines hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total sales cer represents sales growth constant exchange rates analysis sales quarter given financial record pages glaxosmithkline operating financial review prospects cardiovascular urogenital europe coregsales grew per cent million benefiting europe region contributed per cent pharmaceutical sales throughout year new indication treatment although overall sales growth region two per cent severe heart failure good growth recorded several markets including spain central eastern europe government healthcare reforms november levitravardenafil new agent including pricing reimbursement restrictions adversely affected treatment erectile dysfunction received positive opinion sales italy seretide glaxosmithklines largest selling product european cpmp first launch europe planned europe reported notable growth france germany spain march fda issued approvable letter levitrain uk although partly offset expected declines launch expected usa levitrawas sereventand flixotide trizivir showed strong growth researched developed bayer agand copromoted major markets region decline sales herpes glaxosmithkline franchise mainly result generic competition forzovirax january glaxosmithkline launched avodartdutasteride patients switching newer valtrexproduct dhtinhibitor treatment symptomatic benign prostatic hyperplasia bph usa glaxosmithkline plans market international avodartin major european countries launches first four per cent sales growth international region reflected half also january cardiovascular renal mixture good growth middle east africa canada drugs advisory committee fda unanimously supported asia pacific decline seven per cent sales latin use coregin patients heart attack america principally poor economic conditions left ventricular dysfunction recommendation based mexico brazil addition mexico suffered data showed early longterm treatment patients realignment wholesaler stock levels coregcould reduce risk death per cent overall international growth driven seretide seroxatpaxil avandiaand vaccines partly offset declines zantac oncology emesis zovirax sales zofrangrew per cent million driven strong us performance per cent million asia pacific area grew due performance seretide vaccines strong growth number markets partly therapeutic areas offset lower growth three per cent largest market sales relafenfor arthritis fell reflecting generic competition australia reflecting reduced sales zyban zantac usa pharmaceutical sales geographic area regional analysis region cer major markets total growth usa usa usa reported per cent sales growth year europe business currently represents per cent total pharmaceutical france sales sales growth central nervous system products uk per cent driven wellbutrin reflecting increased italy prescribing primary care physicians psychiatrists paxil germany spain following launch crformulation april lamictal central indicated epilepsy recorded sales growth per cent eastern europe advairmaintained strong growth sales million europe driving overall respiratory sales growth per cent however international adversely affected sales constituent products flovent asia pacific serevent showed declinesflonase indicated japan treatment perennial rhinitis grew strongly per cent latin america middle east africa sales antivirals therapeutic area grew per cent led canada strong performance trizivir per cent partially drew sales constituent products valtrex per cent cer represents sales growth constant exchange rates sterling growth calculated sales avandiaincreased per cent benefiting figures given analysis sales quarter given financial record pages sales market within europe adjusted effects parallel launch avandamet november continued decline trade crossborder imports lowpriced markets zantacsales held metabolic gastrointestinal category market growth japan reflected strong growth paxiland growth per cent antibacterial sales declined augmentin flixotidefloventpartly offset decline older product started experience generic competition second half zantac government price reductions year cardiovascular franchise coreg sales increased million reflecting improved market share middle east africa area followed trends markets growth seretide avandia vaccines hiv vaccines grew per cent respiratory franchise per cent canada growth driven seretide paxil avandiaand antivirals partly offset lower sales antibacterialsoperating financial review prospects glaxosmithkline consumer healthcare sales cost sales cost sales reduced percentage sales result benefits cer arising merger manufacturing restructuring savings otc medicines movements stock provisions favourable regional mix analgesics dermatological selling general administration gastrointestinal selling general administration costs benefited cost savings respiratory tract arising merger integration implementation initiatives smoking control together produced reduction percentage points natural wellness support relative expenses expressed percentage sales oral care nutritional healthcare research development total consumer healthcare sales research development rd increased nine per cent reflecting increased clinical trial inlicensing activity reinvestment growth consumer healthcare sales two per cent merger synergies pharmaceuticals rd expenditure represented million due otc medicines sales increase per cent pharmaceutical sales year four per cent nutritional healthcare increase three per cent partly offset decline oral care sales two per cent trading profit business performance trading profit million otc medicines growth per cent stronger sales growth seven per cent smoking control sales growth driven performance demonstrating improved trading margin points nicodermniquitinnicabate usa nicodermgrew strongly per cent compared principally due despite competition private label launch competitor cost savings derived merger integration manufacturing patches niquitin lozenge commit launched usa initiatives november clinical studies show commitcan help smokers tried quit analgesics panadolrecorded good profit taxation business performance sales growth five per cent partly offset declines number brands abreva usa zoviraxin europe analysis discussion profit taxation relates treatment cold sores drove dermatological sales growth business performance five per cent gastrointestinal sales citrucel rose per cent offset declines tumsand tagamet operating incomeexpense oral care royalties income oral care sales grew marginally europe declined highly operating expense competitive us market overall oral care sales declined two per cent principally result reduced aquafresh sales although income equity investments increase sensodynesales partially offset disposals nutritional healthcare nutritional healthcare lucozade ribenareported strong operating incomeexpense includes litigation costs costs growth europe driven increased availability promotion associated product liability claims costs respect horlickssales declined primarily international markets product withdrawals equity investment writedowns due adverse stock market conditions royalty income product disposals equity trading profit business performance investment sales illustrate glaxosmithkline business performance operating expenses million year compared analysis trading profit subsequent discussion million income year year movement excludes merger items integration restructuring costs reflects higher provisions product liability disposal businesses management believes exclusion claims lower proceeds disposals equity nonrecurring items provides better comparison business investment sales performance periods presented accordingly information provided supplement contained consolidated profit disposal interest associate statement profit loss pages prepared disposals interest associates accordance ukgaap group sold million shares quest diagnostics inc realising gain million cer share profitslosses joint ventures associated sales undertakings cost sales share profits associates arises principally groups selling general holding inquest diagnostics inc administration research development trading profit glaxosmithkline operating financial review prospects taxation net interest payable restated interest payable business performance investment income merger restructuring disposal subsidiaries share interest payable associate net interest payable increased compared largely business performance taxation result higher average level net debt driven use cash charge taxation business performance profit fund groups share buyback programme benefit million represents effective tax rate per cent smaller number shares issue reflected earnings per share represents increase compared effective rate per cent restated implementation profit ordinary activities taxation frs deferred tax operating incomeexpense together disposal integrated nature groups worldwide operations involving part interest associate reduced profit significant investment research strategic manufacture million added million profit limited number locations consequential crossborder supply taking account contribution associates net interest routes numerous endmarkets gives rise complexity payable business performance profit tax million delay negotiations revenue authorities profits compared million increase per cent individual group companies liable tax disagreements revenue authorities intragroup merger items restructuring costs disposal businesses transactions particular price goods key items discussed transferred group companies different tax jurisdictions produce conflicting claims revenue authorities merger manufacturing restructuring profits fall taxed individual territories resolution glaxosmithkline made good progress merger issues continuing factoflife glaxosmithkline manufacturing restructuring plans remains track deliver forecast total annual merger manufacturing restructuring usa number years glaxosmithkline savings billion excluding benefits block significant open issues relating transfer pricing issues drug acquisition estimated cost achieving remains affect years present concern number around billion billion charged products although significant relates success st december zantac respect claims us internal revenue service irs substantially exceed groups estimation costs million incurred year respect merger taxation liabilities irs claims completely manufacturing restructuring tax relief million quantified continue subject discussions net charge million costs include us uk tax authorities competent authority provisions severance asset writedowns professional fees site closure double tax convention two countries block drug company inc within discussions wide variation views glaxosmithkline acquired block drug january costs us uk tax authorities exceptionally may incurred integrating business million unable reach agreement settle dispute event including redundancies asset writedowns site closures uk us tax authorities reaching agreement matter may resolved litigation disposal businesses glaxosmithkline uses best advice determining transfer profit disposal businesses million reflects pricing methodology seeking manage transfer pricing final settlements regarding merger related product disposals issues satisfactory conclusion basis external disposal healthcare services businesses professional advice continues believe made adequate provision liabilities likely arise open assessments trading profit statutory group implemented new financial reporting standard frs deferred tax requires deferred tax cer accounted full provision basis rather partial provision sales basis full year business performance tax cost sales charge increased million overall tax charge selling general million net deferred tax asset st december administration reduced million research development merger restructuring trading profit credit taxation merger restructuring items amounting million reflects estimated actual tax rate statutory results include merger items integration applicable transactions territories arise restructuring costs disposal subsidiaries delivered trading profit million sales millionoperating financial review prospects glaxosmithkline earnings legal disputes restated cer glaxosmithkline provides anticipated settlement costs earnings associated expenses arising asserted claims group basic earnings per share p p reasonable estimate may made likely outcome basic earnings per ads dispute companys directors taken legal advice established provisions taking account insurance adjusted earnings agreements regard relevant facts adjusted earnings per share p p circumstances matter accordance accounting adjusted earnings per ads requirements provisions made unasserted claims weighted average number claims reasonable estimate likely shares millions outcome yet made ultimate liability pending unasserted claims may vary amounts provided adjusted earnings adjusted earnings per share presented dependent upon outcome litigation proceedings order illustrate business performance investigations possible settlement negotiations primary measure used management adjusted earnings increased per cent adjusted earnings per share increased per cent intangible assets reflecting reduction weighted average number shares intangible assets acquired glaxosmithkline resulting groups share buyback programme interest third parties costs acquisition capitalised licences cost programme also impacts groups earnings compounds development amortised estimated actual rates exchange business performance eps increased useful lives exceeding years estimated useful lives eight per cent sterling terms compared per cent cer reviewed annually impairment reviews undertaken terms adverse currency impact eps five per cent events occur call question carrying values year reflected significant weakening us dollar relative assets brands acquired businesses capitalised compares three per cent adverse currency impact independently separable longterm sales difference principally arises different mix value group brands amortised estimated currencies profits compared sales useful lives exceeding years except end useful economic life foreseen brands taken together expenses taxation product amortised subject annual impairment reviews future divestments resulted eps pence compared events could cause values intangible assets pence diluted eps pence compared impaired would adverse effect future pence merger manufacturing restructuring results group costs lower result sterling based growth eps per cent significantly higher impairment fixed assets cer based growth business performance eps despite carrying values fixed assets subject depreciation overall negative impact currencies amortisation reviewed impairment indication values assets might impaired dividend impairment determined reference higher net board declared fourth interim dividend pence per realisable value value use measured reference share making total year pence per share discounted cash flows future events could cause assumptions compares dividend pence per share used impairment reviews change consequent adverse effect future results group critical accounting policies consolidated financial statements prepared accordance investment shares ukgenerally accepted accounting principles following glaxosmithkline invested shares employee accounting policies approved board described note share ownership trusts order meet obligations arising financial statements accounting policies management certain companys employee share option schemes required make estimates assumptions affect shares held cost less provision recognise shortfall amounts assets liabilities revenue expenses reported proceeds receivable employee exercise unless financial statements actual amounts results could differ management believes permanent impairment estimates following considered critical value relation period time related share accounting policies adopted options may exercised impairment would adverse effect results group accounting period sales gross sales reduced discounts allowances vary pensions postretirement benefits product arrangements buying groups arrangements costs providing pensions postretirement benefits purchasing organisations dependent upon submission charged profit loss account accordance claims time initial recognition sale ssap period benefit derived provision made time sale estimated discount employees services costs assessed accordance allowance payable amounts subject change dependent advice received independent actuaries basis upon amongst things types buying group product assumptions selected management disclosed note sales mix future events could cause assumptions financial statements employee costs note also gives discounts based change could affect future additional disclosures required frs retirement benefits results group selection different assumptions could affect future results group glaxosmithkline operating financial review prospects financial position resources financial position net debt group net debt st december comprised summarised reclassified presentation group balance sheet set cash liquid investments restated borrowings repayable within one year borrowings repayable one year goodwill intangible fixed assets net debt tangible fixed assets net debt increased million primarily due investments use cash fund purchase shares company working capital cancellation totalling million special cash debtors creditors contributions million groups pension funds provisions taxation pensions deferred taxation group continues account pension arrangements net operating assets accordance ssap transitional provisions frs shares disclosed pension assets liabilities group dividends payable st december show net deficit million net debt allowing deferred taxation million fourth net assets quarter special cash contributions million made reduce funding deficit shareholders funds minority interests company review position annually make contributions appropriate pension service costs higher financing net assets million taken account earnings guidance investments glaxosmithkline investments st december shareholders funds carrying value million million market summary movements equity shareholders funds set value st december million million investments include associates joint ventures mainly equity shares holding derives restated directly groups business including connection beginning year previously reported research collaboration access biotechnology developments prior year adjustment potential interest arising business divestment implementation frs shares beginning year restated st december esots held million profit year glaxosmithkline shares carrying value million dividends market value million future exercise share shares issued exercise share options options share awards valuation shortfall considered shares purchased cancelled represent permanent diminution value context exchange movements length future period related share options goodwill written back may exercised accordingly provision made uktax exchange movements unrealised gain equity investment debtors creditors end year net creditors remained line increase prepaid pension contributions offset increased accruals equity shareholders funds decreased million salesrelated rebates returns st december million st december decrease arises value shares purchased provisions cancelled exchange movements overseas net assets group carried provisions million st december exceeding retained profits respect estimated future liabilities million related pensions postretirement commitments contingent liabilities benefits employees provision made tax legal financial commitments summarised note financial disputes indemnified disposal liabilities costs statements commitments contingent liabilities manufacturing restructuring merger integration extent obligations respect short long term debt set balance sheet date actual constructive obligation note contingent liabilities note financial existed case merger integration manufacturing statements net debt restructuring majority remaining costs expected amounts provided pensions postretirement benefits recognised end restructuring integration plans legal environmental disputes set note financial statements provisions liabilities chargesoperating financial review prospectsglaxosmithkline contractual obligations commitments cash flow following table sets groups contractual obligations summary group cash flow set commitments fall due payment total yr yrs yrs yrs total operating cash flow loans dividends associates finance lease obligations net interest minority operating lease preference share dividends commitments tax payments intangible fixed assets free cash flow tangible fixed assets net capital expenditure commitments net cash operations total dividends shares business acquisitions intangible fixed asset commitments made licensing business disposals agreements principally elbion ag adolor sale less purchase equity investments corporation theravance inc unigene laboratories inc sale less purchase interest associates payments become due future milestones achieved purchase shares share options agreements relate compounds early use shares exercise share options stages development milestone payments continue shares issued exercise share options number years compounds move successfully purchase shares cancellation development process generally closer product redemption preference shares issued marketing approval greater possibility success subsidiary payments shown represent maximum would product divestments paid milestones achieved movements including exchange pension commitments provided note financial increase net debt statements employee costs net cash inflow total operating activities contingent liabilities million increase million following table sets contingent liabilities comprising discounted bills performance guarantees items arising merger restructuring items million net interest normal course business expected payments minority preference share dividends tax expire payments free cash flow representing cash flow discretionary spending amounted million increase total yr yrs yrs yrs million capital expenditure tangible intangible fixed assets guarantees amounted million million contingent liabilities disposals realised million million total total million million realised spent purchases less sales investments equity shares normal course business group provided various indemnification guarantees respect business disposals group purchases shares market cancellation legal disputes subsequently arisen amounted million million relates provision made reasonable estimate made new buyback programme likely outcome dispute included note shares glaxosmithkline plc purchased esots financial statements provisions liabilities charges satisfy future exercises options awards employee groups policy provide settlement costs share incentive schemes million atotal asserted claims environmental disputes reasonable million million received employees estimate may made prior point liability recorded exercise share options exercises satisfied shares previously legal environmental costs discussed risk factors purchased esots yielded million million pages exercises satisfied issue new shares yielded million million effect transfer pricing issues taxation inevitable global business glaxosmithkline group future cash flow significant open issues relating transfer pricing number group expects future operating cash flow years basis external professional advice provision sufficient fund operating debt service costs satisfy made liabilities likely arise open assessments normal levels capital expenditure meet obligations discussed note financial statements existing licensing agreements meet routine taxation commitments including tax dividends subject risk factors discussed pages glaxosmithkline operating financial review prospects subsequent years group expects cash liquidity outflows integrating operations glaxo wellcome group operates globally primarily subsidiary companies smithkline beecham unified glaxosmithkline business established markets group trades due well cash outflows continued implementation nature groups business patent protection many manufacturing restructuring plans ofthe products groups portfolio groups products compete largely product efficacy rather price selling october glaxosmithkline commenced new billion margins sufficient cover normal operating costs share buyback programme followed completion groups operating subsidiaries substantially cash generative billion buyback programme announced exact amount timing future purchases determined operating cash flow used fund investment research company dependent market conditions factors development new products well routine outflows period st january rd march capital expenditure tax dividends repayment maturing shares purchased cancelled cost debt group time time additional demands million finance share purchases acquisitions group may time time additional demands glaxosmithkline operates low levels net debt addition finance acquisitions group access tothe strong positive cash flow normal trading activities sources liquidity banks financial institutions additional liquidity readily available via itscommercial addition cash flow operations forsuch needs paperprogramme current backup facilities including committed lines credit support issuance billion commercial book value net assets decreased million paper programme billion stdecember million st december decrease million reflects purchase group also uncommitted euro medium term note cancellation shares share buyback programme programme billion million issue effect net assets exchange rate movements partly st december plans establish similar uncommitted offset retained profits million providing borrowing programme usa dividends treasury operations payment policies objective treasury activity manage posttax net costincome financial operations benefit group group companies responsible monitoring managing earnings corporate treasury operate profit centre working capital terms sales collections supplier payments reflect local commercial practice glaxosmithkline uses variety financial instruments including derivatives finance operations manage market risks uk company uk subsidiaries operations financial instruments comprise cash policies ensure suppliers paid time particular liquid resources borrowings spot foreign exchange contracts uk companies seek number derivative financial instruments used manage settle terms payment suppliers agreeing market risks treasury operations derivative instruments terms transaction principally comprising forward foreign currency contracts interest ensure suppliers made aware agreed terms rate currency swaps used swap borrowings liquid ofpayment assets currencies required group purposes abide terms payment manage exposure funding risks changes foreign policy includes arrangements accelerated payment exchange rates interest rates small suppliers glaxosmithkline balances use borrowings liquid assets regard cash flow operating activities payment performance thecurrencies earned tax cost intragroup st december average number days purchases distributions currencies business assets represented trade fixed asset creditors company denominated posttax cost borrowings compared wasnil days nil days respect company totheposttax return liquid assets uk subsidiaries aggregate days days liquid assets surplus immediate operating requirements treasury policies group companies invested managed centrally corporate treasury requirements group companies glaxosmithkline plc uk based business reporting sterling operating finance met whenever possible central paying dividends sterling profits resources role corporate treasury glaxosmithkline manage external borrowings mainly managed centrally corporate monitor groups external internal funding requirements treasury comprise portfolio long mediumterm financial risks support group corporate objectives instruments shortterm finance treasury activities governed policies procedures approved board monitored treasury management group glaxosmithkline hold issue derivative financial glaxosmithkline maintains treasury control systems procedures instruments trading purposes groups treasury policies monitor foreign exchange interest rate liquidity credit specifically prohibit activity transactions financial financial risks instruments undertaken manage risks arising underlying business activities speculationoperating financial review prospects glaxosmithkline funding maturity counterparty risk group uses limited number interest rate swaps group invests centrally managed liquid assets primarily redenominate external borrowings intothe interest rate coupon government bonds shortterm corporate debt instruments required group purposes duration swaps matches minimum shortterm credit rating ap standard duration theprincipal instruments interest rate derivative poors moodys investors services respectively group instruments accounted hedges relevant assets manages net borrowing requirement portfolio liabilities long mediumterm borrowings including bonds together group manages centrally shortterm cash surpluses shortterm finance us dollar commercial paper borrowing requirements subsidiary companies uses forward programme million per cent coupon bond contracts hedge future repayments back originating two us dollar denominated floating rate bonds totalling currency million issued european medium term note programme group also raised million floating rate debt sensitivity analysis considers sensitivity groups net debt private financing arrangement hypothetical changes market rates assumes variables remain constant based composition net debt groups mediumterm borrowings mature dates st december one percentage point basis points private financing matures increase decrease average interest rates would result longdated sterling bond matures private financing negligible change groups annual interest expense may redeemed glaxosmithkline time particular event accelerating event would equity risk management increase cost funding group group also equity investments classified current assets available sale outstanding million flexible auction market preferred group manages disposals meet overall business stock flex amps million auction rate preference requirements arise group regularly monitors value stock arps originally issued million flex equity investments enters hedges selectively amps may redeemed glaxosmithkline time approval board july remainder flex amps arps may redeemed glaxosmithkline time financial assets liabilities glaxosmithklines longterm debt rating aa standard analysis net debt given note financial poors aa moodys investors services agencies statements net debt analysis financial assets liabilities shortterm rating paper issued groups commercial carrying value fair value reconciliation net debt paper programme p respectively given innote financial statements financial instruments related disclosures together discussion derivative foreign exchange risk management financial instruments quantitative disclosures market riskin glaxosmithkline foreign currency transaction exposure arising accordance requirements financial reporting standard normal trade flows respect external intragroup group continues benefit strong positive cash flow trade hedged glaxosmithklines policy minimise group net debt would decreased significantly year exposure overseas operating subsidiaries transaction risk st december except groups purchase bymatching local currency income local currency costs shares market million forthispurpose intragroup trading transactions matched centrally intragroup payment terms managed reduce financial assets liabilities st december risk exceptional foreign currency cash flows hedged selectively representative treasury policies strategies management corporate treasury glaxosmithkline applied consistently year significant changes policies throughout year significant proportion group borrowings including commercial paper programme us dollars benefit esot share purchases shares purchased cancellation liquidity us dollar denominated capital markets certain esots make market purchases shares borrowings swapped currencies glaxosmithkline plc million shares held required group purposes group seeks denominate trusts satisfy future exercises options awards borrowings currencies principal overseas assets group share option award schemes proportion borrowings denominated swapped foreign currencies shares held trusts respect options rules match investments overseas group assets treated scheme require company satisfy exercises hedge relevant net assets market purchases rather issue new shares based composition net debt st december shares held trusts matched options granted per cent appreciation sterling major currencies would diminish dilutive effect new share issues shareholders ' result reduction groups net debt approximately capital earnings million per cent weakening sterling major currencies would result increase groups net debt annual general meeting shareholders renewed approximately million approval glaxosmithkline make market purchases shares september billion share repurchase interest rate risk management programme announced october completed glaxosmithklines policy interest rate risk management requires rd october glaxosmithkline announced share amount net borrowings fixed rates increases repurchase programme billion exact amount timing ratio forecast net interest payable trading profit future purchases depend market conditions factors glaxosmithkline purchased million shares cancellation total cost million glaxosmithkline operating financial review prospects outlook risk factors outlook generic drug manufacturers seeking market generic versions number groups important products including pharmaceutical sales growth existing products key driver paxiland wellbutrin prior expiration groups patents glaxosmithklines current business performance group plans may products future generic products launch new products line extensions next two competitive augmentinwere launched usa years significant impact groups sales earnings merger manufacturing restructuring savings efforts generic manufacturers may involve challenges estimated billion group track deliver total validity patent assertion alternative compounds annual merger manufacturing restructuring savings infringe groups patents group successful rd reinvestment least billion end maintaining exclusive rights market one major savings measured projected levels products particularly usa group highest expenditure forecast glaxo wellcome smithkline margins sales country patent protection beecham immediately prior merger period groups revenues margins would adversely affected see note financial statements legal glaxosmithkline engaged legal proceedings regarding validity proceedings discussion patentrelated proceedings infringement groups patents relating many group involved products particular relating augmentin paxilseroxat wellbutrin discussed risk factors countries group operates patent note financial statements legal proceedings protection may significantly weaker usa european union addition effort control public health result pending matters possible timing generic crises developing countries south africa brazil competition paxilin usa unclear consequently recently announced plans substantial reductions glaxosmithklines published earnings guidance remains scope patent protection pharmaceutical products previously stated guidance high single digit percentage particular countries could facilitate competition within growth business performance earnings per share constant markets generic manufacturers would otherwise exchange rates assuming generic competition paxilin unable introduce competing products number years usa generic launch paroxetine hydrochloride became loss patent protection likely affect adversely imminent glaxosmithkline would reassess guidance groups operating results group net debt billion low relative pharmaceutical product prices subject controls pressures market capitalisation positions take advantage many markets governments intervene directly setting opportunities might arise build business prices addition markets major purchasers risks uncertainties inherent business pharmaceutical products whether governmental agencies may affect future performance including expected earnings private healthcare providers economic power exert growth discussed risk factors substantial pressure prices group predict whether existing controls increase new controls introduced risk factors reduce groups margins affect adversely ability introduce new products profitably risks uncertainties relevant groups business factors listed group thinks could example usa group highest margins cause groups actual results differ materially expected sales country pricing pressures could significantly historical results factors besides listed could increase various proposals consideration reform also adversely affect group medicare federal state programmes control cost pharmaceuticals adopted medicare programme group operates highly competitive businesses provide outpatient pharmaceutical coverage pharmaceuticals business faces competition proprietary beneficiaries us government enormous purchasing products large international manufacturers producers power programme could demand discounts may generic pharmaceuticals significant product innovations technical implicitly create price controls prescription drugs additionally advances intensification price competition competitors number states proposed implemented various schemes could adversely affect groups operating results continued control prices senior citizens drug programmes consolidation pharmaceutical industry could adversely affect including importation countries bulk purchasing groups competitive position continued consolidation drugs growth number patients covered among groups customers may increase pricing pressures large managed care institutions usa would likely particular group faces intense competition increase medicare reform also increases pricing pressures manufacturers generic pharmaceutical products groups products trends may adversely affect major markets generic products often enter market upon groups revenues margins sales usa expiration patents data exclusivity periods groups group must comply broad range regulatory controls products introduction generic products typically leads testing approval manufacturing marketing many dramatic loss sales reduces groups revenues pharmaceutical consumer healthcare products margins proprietary products expiration dates countries including usa european union patents groups major products set regulatory controls become increasingly demanding increasing description business patents cost product development also time required reach market uncertainty successfully group expects trend continue extend countriesoperating financial review prospectsglaxosmithkline stricter regulatory controls also heighten risk withdrawal group eight products million regulators approval previously granted would reduce billion annual global sales among revenues result product recalls product liability products paxilseroxatand wellbutrin respect lawsuits addition cases group may voluntarily group currently defending intellectual property cease marketing product face declining sales based rights usa groups major concerns efficacy safety whether scientifically products become subject problem loss justified even absence regulatory action patent protection unexpected side effects regulatory proceedings publicity affecting doctor patient confidence continued development commercially viable new products pressure competing products new critical groups ability replace sales older products effective treatment introduced impact decline upon expiration exclusive rights increase overall groups financial results could significant sales developing new products costly lengthy uncertain process new product candidate fail stage group conducts substantial portion operations process one latestage product candidates could fail outside united kingdom fluctuations exchange rates receive regulatory approval new product candidates may appear sterling currencies especially us dollar promising development significant investment fail euro materially affect groups financial results reach market limited commercial success group increasingly dependent information technology result efficacy safety concerns inability obtain necessary systems including internet based systems internal regulatory approvals difficulty excessive costs manufacture communication well communication customers infringement patents intellectual property rights suppliers significant disruption systems whether others due computer viruses outside incursions could group currently defendant number product liability materially adversely affect groups operations lawsuits including class actions involve substantial claims group control changes inflation interest damages related groups pharmaceutical products see rates foreign currency exchange rates controls note financial statements legal proceedings economic factors affecting businesses possibility discussion proceedings group currently involved political unrest legal regulatory changes nationalisation litigation particularly usa inherently unpredictable jurisdictions group operates factors class actions sweep together persons prescribed could materially affect groups future financial results groups products may inflate potential liability force numbers claims pain suffering punitive damages effective tax rate groups earnings benefits frequently asserted product liability actions allowed fact portion earnings taxed favourable may represent potentially openended exposure unfavourable rates jurisdictions outside united kingdom resolution similar future proceedings may material changes tax laws application respect groups financial results group may also make material matters transfer pricing see note financial provisions related legal proceedings would reduce statements taxation relate portion groups earnings earnings taxed favourable rates could increase groups effective tax rate adversely affect financial recent loss experience within insurance industry whole results including pharmaceutical product liability exposures increased cost insurance coverage pharmaceutical companies new revised accounting standards rules promulgated generally including group order contain insurance costs time time uk us international accounting group adjusted coverage profile standardsetting boards could material adverse impact accepting greater degree uninsured exposure groups financial results group responding governmental investigations usa pricing marketing reimbursement several prescription drug products investigations could result related restitution civil false claims act litigation behalf federal state governments proceedings initiated glaxosmithkline behalf consumers private payers unfavourable resolution similar future government investigations may material groups financial results group may also make material provisions related investigations would reduce earnings environmental laws various jurisdictions impose actual potential obligations group remediate contaminated sites group also identified potentially responsible party us comprehensive environmental response compensation liability act number sites remediation costs relating groups use ownership sites see note financial statements legal proceedings discussion environmentalrelated proceedings group involved glaxosmithkline operating financial review prospects year accordance ussec disclosure requirements following respiratory discussion compares results year st december successful launch asthma treatment seretideadvair results year st december usa number countries europe international helped boost sales growth product exchange combination flixotidefloventand serevent available countries worldwide sales seretideadvairexceeded billion average sterling exchange rates weaker usa three million prescriptions written us dollar euro stronger yen nine months following launch april speed compared aggregate currency movements patients adopted seretideadvairin usa made one compared net favourable effect sterling successful pharmaceutical product launches ever results two per cent respect sales five per cent seretideadvair wasglaxosmithkline 's largest product europe respect business performance earnings per share sales million pharmaceutical sales application eu registration seretidefor treatment total pharmaceutical sales million compared chronic obstructive pulmonary disease copd submitted million increase nine per cent like september january fda advisory committee like basis sales products divested part recommended approval advairand floventfor treatment regulatory approval merger glaxo wellcome copd associated bronchitis flixotideand sereventas smithkline beecham excluded sales grew per cent individual agents already approved several countries million approximately one per cent treatment copd overall growth came price increases expected sales flixotidefloventand sereventdeclined within glaxosmithklines existing portfolio sales new products various markets due increased momentum launched major market within last five years seretideadvair sales flixonaseflonase used treatment accounted per cent total sales grew per cent perennial rhinitis grew strongly million sales established franchise products older respiratory products ventolinand becotidecontinued amounted million representing per cent total decline patients converted newer products sales growth per cent compared last year older products less actively promoted million accounted antibacterials per cent total sales declined seven per cent although overall sales antibacterials showed little growth pharmaceutical sales growth fourth quarter broadspectrum antibiotic augmentinwas still one highest per cent million sales usa contributing selling products groups portfolio achieved per cent million growth per cent although us wholesaler growth worldwide augmentin esextra strength buying patterns distorted product sales total reported sales launched usa october treatment children growth line underlying demand indicated recurrent persistent middle ear infections submission fda prescription data europe sales improved five per cent approval augmentin xrextended release submitted million international sales improved per cent extra data information requested fda million overall sales older products zinnatceftin fortumand amoxilcontinued decline although sales zinnatceftin pharmaceutical sales therapeutic area grew central eastern europe per cent central nervous system major therapeutic area glaxosmithklines portfolio recorded antivirals sales growth per cent seroxatpaxiland wellbutrindrove glaxosmithkline continued expand leadership hivaids sales growth antidepressant sector per cent april global market share per cent paxilwas approved us fda treatment trizivir glaxosmithklines new triple combination medicine generalised anxiety disorder gad december hivaids available one tablet key driver growth treatment posttraumatic stress disorder ptsd seroxatpaxilis hivaids franchise launched number key approved countries treatment gad markets year including much europe usa countries treatment ptsd wellbutrinsales canada driven us sales growth per cent result increased awareness amongst physicians efficacy favourable side sales combivir combination epivirand retrovir effect profile nonanxious depressed patients grew five per cent major growth markets japan asia pacific middle east latin america africa migraine sector successful launch japan imigran tablets treatment previously available sales ziagenincreased five per cent approval received injection helped imigranimitrexsales grow four per cent paediatric indication october use eu ziagenhad lamictalfor treatment epilepsy grew strongly sales approved already countries worldwide requipfor parkinsons disease zybanthe smoking cessation treatment hivaids adults product launched france sales zeffix hepatitis b grew market regions usa zeffix marketed name epivirhbv approved treatment children two years old augustoperating financial review prospectsglaxosmithkline pharmaceutical sales therapeutic area total usa europe international therapeutic area cer cer cer cer major products total growth growth growth growth cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antivirals hiv trizivir combivir epivir retrovir ziagen agenerase herpes valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic gastrointestinal avandia zantac vaccines hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total sales continuing business divested products total pharmaceutical sales cer represents sales growth constant exchange rates glaxosmithkline operating financial review prospects performance herpes treatments valtrexand zovirax cns therapeutic area seroxatpaxil launched generalised produced combined sales growth five per cent usa anxiety disorder april grew strongly wellbutrincontinued valtrex sales helped dtc advertising campaign good growth record products benefited approval usa shorter threeday course therapy growing antidepressant market usa lamictalindicated recurrent genital herpes decline zoviraxin regions epilepsy grew per cent world resulted transfer newer valtrex antibacterials sector augmentinreflected gains share product generic competition adult paediatric markets growth bolstered launch es extra strength formulation indicated metabolic gastrointestinal treatment children acute otitis media middle ear avandia glitazone treatment type diabetes infections key driver growth metabolic gastrointestinal therapy area usa avandiasales benefited increased combination treatment trizivirwas launched us market acceptance revolutionary class drugs record growth late sales first full financial year amounted per cent avandia launched china italy million helping produce per cent sales growth approved countries filed marketing approval hivaids sector antivirals also antivirals market valtrex japan december herpes showed strong performance sales zantaccontinued decline face generic europe competition europe region contributed per cent pharmaceutical sales largest market france showing strong growth good vaccines growth recorded major markets including italy spain infanrix glaxosmithklines combination vaccine diphtheria central eastern europe seretidewas major sales driver tetanus pertussis whooping cough drove total vaccines region although usa affected sales sales growth per cent together strong growth constituent products seretideadvairwas largest product priorix tritanrixand typherixmore offset decline europe sales million hepatitis portfolio twinrix havrixand engerixb subsequent year end glaxosmithkline announced discontinuation cns area seroxat coupled launch zybanin lymerixin usa result poor demand product markets contributed growth launches trizivir helped produce per cent growth hivaids sector oncology emesis metabolic gastrointestinal zantacsales continued decline continued sales growth zofran used management face increased generic competition partially nausea vomiting associated chemotherapy offset performance avandiawith launchesin number radiotherapy cancer treatment benefited oncology emesis markets including uk germany therapy area grew per cent overall sales hycamtin approved treatment recurrent ovarian cancer declined antibacterials declined one per cent reflecting generic competition nineper cent principally result adverse wholesaler augmentinand amoxil vaccines showed growth due buying patterns usa decline hepatitis market germany although sales improved european countries principally uk spain italy cardiovascular oncology area growth attributable strong sales coreggrew per cent november fda gave sales zofranin france germany offset decline approval treatment severe heart failure coregis hycamtinsales european countries betablocking agent indicated increase survival mild moderate severe heart failure patients glaxosmithkline international exclusive rights market coregin usa per cent sales growth international region reflected strong growth major markets region therapeutic areas sales relafenfor arthritis fell reflecting generic competition market growth japan driven number therapeutic usa areas launch tablet form imigranin august seroxatin late key drivers switch regional analysis becotideto newer product flixotideand zoviraxto newer valtrexcontributed sales growth newer usa products led also decline older products group earned per cent total pharmaceutical revenue canada significant growth achieved seretideand usa year recording growth per cent avandia launched march therapeutic advairseretide launched midapril achieved sales areas trizivirfor hiv treatment launched november million although launch slowed sales growth constituent products flixotidefloventand serevent combined seven per cent total sales derived asia pacific sales three products amounted million area principally australia sales growth per cent growth per cent metered dose inhaler seretidewas launched market may sales zybangrew successful launch late operating financial review prospectsglaxosmithkline latin america reported eight per cent sales growth reflecting strong trading profit business performance growth mexico per cent area predominately benefited illustrate glaxosmithkline business performance seretidesereventflixotidemarket grew per analysis trading profit subsequent discussion cent hivaids vaccines markets showed good return excludes merger items integration restructuring costs antibacterials declined due generic competition disposal businesses management believes exclusion middle east africa area followed trends nonrecurring items provides better comparison business markets growth seretide avandiaand hivaids performance periods presented accordingly information markets vaccines area recorded growth per cent provided supplement contained consolidated zofranin oncology area drove growth per cent statement profit loss pages prepared accordance ukgaap subsaharan south africa key drivers growth antivirals vaccines consumer healthcare sales cer sales cer cost sales otc medicines selling general oral care administration nutritional healthcare research total sales continuing business development divested products trading profit total consumer healthcare sales acquisition block drug company inc completed cost sales january adding million sales purchase added cost sales increased percentage sales loss sensodynetoothpaste brand range denture care brands highmargin products divested december inclusion worldwide significant additions groups otc medicines lower margin block drug products higher stock provisions largely usa former block drug business integrated partly offset benefits merger manufacturing glaxosmithkline restructuring savings result acquisition glaxosmithkline became number selling general administration two company globally oral care added significant extra scale selling general administration sga costs benefited business particularly north america japan europe merger savings principally general administration expenditure inclusion block drug costs distorted year otc medicines year comparison excluding estimated block drug expenses reported sales otc medicines grew eight per cent growth sga expenses would four per cent million primarily result acquisition block drug sga expressed percentage sales would excluding block drug otc medicines declined two per cent per cent lower reflecting private label competition smoking control us market sluggish growth global otc market research development june glaxosmithkline reached agreement taisho research development expenditure broadly level last establish partnership introduce nicotine replacement year savings merger made expenditure products japan research development planned increase future merger savings begin reinvested area significant new product introductions otc medicines included niquitin lozenge effective otc product launched trading profit tohelp smokers quit eumovate topical steroid first business performance trading profit growth per cent glaxosmithkline switch prescription otc two major reflecting improved trading margins trading margin improved new extensions panadolanalgesic fast acting formula per cent per cent result cost savings marketed actifast slow release product targeted merger integration partly offset divestment certain high persistent pain introduced scandinavia extend margin products required regulatory authorities condition merger oral care acquisition block drug added number brands profit taxation business performance oral care business namely sensodyne polidentand poligrip excluding block drug oral care sales grew three per cent analysis discussion profit taxation relates reflecting strong growth europe partly offset strong business performance competitive pressures aquafreshin us market operating incomeexpense nutritional healthcare royalties income nutritional healthcare business grew seven per cent reflecting operating expense strong performances lucozadeand horlicks income equity investments glaxosmithkline operating financial review prospects operating income significantly lower disposal businesses due lower sales equity investments lower product loss disposal businesses primarily arose disposals higher costs related product withdrawals sale affymax charge includes million writeoff goodwill previously eliminated reserves profit disposal interest associate group sold million shares quest diagnostics inc taxation restated restated year realising gain million st december share split quest share sale business performance glaxosmithkline held million shares merger restructuring disposal subsidiaries share profitslosses joint ventures associated undertakings share profits associates arose principally groups holding inquest diagnostics inc group implemented frs deferred tax requires deferred tax accounted full provision basis rather partial provision basis earlier years change net interest payable basis accounted prior year adjustment interest payable comparative information restated necessary investment income business performance taxation share interest payable associate charge taxation business performance profit amounting million represents effective tax rate per cent tax rate benefits lower rates tax applicable net interest payable lower due lower average level net manufacturing operations singapore puerto rico ireland debt lower interest rates merger restructuring profit taxation credit taxation merger restructuring items operating incomeexpense together disposal amounting million reflected estimated actual tax rate part interest inanassociate added million profit applicable transactions territories arose taxation compared million reduction onetime profits planned improve overall earnings restated restated quality groups earnings taking account contribution earnings associates comprising share profit less share ofinterest basic earnings per share p p less thegroups net interest payable business performance basic earnings per ads profit tax million compared million increase per cent adjusted earnings adjusted earnings per share p p merger items restructuring costs disposal businesses adjusted earnings per ads key items discussed weighted average number shares millions merger adjusted earnings adjusted earnings per share costs arising integration glaxo wellcome glaxosmithkline presented order illustrate business smithkline beecham businesses unified glaxosmithkline performance primary measure used management business referred merger integration costs amounted discussed earlier million costs primarily include consultancy fees severance asset writeoffs share option retention incentives manufacturing restructuring costs million incurred implementing previously announced glaxo wellcome smithkline beecham plans restructuring manufacturing activities million charged respect postmerger restructuring activities costs include consultancy fees severance asset writeoffs block drug company inc glaxosmithkline acquired block drug january costs incurred acquiring integrating business million comprising professional fees severance asset writeoffsoperating financial review prospectsglaxosmithkline selected financial data ukusgaap profit loss account restated restated restated restated amounts accordance uk gaap sales operating profit profit taxation earnings basic earnings per share p p p p p diluted earnings per share p p p p p weighted average number shares issue basic diluted dividends per glaxosmithkline share p glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividends expressed terms glaxosmithkline share amounts accordance us gaap sales operating profit profitloss tax net incomeloss basic net incomeloss per share pence p p p p p diluted net incomeloss per share pence p p p p p information presents us gaap net incomeloss net incomeloss per share results years ended st december adjusted reverse amortisation expense goodwill indefinitelived intangible assets sfas also applied years adjusted net incomeloss adjusted basic net incomeloss per share pence p p p p adjusted diluted net incomeloss per share pence p p p p balance sheet amounts accordance uk gaap total assets net assets equity shareholders funds amounts accordance us gaap total assets net assets shareholders equity exchange rates guide holders adrs following tables set periods indicated information exchange rate us dollars sterling reported federal reserve bank new york noon buying rate average average rate year calculated average noon buying rates last day month year feb jan dec nov oct sept high low noon buying rate rd march us frs deferred tax implemented group ukgaap frs requires deferred tax accounted full provision basis rather partial provision basis earlier years change accounted prior year adjustment ukgaap purposes comparative information restated necessary change impact usgaap results glaxosmithkline operating financial review prospects results us accounting principles review discusses results glaxosmithkline plc prospects years shareholders equity st december glaxosmithkline published expectations future growth prepared us accounting principles see note earnings per share ukgaapbasis excluding merger financial statements reconciliation usaccounting principles restructuring items see outlook results recent financial accounting standards board fasb summary results pronouncements june fasb approved sfas accounting sales obligations associated retirement longlived assets trading profit requires fair values obligation associated operating profit retirement longlived assets capitalised part profit tax cost implemented group effect net incomeloss changes st january group believe adoption accounting principles standard material impact results cumulative effect changes accounting principles st january sfas accounting impairment net incomeloss disposal longlived assets adopted group basic net incomeloss per share pence sfas develops one accounting model longlived assets including discontinued operations disposed sale operating profit lower usgaapbasis uk gaap requires longlived assets measured lower basis primarily result amortisation impairment carrying amount fair value less cost sell whether reported intangible assets recorded balance sheet uk continuing discontinued operations adoption sfas gaap operating profit also includes charge sfas material impact groups financial stockbased compensation charge pension post statements retirement benefits partially offset net income april sfas rescission fasbstatements related deferred tax credits amendment fasbstatement technical group adopted sfas st january corrections issued statement updates clarifies implementation sfas resulted initial impairment simplifies existing accounting standards group million net tax indefinite lived intangible assets believe adoption standard material impact group also aligned measurement date results pension plans st december impact million sfas accounting costs associated exit disposal credit net tax changes reflected cumulative effects activities issued june sfas requires companies changes accounting principles recognise costs associated exit disposal activities effect differences ukgaap leads incurred rather date commitment usgaap profit tax million tax exit disposal plan applied prospectively exit minority interest cumulative effect changes disposal activities initiated st december group accounting principles net income year million currently assessing impact standard profit tax million tax november fasb published interpretation minority interest net loss million guarantors accounting disclosures requirements guarantees including indirect guarantees indebtedness shareholders equity st december others fin fin expands accounting guidance sfass fins provisions initial recognition changes shareholders equity measurement applied guarantees issued modified beginning year st december disclosure requirements net incomeloss effective financial years ending th december shares purchased cancelled group believe adoption fin share issues share options material impact results treasury stock dividends january fasb published interpretation minimum pension liability consideration variable interest entities fin fin primary beneficiary entity must consolidate certain entities known variable interest entities measurement end year principles apply groups financial statements group believe adoption fin book values glaxosmithkline net assets ukgaap basis material impact results adjusted normal ukusgaap differences principal adjustments net assets differences uk usgaap include goodwill intangible assets glaxos acquisition wellcome glaxo wellcomes acquisition smithkline beecham dividends declared rather proposed basis treatment shares held esots treasury stock rather investments inclusion minimum pension liability net assetsglaxosmithkline financial statements section comprises directors statements independent auditors report financial statements financial statements consisting principal financial statements supporting notes additional financial data directors statements responsibility independent auditors report financial statements consolidated statement profit loss consolidated statement total recognised gains losses consolidated statement cash flow consolidated balance sheet reconciliation movements equity shareholders funds company balance sheet notes financial statements presentation financial statements accounting policies new accounting policies requirements exchange rates merger glaxo wellcome smithkline beecham segment information merger items restructuring costs divested businesses operating incomeexpense operating profit joint ventures associated undertakings net interest payable taxation earnings per share dividends goodwill intangible assets tangible fixed assets fixed asset investments equity investments stocks debtors creditors provisions liabilities charges contingent liabilities net debt commitments share capital share premium account nonequity minority interests reserves legal proceedings acquisitions disposals financial instruments related disclosures employee costs employee share schemes related party transactions glaxosmithkline plc investment subsidiary companies reconciliation us accounting principles principal group companies financial record quarterly trend five year record glaxosmithkline directors statements responsibility directors statement responsibility relation internal control tothefinancial statements board audit committee reviewed directors assessment risks internal control framework operates glaxosmithkline considered effectiveness responsible ensuring maintenance proper accounting system internal control operation inthegroup records disclose reasonable accuracy financial year covered report date approval position group time financial board directors statements beprepared comply companies act combined code required law prepare financial statements financial period give true fair view state board considers glaxosmithkline plc applies principles affairs company group end combined code asdescribed corporate governance financial period ofthe profit loss period pages complied requirements responsible also ensuring operation systems combined codewiththeexception provisions relating internalcontrol taking reasonable steps safeguard executive directors service contracts pensionable bonuses assets group preventing detecting terminationcommitments companys position fraud irregularities described remuneration report financial statements year ended st december required listing rules financial services authority comprising principal statements supporting notes set auditors haveconsidered directors statement infinancial statements pages report compliance relation points combined code specified theirreview directors confirm suitable accounting policies consistently applied preparation financial statements annual report supported reasonable prudent judgements estimates asnecessary applicable accounting standards followed annual report year ended st december financial statements prepared going comprising report directors directors remuneration concern basis report financial statements additional information investors approved board directors signed responsibilities auditors relation financial behalf statements set independent auditors report opposite sir christopher hogg financial statements year ended st december chairman included annual report published th march hardcopy printed form website directors responsible maintenance integrity annual report website accordance uk legislation governing preparation dissemination financial statements access website available outside uk comparable legislation may different directors remuneration remuneration report pages report sets remuneration policies operated glaxosmithkline disclosures directors remuneration disclosable information relating directors officers interests prepared accordance companies act amended directors remuneration report regulations complies section b combined code going concern basis making enquiries directors reasonable expectationthat group company adequate resources continue operational existence foreseeable future forthis reason continue adopt going concern basis inpreparing financial statementsglaxosmithkline independent auditors report members glaxosmithkline plc audited consolidated financial statements planned performed audit obtain comprise consolidated statement profit loss information explanations considered necessary consolidated statement total recognised gains losses order provide us sufficient evidence give reasonable consolidated statement cash flow consolidated balance sheet assurance consolidated financial statements related notes prepared auditable part directors remuneration report free historical cost convention accounting policies set material misstatement whether caused fraud statement accounting policies also audited irregularity error forming opinion also evaluated disclosures required part schedule companies overall adequacy presentation information act contained directors remuneration report consolidated financial statements auditable part united kingdom opinion respective responsibilities directors auditors opinion directors responsibilities preparing annual report financial statements give true fair view state directors remuneration report consolidated financial affairs company group st december statements accordance applicable united kingdom law profit cash flows group year accounting standards set statement financial statements properly prepared directors responsibilities accordance companies act parts directors remuneration report required responsibility audit consolidated financial statements part schedule companies act auditable part directors remuneration report properly prepared accordance companies act accordance relevant legal regulatory requirements united kingdom auditing standards issued auditing united states opinion practices board opinion financial statements present fairly report opinion whether consolidated material respects consolidated financial position group financial statements give true fair view whether st december results consolidated financial statements auditable part consolidated operations consolidated cash flows directors remuneration report properly prepared three years period ended st december accordance companies act also report conformity accounting principles generally accepted opinion report directors consistent united kingdom consolidated financial statements company kept proper accounting records received accounting principles generally accepted united kingdom information explanations require audit vary certain significant respects accounting principles information specified law regarding directors remuneration generally accepted united states application transactions disclosed latter would affected determination consolidated net income expressed sterling three years read information contained annual report period ended st december determination consider implications report become aware consolidated shareholders equity also expressed sterling apparent misstatements material inconsistencies st december extent summarised note consolidated financial statements information consolidated financial statements comprises report directors joint statement chairman chief executive officer operating financial review prospects corporate governance pricewaterhousecoopers llp statement chartered accountants registered auditors review whether corporate governance statement reflects southwark towers companys compliance seven provisions london england combined code specified review listing rules th march financial services authority report required consider whether boards statements internal control cover risks controls form opinion effectiveness companys groups corporate governance procedures risk control procedures basis audit opinion conducted audit accordance auditing standards issued united kingdom auditing practices board auditing standards generally accepted united states audit includes examination test basis evidence relevant amounts disclosures financial statements auditable part directors remuneration report also includes assessment significant estimates judgements made directors preparation consolidated financial statements whether accounting policies appropriate company groups circumstances consistently applied adequately disclosed glaxosmithkline consolidated statement profit loss year ended st december merger restructuring business disposal performance subsidiaries statutory notes turnover cost sales gross profit selling general administrative expenditure research development expenditure trading profit operating incomeexpense operating profit share profitslosses joint ventures associated undertakings profit disposal interest associate product divestments merger transaction costs profitloss disposal businesses profit interest net interest payable profit ordinary activities taxation taxation profit ordinary activities taxation minority interests preference share dividends earnings profit attributable shareholders basic earnings per share p adjusted earnings per share p diluted earnings per share p profit attributable shareholders dividends retained profit items dealt arriving business performance operating profit relate continuing activities difference profit ordinary activities taxation retained profit stated historical cost equivalents frs deferred tax implemented group frs requires deferred tax accounted full provision basis rather partial provision basis earlier years change accounted prior year adjustment comparative information restated necessary consolidated statement total recognised gains losses year ended st december profit attributable shareholders exchange movements overseas net assets uk tax exchange movements unrealised gains equity investments total recognised gains losses relating year prior year adjustment implementation frs total recognised gains losses consolidated statement profit lossglaxosmithkline merger merger restructuring restructuring business disposal business disposal performance subsidiaries statutory performance subsidiaries statutory restated restated restated restated restated restated p p p p p p restated restated glaxosmithkline consolidated statement cash flow year ended st december reconciliation operating profit operating cash flows notes operating profit depreciation impairment assets written amortisation goodwill intangible fixed assets loss sale tangible fixed assets profit sale equity investments increasedecrease stocks increase trade debtors increase trade creditors increase pension provisions merger transaction costs paid net cash inflow operating activities cash flow statement net cash inflow operating activities dividends joint ventures associated undertakings returns investment servicing finance taxation paid capital expenditure financial investment acquisitions disposals equity dividends paid net cash inflowoutflow management liquid resources financing management liquid resources financing increasedecrease cash year reconciliation net cash flow movement net debt net debt beginning year increasedecrease cash year cash outflowinflow management liquid resources net increase longterm loans net repayment shortterm loans net repayment ofincrease obligations finance leases net noncash funds subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year consolidated statement cash flowglaxosmithkline analysis cash flows returns investment servicing finance interest received interest paid dividends paid minority shareholders dividends paid preference shares capital expenditure financial investment purchase tangible fixed assets sale tangible fixed assets purchase intangible assets sale intangible assets product divestments purchase shares employee share options awards proceeds shares employee share options purchase equity investments sale equity investments acquisitions disposalsnote purchase businesses cash acquired subsidiary disposal businesses investment joint ventures associated undertakings disposal interests associates financing issue share capital redemption preference shares issued subsidiary share capital purchased cancellation financing cash flows increase longterm loans repayment longterm loans net repayment shortterm loans net repayment ofincrease obligations finance leases analysis changes net debt cash flow acquisitions exchange cash bank overdrafts debt due within one year commercial paper debt due one year euro bonds mediumterm notes private financing management liquid resources liquid investments net debt glaxosmithkline consolidated balance sheet st december restated notes goodwill intangible assets tangible assets investments fixed assets equity investments stocks debtors liquid investments cash bank current assets loans overdrafts creditors creditors amounts due within one year net current assets total assets less current liabilities loans creditors creditors amounts due one year provisions liabilities charges net assets called share capital share premium account reserves profit loss account equity shareholders funds nonequity minority interests equity minority interests capital employed approved board sir christopher hoggchairman th march reconciliation movements equity shareholders funds year ended st december restated notes equity shareholders funds beginning year previously reported prior year adjustment implementation frs equity shareholders funds beginning year restated total recognised gains losses year dividends share capital issued share capital purchased cancelled exchange movements goodwill written reserves goodwill written back equity shareholders funds end year glaxosmithkline company balance sheet st december notes shares subsidiary companies cost fixed assets amounts owed group undertakings taxation current assets taxation dividends payable amounts owed group undertakings creditors amounts due within one year net current assetsliabilities net assets called share capital share premium account reserves profit loss account equity shareholders funds approved board sir christopher hoggchairman th march glaxosmithkline notes financial statements presentation financial statements additional information accordance requirements usgenerally accepted accounting principles us gaap included description business notes financial statements note statement glaxosmithkline major global healthcare group differences reconciliation net income shareholders engaged creation discovery development manufacture equity uk us gaap provided principal marketing pharmaceutical products including vaccines financial statements presented accordance us gaap overthecounter otc medicines healthrelated consumer andin usgaap format products glaxosmithklines principal pharmaceutical products include medicines following therapeutic areas merger glaxowellcome plc smithkline beecham plc central nervous system respiratory antivirals antibacterials glaxosmithkline plc acquired glaxo wellcome plc smithkline metabolic gastrointestinal vaccines oncology emesis beecham plc way scheme arrangement merger cardiovascular arthritis two companies became effective th december financial period ukgaap financial statements glaxosmithkline plc financial statements cover financial year prepared merger glaxowellcome plc smithkline st january stdecember comparative figures beecham plc comparative figures year financial years st january st december st december therefore include results glaxo st january tost december wellcome plc smithkline beecham plc us gaap financial statements glaxosmithkline plc composition group prepared acquisition smithkline beecham plc list subsidiary associated undertakings glaxo wellcome plc th december accordingly opinion directors principally affected amount profit results smithkline beecham periods prior date net assets group given principal group consolidated companies note presentation statement profit loss composition financial statements columnar presentation adopted statement consolidated financial statements drawn accordance profit loss order illustrate underlying business performance uk generally accepted accounting principles ukgaap primary measure used management uk accounting presentation purpose certain items identified separately excluded financial statements comprise business performance comprise merger integration items including product divestments costs relating previously consolidated statement profit loss announced manufacturing restructuring theeffect consolidated statement total recognised gains losses disposals subsidiaries consolidated statement cash flow consolidated balance sheet trading profit reflects sales less cost sales comprising costs reconciliation movements equity shareholders funds ofmanufacture external royalties selling general company balance sheet administrative expenditure comprising costs selling notes financial statements distribution medical support currently marketed products costs administration costs research permitted section companies act development create future products sale profitand loss account company presented consolidated statement total recognised gains losses accounting convention includes financial statements prepared using historical cost convention realised profit attributable shareholders reflected theconsolidated profit loss account accounting standards unrealised gain loss value groups overseas financial statements comply applicable uk accounting net assets less related foreign currency borrowings attributable standards currency movements period reconciliation movements equity shareholders funds accounting principles policies comprises items contributing increase decrease preparation financial statements conformity generally period shareholders funds items include accepted accounting principles requires management make estimates assumptions affect reported amounts total recognised gains losses period assets liabilities disclosure contingent assets dividends paid proposed liabilities date financial statements reported proceeds shares issued period amounts revenues expenses reporting period cost shares purchased cancellation actual results could differ estimates share buyback programme changes goodwill arising acquisitions prior financial statements prepared accordance st january set directly reserves companys accounting policies approved board described note company implemented one new financial reporting standard described innote notes financial statements glaxosmithkline accounting policies foreign currency transactions foreign currency transactions group companies booked consolidation inlocal currency exchange rate ruling date consolidated financial statements include transaction forward rate hedged forward assets liabilities results cash flow exchangecontract foreign currency assets liabilities company subsidiary undertakings including employee translated local currency rates exchange ruling share ownership trusts esots balance sheet date forward rate exchange differences groups share net assets results joint ventures areincluded trading profit associated undertakings revenue financial statements undertakings consolidated made revenue recognised profit loss account goods st december services supplied external customers orders undertakings group material interest received turnover represents net invoice value accounted subsidiaries group exercises dominant deduction discounts given point sale products influence joint ventures group exercises joint control despatched available collection customers less associates group exercise significant accruals estimated future rebates returns value added tax influence esots accounted subsidiaries grounds sales taxes excluded revenue group de facto control expenditure interests acquired undertakings consolidated expenditure recognised respect goods services received effective date acquisition interests sold consolidated supplied accordance contractual terms provision upto date disposal made obligation exists future liability respect transactions balances subsidiary undertakings past event amount obligation reliably eliminated profit taken sales subsidiary estimated advertising expenditure charged profit loss undertakings sales joint ventures associated undertakings account incurred shipment costs intercompany transfers products sold customers outside group charged cost sales distribution costs sales customers included selling general administrative expenditure goodwill arising acquisition interestsin subsidiary restructuring costs recognised respect direct undertakings joint ventures associated undertakings expenditures business reorganisation plans representing excess purchase consideration sufficiently detailed well advanced appropriate groups share separable net assets acquired capitalised communication affected undertaken asa separate item case subsidiary undertakings balance sheet date part cost investment case joint ventures associated undertakings goodwill denominated currency research development inwhich acquisition made financed case research development expenditure charged profit acquisitions prior goodwill written loss account period incurred tangible reserves subsequent disposal assets acquisitions fixed assets used research development depreciated related goodwill removed consolidated reserves accordance groups policy charged consolidated profit lossaccount groups interests joint ventures accounted using environmental expenditure thegross equity method groups interests associated environmental expenditure related existing conditions resulting undertakings accounted using equity method past current operations current future benefit discernible charged profit loss deferred taxation relief unrealised intragroup profit account group determines liability sitebysite basis accounted extent considered recoverable records liability time probable assets liabilities overseas subsidiary associated reasonably estimated liability includes groups portion undertakings joint ventures including related goodwill costs also portion potentially responsible translated sterling rates exchange ruling balance parties costs probable able satisfy sheet date results cash flows overseas subsidiary respective shares cleanup obligation recoveries associated undertakings joint ventures translated reimbursements virtually certain recorded assets sterling using average rates exchange exchange adjustments arising opening net assets profits theyear legal disputes retained overseas subsidiary associated undertakings provision made anticipated settlement costs legal joint ventures translated sterling less exchange differences expenses associated claims received legal arising related foreign currency borrowings taken directly disputes group reasonable estimate reserves reported statement total recognised made likely outcome dispute provision made gains andlosses unasserted claims obligation exists dispute possible make reasonable estimate costs associated translating sterling assets liabilities results cash flows claims made group third parties charged overseas subsidiary associated undertakings joint ventures profit loss account incurred reported currencies hyperinflationary economies adjustments aremade reflect current price levels loss net monetary assetsis charged consolidated profit loss account glaxosmithkline notes financial statements accounting policiescontinued tangible fixed assets tangible fixed assets stated cost less provisions pensions postretirement benefits depreciation impairment costs acquiring developing cost providing pensions employee postretirement computer software internal use internet sites external benefits charged consolidated profit loss account use capitalised tangible fixed asset software systematic rational basis based actuarial assumptions site supports significant business system expenditure period benefit derived employees services leads creation durable asset difference charge contributions paid included asset liability consolidated balance sheet depreciationis calculated write cost tangible fixed assets excluding freehold land equal annual instalments employee share plans expected useful lives normal expected useful lives incentives form shares provided employees major categories tangible fixed assets reviewed annually share option share award schemes respect award schemes certain share option grants company provides finance esots purchase company shares open market freehold buildings years meet companys obligation provide shares leasehold land shorter lease term employees exercise option award anyexcess buildings years purchase price shares exercise price options plant machinery years awards charged profit loss account fixtures equipment years periods service respect options awards erp systems software years granted respect share option grants share options computer software years exercised accounted share issues exercise price erp systems software generally involves significant customisation additional employer costs respect options awards prior implementation expected useful economic charged profit loss account periods service life seven years rather maximum five years costs running esots charged profit loss computer software account shares held esots accounted fixed asset ondisposal tangible fixed asset cost related investments held cost less provision recognise shortfall accumulated depreciation removed financial proceeds receivable employees exercise unless statements net amount less proceeds taken deemed permanent impairment value consolidated profit loss account goodwill leases goodwill stated cost less provision amortisation leasing agreements transfer group substantially amortisation calculated write cost equal annual benefits risks ownership asset treated instalments expected useful life useful life finance leases asset purchased outright normally expected exceed years assets included intangible fixed assets capital element leasing commitments shown obligations finance intangible fixed assets leases assets held finance leases depreciated intangible assets stated cost less provision amortisation shorter ofthe lease terms useful lives assets acquired licences patents knowhow marketing rights interest element lease rental charged profit amortised estimated useful lives equal instalments leases operating leases annual rentals longer years items capitalised restricted charged profit straightline basis lease term related specific compounds products developed commercial applications estimated useful lives impairment fixed assets determining amortisation charge reviewed annually carrying values fixed assets reviewed impairment andtake account estimated time takes bring indication assets might impaired compounds products market marketable products provision impairment charged profit year anydevelopment costs incurred group concerned firstyear impairment reviews conducted areassociated acquired licence patent knowhow acquired goodwill intangible assets certain intangibles marketing rights written profit loss account considered anindefinite life therefore whenincurred amortised intangibles subject annual impairment tests impairment determined byreference higher net brands valued independently part fair value realisable value value use measured reference businesses acquired third parties brand value discounted future cash flows value shares held substantial longterm brands esots reviewed quarterly determine permanent sold separately rest businesses acquired brands impairment areamortised estimated useful lives longer years except end useful economic life investments joint ventures associates brand foreseen investments joint ventures associated undertakings prior acquired minor brands similar intangibles carried consolidated balance sheet groups share eliminated group balance sheet reserves year oftheir net assets date acquisition post acquisition acquisition retained profits losses together goodwill arising acquisition net amortisationnotes financial statementsglaxosmithkline accounting policiescontinued debt instruments debt instruments stated amount net proceeds stocks adjustedto amortise issue cost debt evenly term stocksare included financial statements lower cost debt including manufacturing overheads appropriate net realisable value cost generally determined first first new accounting policies future requirements basis group implemented financial reporting standard taxation deferred tax requires deferred tax accounted group accounts taxation deferred accelerated full provision basis rather partial provision basis reason timing differences originated comparative information restated necessary reversed balance sheet date deferred tax assets effect increase business performance tax recognised extent considered recoverable charge million million overall tax charge future taxable profits deferred tax retained earnings million million net deferred tax asset overseas subsidiaries provided binding st december reduced million commitment distribute past earnings future periods june council european union adopted deferred tax measured average tax rates expected regulation requiring listed companies member states apply periods timing differences expected prepare consolidated financial statements accordance reverse deferred tax liabilities assets discounted international accounting standards group initiated project plan implement conversion current asset investments ukgaap international financial reporting standards ifrss current asset investments stated lower cost net first annual report prepared ifrss realisable value year ending st december first financial results announcement prepared accordance ifrss case securities acquired significant premium first quarter discount maturity value intended held redemption cost adjusted amortise premium discount life exchange rates tomaturity security floating rate bonds stated cost interest income taken profit loss account group uses average exchange rates prevailing receivable basis period translate results cash flows overseas group subsidiary joint venture associated undertakings sterling equity investments included current assets regarded period end rates translate net assets asavailable sale undertakings thecurrencies influence translations relevant exchange rates derivative financial instruments group hold issue derivative financial instruments trading purposes average rates derivative financial instruments used manage exposure us market risks treasury operations principal derivative euro instruments currency swaps forward exchange contracts yen interest rate swaps derivative contracts treated period end rates inception economic hedge underlying financial us instrument matching accounting treatment cash flows euro derivative contracts high correlation specific yen financial instrument hedged inception throughout hedge period derivative instruments longer merger glaxo wellcome smithkline beecham designated hedges restated market value future combination glaxo wellcome plc smithkline beecham plc changes value taken directly profit loss account treated merger th december uk gaap currency swaps forward exchange contracts used fix merger accounting shares issued glaxosmithkline plc value related asset liability contract currency acquire glaxo wellcome smithkline beecham accounted contract rate accrued profit loss account par share premium arose shares acquired life contract gains losses foreign exchange glaxosmithkline glaxo wellcome smithkline beecham contracts designated hedges forecast foreign exchange similarly accounted nominal value shares issued transactions deferred included measurement inthe consolidated financial statements glaxosmithkline related foreign currency transactions period occur results netassets glaxo wellcome smithkline beecham gains losses balance sheet hedges accrued combined book amounts subject alignment taken directly reserves except forward premiumdiscounts adjustments recognised interest life contracts inview proximity merger date financial year end interest differentials interest swap agreements recognised date relative insignificance business activity profit loss account adjustment ofinterest expense th december st december accounting life agreement date merger practical purposes taken stdecember whole profit financial year glaxo wellcome plc smithkline beecham plc wasdeemed relate period prior merger date glaxosmithkline notes financial statements segment information analysis turnover profit taxation total assets net assets tangible fixed assets business geographical sector areset belowthe business sectors consist pharmaceuticals prescription pharmaceuticals vaccines consumer healthcare oralcare otc medicines nutritional healthcare thegeographical sectors reflect groups significant regional markets consistent groups regional market management reportingstructure business sector data includes allocation corporate costs sector sales business sectors groups activities organised global basis geographical sector figures therefore influenced location groups operating resources particular manufacturing research variations time intragroup trading funding arrangements restated restated turnover business sector pharmaceuticals consumer healthcare external turnover profit tax business sector pharmaceuticals consumer healthcare operating profit share profitslosses joint ventures associated undertakings profit disposal interest associate profit disposal businesses product divestments merger transaction costs net interest payable profit taxation profit taxation taxation minority interests preference share dividends earnings total assets business sector pharmaceuticals consumer healthcare total assets net assets business sector pharmaceuticals consumer healthcare net assets notes financial statementsglaxosmithkline segment informationcontinued restated restated turnover location subsidiary undertaking usa europe international gross turnover usa europe international intersegment turnover usa europe international external turnover turnover location customer usa europe international external turnover profit tax location subsidiary undertaking usa europe international operating profit share profitslosses joint ventures associated undertakings profit disposal interest associate profit disposal businesses product divestments merger transaction costs net interest payable profit taxation profit taxation taxation minority interests preference share dividends earnings total assets location subsidiary undertaking usa europe international total operating assets cash bank liquid investments total assets net assets location subsidiary undertaking usa europe international net operating assets net debt net assets glaxosmithkline notes financial statements segment informationcontinued plant land equipment computer assets buildings vehicles software construction total total tangible fixed assets location subsidiary undertaking usa europe international total uk segment information given separately respect uk although included groups europe market region considered groups home segment purposes segmental reporting restated turnover location customer gross turnover intersegment turnover turnover location subsidiary operating profit total assets net operating assets merger items restructuring costs divested businesses manufacturing restructuring costs incurred glaxosmithkline implementation previously announced plans restructuring manufacturing activities costs also incurred glaxo wellcome smithkline beecham merger integration costs relate integration glaxo wellcomeand smithkline beecham unified glaxosmithkline business costs include consultancy fees respect integration planning severance costs asset writeoffs costs related early vesting lapse performance conditions share options share incentive awards costs programme encourage staff convert glaxo wellcome smithkline beecham share options glaxosmithkline share options integration costs incurred relating integration block drug businesses costs include professional fees severance costs asset writeoffs product divestment income arising related finalisation disposals famvir kytrilandother products required order obtain regulatory approval merger merger transaction costs incurred order effect themerger costs comprise fees expenses incurred preparing implementing scheme arrangement merger disposal businesses related finalisation disposals clinical laboratories healthcare services disposal businesses primarily arose sale affymax included million write goodwill previously eliminated group reserves disposal businesses relates disposal healthcare services restructuring costs incurred healthcare services disposal share associate related restructuring costs incurred quest diagnostics restruc disposal merger turing block drug subsidiaries total manufacturing restructuring merger integration costs block drug integration costs effect operating profit product divestments profit disposal businesses effect profit tax effect taxation operating items effect taxation nonoperating items effect taxation effect earnings notes financial statementsglaxosmithkline merger items restructuring costs divested businesses continued restruc disposal total merger turing block drug subsidiaries restated manufacturing restructuring merger integration costs block drug integration costs effect operating profit loss disposal businesses effect profit tax effect taxation operating items effect taxation nonoperating items effect taxation effect earnings restruc disposal total merger turing associate subsidiaries restated manufacturing restructuring merger integration costs effect operating profit share associate product divestments merger transaction costs loss disposal business effect profit tax effect taxation operating items effect taxation nonoperating items effect taxation effect earnings operating incomeexpense royalties income operating expense income equity investments disposals royalties income principally core recurring income form royalties outlicensing intellectual property operating expense comprises nonrecurring costs related product liability claims costs respect product withdrawals income equity investments disposals arises equity investment sales equity investment writedowns due adverse market conditions product property disposals glaxosmithkline notes financial statements operating profit following items charged operating profit employee costs note advertising distribution costs depreciation tangible fixed assets owned assets leased assets amortisation goodwill amortisation intangible fixed assets exchange losses foreign currency depositsloans operating lease rentals plant machinery land buildings audit fees fees auditors work auditors ukfirm auditors overseas firms analysis fees auditors work nonstatutory assurance services tax advisory services merger glaxo wellcome smithkline beecham services included within audit fees fee relating company audit glaxosmithkline plc included within fees auditors work amounts million millionpaid auditors management consulting practice sold joint ventures associated undertakings associated undertakings share profits quest diagnostics inc share losses associated undertakings amortisation goodwill share lossesprofits joint ventures share turnover joint ventures sales joint ventures associated undertakings net interest payable interest payable bank loans overdrafts loans respect finance leases share interest payable associate investment income interest income realised gains provision market value adjustments notes financial statements glaxosmithkline taxation restated restated taxation charge based profits period uk corporation tax uk statutory rate less double taxation relief overseas taxation deferred taxation share taxation charge associates reconciliation current taxation rate group profits restated restated ukstatutory rate taxation overseas taxes average group tax rate effect special tax status manufacturing locations share option deductions usa merger restructuring costs rd credits previously recognised permanent differences capital allowances excess depreciation intragroup profit reversing timing differences tax losses timing differences prior year items current tax rate ordinary activities capital allowances excess depreciation intragroup profit reversing timing differences tax losses timing differences share associates taxation prior year items tax rate ordinary activities group operates countries tax rate differs ukrate standard rate tax group estimated aggregating local standard tax rates weighting proportion accounting profits profits arising manufacturing operations singapore puerto rico ireland taxed reduced rates effect reduction taxation charge increased earnings per share p p p integrated nature groups worldwide operations involving significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable tax disagreements revenue authorities intragroup transactions particular price goods transferred group companies different tax jurisdictions produce conflicting claims revenue authorities profits fall taxed individual territories resolution issues continuing factoflife glaxosmithkline usa number years glaxosmithkline significant open issues relating transfer pricing issues affect years present concern number products although significant relates success zantac respect claims us internal revenue service irs substantially exceed groups estimation taxation liabilities irs claims completely quantified continue subject discussions us uk tax authorities competent authority provisions double tax convention two countries within discussions wide variation views us uk tax authorities exceptionally may unable reach agreement settle dispute event uk us tax authorities reaching agreement matter may resolved litigation glaxosmithkline uses best advice determining transfer pricing methodology seeking manage transfer pricing issues satisfactory conclusion basis external professional advice continues believe made adequate provision liabilities likely arise open assessments glaxosmithkline notes financial statements taxation continued except shown financial statements provision made taxation would arise distribution profits retained overseas subsidiary associated undertakings grounds remittance profit retained st december required way incremental tax arise st december group corporate tax losses approximately million capital losses estimated excess billion recognised deferred tax assets insufficient evidence losses used current deferred deferred tax creditor tax debtor tax provision tax balances st january previously reported prior year adjustment st january restated exchange adjustments charge profit loss account cash paid movements st december restated deferred taxation assetliability accelerated capital allowances stock valuation adjustment intragroup profit product business disposals pensions postretirement benefits tax losses legal disputes manufacturing restructuring net timing differences categories provided deferred taxation stock valuation adjustments intragroup profit timing differences arecurrent deferred taxation movements arise origination reversal timing differences group implemented new financial reporting standard frs deferred tax requires deferred tax accounted full provision basis rather partial provision basis full year business performance tax charge increased million total tax charge million net deferred tax asset st december reduced millionnotes financial statements glaxosmithkline earnings per share restated restated p p p basic earnings per share adjustment merger items restructuring costs disposal subsidiaries merger integration transaction costs product divestments restructuring costs block drug integration costs disposal businesses associates adjusted earnings per share diluted earnings per share basic adjusted earnings per share calculated dividing profit attributable shareholders weighted average number ofshares issue period numbers used calculating basic diluted earnings per share reconciledbelow illustrate business performance primary performance measure used management adjusted earnings adjusted earnings per share presented excluding merger items integration restructuring costs disposal businesses management believes exclusion nonrecurring items provides better comparison business performance periods presented accordingly information provided supplement contained consolidated statement profit loss pages prepared accordance ukgaap basic diluted earnings per share include nonrecurring items net profit period attributable shareholders earnings basic diluted adjustments merger items restructuring costs disposal subsidiaries adjusted earnings weighted average number shares issue millions millions millions basic adjusted dilution share options diluted shares held employee share ownership trusts esot excluded trustees waived rights dividends shares held esots glaxosmithkline notes financial statements dividends glaxosmithkline plc first interim second interim third interim fourth interim glaxo wellcome plc interim second interim final smithkline beecham plc first interim second interim third interim fourth interim dividends per share p p glaxosmithkline plc first interim second interim third interim fourth interim p glaxo wellcome plc per glaxo wellcome share interim second interim final equivalent dividend per glaxosmithkline share dividend per glaxo wellcome share smithkline beecham plc per smithkline beecham share first interim second interim third interim fourth interim smithkline beecham plc equivalent dividend per glaxosmithkline share first interim second interim third interim fourth interim notes financial statements glaxosmithkline goodwill total cost st january exchange adjustments additions note cost st december amortisation st january exchange adjustments provision year amortisation st december net book value st january net book value st december licences intangible assets patents etc brands total cost st january exchange adjustments additions acquisition businesses assets written cost st december amortisation st january exchange adjustments provision year assets written amortisation st december impairment st january exchange adjustments impairment loss impairment st december net book value st january net book value st december licences patents acquired year relate acquisition various compound rights research based agreements see note brands largely comprise portfolio sterling products panadol solpadeineand hedex block drug products sensodyne polidentand poligrip considered indefinite life given strength durability brand level marketing support accordingly amortised thevaluation sterling brand reviewed annually using year cash flow forecast basis original independent assessment acquired posttax discount rate eight per cent valuation block drug brand also reviewed annually using five year cash flow forecast posttax discount rate eight per cent glaxosmithkline notes financial statements plant land equipment computer assets tangible fixed assets buildings vehicles software construction total cost st january exchange adjustments additions acquisitions disposals reclassifications cost st december depreciation st january exchange adjustments provision year disposals reclassifications depreciation st december impairment st january exchange impairment loss disposals reclassifications impairment st december net book value st january net book value st december net book value st december groups land buildings comprises freehold properties million st january million properties leases years million st january million properties leases less years million stjanuary million included plant equipment vehicles st december leased assets cost million st january million accumulated depreciation million st january million net book value million st january million impairment loss principally relates reductions forecast cash flows resulting decisions close manufacturing facilities andhasbeen measured reference value use typically using discount rate eight per cent joint associated equity fixed asset investments ventures undertakings investments shares total st january exchange adjustments additions charge year impairment transfers disposals retained profit year goodwill amortisation st december investments joint ventures comprise million share gross assets million million share gross liabilities million principal associated undertaking quest diagnostics inc us clinical laboratory business listed new york stock exchange investment book value st december million million market value million millionat st december group owned percent quest per cent holding reduced per cent february following quests acquisition unilab corporation book value includes goodwill amortised years amortisation charge million goodwill st december amounts million million goodwill million relates continuing group interest clinical laboratories assets attributed quest remains eliminated group reserves equity investments comprise listed investments million million unlisted investments million million market value listed investments million million investments shares consist shares held employee share ownership trusts see note market value shares st december million million valuation shortfall considered represent permanent diminution value context length future period related share options may exercised accordingly provision madenotes financial statements glaxosmithkline equity investments total st january exchange adjustments additions transfer fixed asset investments impairment disposals st december equity investments include listed investments million million themarket value listed investments million million stocks raw materials consumables work progress finished goods debtors restated amounts due within one year trade debtors debtors prepaid pension contributions prepayments accrued income amounts due one year debtors prepayments accrued income deferred taxation note debtors include trading balances nil million due joint ventures associated undertakings creditors amounts due within one year trade creditors taxation note social security creditors accruals deferred income dividends payable amounts due one year creditors accruals deferred income accruals include obligations wages salaries million million glaxosmithkline notes financial statements provisions pensions legal postretirement manufacturing merger deferred liabilities charges benefits restructuring integration disputes taxation provisions total st january previously reported prior year adjustment note st january restated exchange adjustments charge year applied reclassifications movements st december december group made special cash contributions totalling million uk us german pension schemes contributions relating us german pension schemes included within amounts applied provision contribution relating uk pension scheme increased prepayment amount shown debtors note group recognised costs respect plans manufacturing restructuring initiated following merger glaxo wellcome smithkline beecham acquisition block drug plans largely completed costs recognised provision principally respect identified severances sites announced manufacturing activities cease expected incurred mainly costs asset writedowns recognised impairment fixed assets group recognised costs respect plans integration glaxo wellcome smithkline beecham businesses additional costs incurred implementation integration following merger continues costs recognised provision respect identified severances expected incurred respect programme encourage staff convert glaxo wellcome smithkline beecham share options glaxosmithkline share options employees exercise options provisions legal disputes matters include amounts relating us antitrust product liability contract terminations selfinsurance environmental cleanup property rental companys directors taken legal advice established provisions taking account insurance agreements regard relevant facts circumstances matter accordance accounting requirements provisions made unasserted claims ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings investigations possible settlement negotiations glaxosmithkline involved number legal disputes including notification possible claims early stage matter reliable estimate outcome made accordingly provision recorded matters unasserted claims nature groups business number matters may subject negotiation litigation several years largest individual amounts provided expected settled within two years discussion litigation issues refer legal proceedings note contingent liabilities contingent liabilities comprising guarantees discounted bills items arising normal course business amounted st december million millionnotes financial statements glaxosmithkline net debt liquid investments cash bank loans overdrafts due within one year bank loans overdrafts commercial paper eurobonds mediumterm notes obligations finance leases loans loans due one year bank loans eurobonds mediumterm notes private financing loan stock obligations finance leases loans net debt balance sheet date groups liquid investments aggregate market value million million loans overdrafts due within one year commercial paper comprises us billion programme million issue st december st december million backed committed facilities days duration million renewable annually liquid investments million weighted average interest rate commercial paper borrowings st december per cent loans due one year million per cent coupon bond two usdollar denominated floating rate bonds totalling million issued european medium term note programme group also raised million floating rate debt private financing arrangement may redeemed group time particular event accelerating event would increase cost funding group loans due one year repayable various periods follows one two years two three years three four years four five years five years loans repayable five years carry interest effective rates per cent per cent repayment dates range glaxosmithkline notes financial statements net debt continued secured loans loans amounting million million secured charges fixed current assets finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total finance lease obligations financial instruments information given note commitments capital commitments contracted provided financial statements intangible fixed assets tangible fixed assets number commitments made licensing agreements principally elbion ag adolor corporation theravance inc unigene laboratories inc payments become due future milestones achieved agreements relate compounds early stages development milestone payments continue number years compounds move successfully development process generally closer product marketing approval greater possibility success group also commitments million relating payments made licences alliances principally exelixis inc commitments operating leases pay rentals next year operating leases land buildings expire one year less one five years five years operating leases plant equipment vehicles expire one year less one five years five years commitments operating leases pay rentals future years thereafter notes financial statements glaxosmithkline share share capital share premium account redeemable preference shares ordinary shares p p ccm oi uu nm number number share capital authorised st december st december share capital issued fully paid st january share capital redeemed par share capital issued share option schemes share capital purchased cancelled st december share capital issued share option schemes share capital purchased cancelled st december number number shares issuable outstanding options note st december st december number unissued shares option st december st december redeemable preference shares redeemed company st august nominal amount redeemable preference shares converted ordinary shares pence resulting authorised share capital st december billion ordinary shares pence october glaxosmithkline commenced new billion share buyback programme follows completion billion buyback programme announced total millionwas spent million relates new buyback programme exact amount timing future purchases determined group dependent market conditions factors period st january rd march shares purchased cancelled cost million details substantial shareholdings refer substantial shareholdings nonequity minority interests smithkline beecham holdings corporation sbh corp subsidiary incorporated delaware usa issue million flexible auction market preferred stock flex amps comprising shares issued six series dividend half shares fixed issuance seven year period dividend half fixed five year period ended varies predominately prevailing interest rates set every seven weeks auction shares also traded sbh corp also issue million auction rate preference stock arps comprising shares issued five series dividend also varies conditions similar flex amps described together arps flex amps constitute preference shares represent nonequity minority interest smithkline beecham plc certain circumstances guaranteed payment dividends declared preference shares smithkline beecham plc also agreed sbh corp certain circumstances provide support sbh corp relation principal however guarantee support limited circumstances could holder preference shares favourable position holder preference share smithkline beecham plc preference shares represent longterm nonequity minority interest group balance sheet accordance frs capital instruments uitf obligations capital instruments glaxosmithkline notes financial statements profit loss account total reserves reserves restated restated st december goodwill written back exchange movements uk tax exchange movements shares issued profit attributable shareholders dividends revaluation goodwill due exchange st december goodwill written back exchange movements shares purchased cancellation profit attributable shareholders dividends revaluation goodwill due exchange st december exchange movements uktax exchange movements shares purchased cancellation profit attributable shareholders dividends unrealised gains equity investments st december goodwill arising acquisitions st january written reserves amounts million including goodwill million previously held goodwill reserve offset reserves goodwill written back relates primarily disposals affymax part groups holding quest diagnostics inc goodwill denominated local currencies subject revaluation amounted million st december goodwill acquisitions st january capitalised accordance accounting policy set note exchange movements taken reserves include losses million losses million losses million foreign currency loans less deposits gains million losses million gains million retranslation net assets nil losses million losses million goodwill eliminated reserves uk tax exchange movements year million nil million credit relates uk taxable element foreign currency loans less deposits taken reserves exchange adjustments debited reserves cumulatively amount million reserves include merger reserve created merger glaxo wellcome smithkline beecham amounting million st december million million reserves also include capital redemption reserve created result share buyback programme amounting million st december million nil total reserves amounted million st december million million million million nil relates company million million million relates joint ventures associated undertakings profit glaxosmithkline plc year million million th december st december nil dividends million million th december st december nil gave retained profit million million th december st december nil cost shares purchased cancellation million million th december st december nil unrealised profit capital reduction subsidiary million nil th december st december nil profit loss account reserve st december stood million million nilnotes financial statementsglaxosmithkline legal proceedings even fda approve pentech anda glaxosmithkline believes pentech capsule would group involved various legal administrative substitutable paxiltablets proceedings principally product liability intellectual property antitrust governmental investigations related private october glaxosmithkline filed action synthon litigation significant matters described pharmaceuticals us district court middle district north carolina infringement groups patents intellectual property paroxetine hydrochloride paroxetine mesylate synthon usa number distributors generic drugs filed filed b application paper nda fda using applications fda market generic versions paroxetine mesylate different salt form paroxetine paxilseroxatparoxetine hydrochloride prior expiration used marketed form paxil even fda approves groups patent paroxetine hydrochloride synthon application glaxosmithkline believes synthon hemihydrate distributors looking bring market compound would substitutable paxil briefing anhydrate versions paroxetine hydrochloride one summary judgement motions filed parties case paroxetine mesylate cases complex group completed motions remain pending trial date believes generic anhydrate versions infringe set hatchwaxman stay fda approval synthon contain andor convert hemihydrate form application expires april andor infringe group patents response group filed actions distributors infringement following expiration data exclusivity period europe various groups patents marketing authorisation issued synthon bvgenthon october regulatory authorities denmark paroxetine july glaxosmithkline filed action apotex mesylate different salt form paroxetine used us district court northern district illinois infringement marketed form seroxatpaxil marketing authorisations since groups patent paroxetine hydrochloride hemihydrate granted nine european countries one national apotex filed abbreviated new drug application anda approval eight approvals mutual recognition process fda seeking approval introduce generic form paxil based original danish approval generic products containing following trial february judge ruled paroxetine mesylate launched denmark germany glaxosmithklines patent valid infringed apotexs netherlands austria ireland sweden italy although product glaxosmithkline appealing ruling non product austria denmark withdrawn following infringement us court appeals federal circuit award patent interim injunctions group initiated cafc hears appeals usdistrict courts litigation challenging approval danish medicines agency intellectual property matters grounds authorisation granted june glaxosmithkline filed action geneva abridged procedure paroxetine mesylate pharmaceuticals subsidiary novartis pharmaceuticals essentially similar seroxat marketing authorisations also us district court eastern district pennsylvania issued eleven european countries products containing infringement groups patents paroxetine hydrochloride paroxetine hydrochloride anhydrate another variant groups following notice genevas anda filing case product generic products containing anhydrate consolidated similar infringement actions market germany austria denmark netherlands spain generic companies subsequently filed andas additional sweden finland glaxosmithkline believes marketing infringement actions brought based patents issued either paroxetine hydrochloride anhydrate product paroxetine subsequent original filing apotex northern mesylate product third parties european countries infringes district illinois group also filed action apotex patents litigating position actions many european relating new patents eastern district pennsylvania countries outside usa june european patent december judge granted part denied part office opposition division rejected opposition filed synthon summary judgement motions filed apotex result groups european patent covering crystal form issues validity infringement three four new patents paroxetine mesylate used synthons product decision move toward trial glaxosmithkline petitioned district appeal contrast following action initiated court permit interim appeal cafc last expire synthon uk court revoked corresponding uk patent relating hatchwaxman stay fda approval apotex anda expires paroxetine mesylate december appeal september court appeal expected commence may february dutch court revoked corresponding dutch february cafc heard apotexs appeal decision patent decision also appealed us district court district columbia denying apotexs request fda required delist certain response challenge basf groups uk patent groups patents paxilfrom orange book cafc paroxetine hydrochloride anhydrate uk high court yet ruled matter addition apotex applied july judge decided patent partly valid court litigation eastern district pennsylvania partly invalid claims held valid asserted apotex order glaxosmithkline delist certain patents neolab waymade healthcare interim injunction preventing sale version product granted march glaxosmithkline filed action pentech november decision granting injunction affirmed pharmaceuticals us district court northern district appeal early february full trial relating alleged illinois infringement groups patents paroxetine infringement alleged invalidity take place june hydrochloride pentech filed anda capsule version paxil asserting compound presentation infringe groups patents patents invalid glaxosmithkline notes financial statements legal proceedings continued month hatchwaxman stay final fda approval expires april final fda approval may also held view may geneva pharmaceuticals commenced action rights day marketing exclusivity may held us district court eastern district virginia four andrx patents recently issued glaxosmithkline covering clavulanic acid key ingredient augmentinand timentin geneva asked group filed action infringement patents court declare new patents expire cefuroxime axetil active ingredient groups ceftinanti invalid august geneva extended complaint cover infective product ranbaxy pharmaceuticals us district three additional patents expired september court new jersey preliminary injunction granted teva pharmaceuticals filed similar action challenging four favour group cafc subsequently vacated recently issued patents patent expiring december injunction remanded case district court full cover augmentin december ranbaxy pharmaceuticals trial merits thereafter ranbaxy launched generic version filed action challenging four patents expiring march trial scheduled begin th july since ranbaxy teva actions consolidated patent group claims infringement expires geneva case december march hearings may group seeks monetary damages based tevas motions summary judgement trial judge held ranbaxys sales group filed similar action apotex groups patents expiring invalid second distributor generic pharmaceutical products us consolidated trial may judge ruled district court northern district illinois preliminary patents expiring invalid fda granted injunction granted favour group june apotex approval three companies lek pharmaceuticals subsequently obtained fda approval generic product generic products four marketed usa full trial apotex concluded january group continues believe patents valid appealed date report decision announced district court decisions cafc hearing appeal august group commenced action us district heard th march date report court district new jersey reddycheminor cafc yet ruled appeal dr reddys laboratories alleging infringement three patents august group commenced proceedings ondansetron active ingredient zofrantablets fda approval geneva pharmaceuticals parent novartis ag biochemie anda filed reddy stayed earlier january gmbh biochemie spa us international trade resolution patent infringement litigation march commission colorado state court alleging group filed similar action teva alleged manufacture sale usa genevas genericaugmentin invalidity noninfringement two method use patents product using production strain stolen earlier compound patent expiring us district court glaxosmithkline constitutes misappropriation groups trade district delaware trial date th november secrets unfair competition proceedings seek prevent set teva case third ondansetron case involving importation sale usa generic augmentin orally disintegrating zofran tablets commenced february containing clavulanate made using stolen glaxosmithkline kali laboratories us district court production strain colorado action seeks damages well district new jersey similar state court actions initiated teva lek august group commenced action us district ranbaxy court district new jersey teva alleging five distributors generic pharmaceutical products filed infringement groups compound patent lamotrigine andas sustained release bupropion hydrochloride tablets active ingredient lamictaloral tablets patent expires july wellbutrin srand zyban usa accompanied case defendant filed anda fda certification invalidity groups patents group certification invalidity groups patent fda approval brought suit patent infringement filing anda stayed earlier january resolution parties group filed suit andrx pharmaceuticals first patent infringement litigation case early stages file anda us district court southern district october pfizer inc filed action bayer ag florida february district court judge granted andrxs glaxosmithkline us district court district summary judgement motion ruled product delaware alleging manufacture sale levitra infringe groups patents group appealed decision vardenafil would infringe patent newly issued pfizer cafc oral argument appeal held asking bayer glaxosmithkline permanently enjoined december date report cafc case early stages ruled appeal actions also filed watson pharmaceuticals us district court southern district january cipla neolab filed action uk high ohio eon labs manufacturing us district court court seeking revocation one groups patents relating southern district new york impax laboratories us district asthma treatment seretideadvair patent set expire court northern district california excel including supplementary protection certificate protection pharmaceuticals us district court district new relates combination active ingredients salmeterol jersey us district court eastern district virginia fluticasone propionate separate patents exist watson case settled judges granted summary challenged providing patent protection uk judgement noninfringement impax excel cases late several uk seretide patents example appeal cafc summary judgement relating diskusdevice cfcfree mdi device denied eon eons motion reconsideration judge expire respectively confirmed denial summary judgement trial date yet challenged challenge groups patents set eon case point eon distributor relating seretideadvairin usa countries tentative fda approval generic version productnotes financial statementsglaxosmithkline legal proceedings continued following report yale haemorrhagic stroke project found suggestion association first use february group received paragraph iv notification phenylpropanolamine ppa decongestant haemorrhagic noninfringement patent relating film coating forimitrex stroke group manufacturers voluntarily sumatriptan connection anda filing ranbaxy withdrew consumer healthcare products ppa active respect imitrex paragraph iv notification extend ingredient since ppa product withdrawal group basic us patents product expire named defendant numerous personal injury class action lawsuits filed state federal courts alleging personal injury february fda website posted receipt agency increased risk injury use products containing ppa anda filing respect valtrex date report unfair deceptive business practices plaintiffs seek remedies group yet received notice paragraph iv notification including compensatory punitive damages refunds invalidity andor noninfringement respect product federal cases consolidated multidistrict litigation groups us patent active ingredient valtrex proceeding us district court district washington valaciclovir expires judge responsible proceedings initially denied class certification struck class allegations federal personal product liability injury consumer refund class actions granted plaintiffs leave fda became aware reports cardiac valvular file renewed motion certify consumer refund class problems individuals fenfluramine dexfenfluramine consisting persons possessing ppacontaining products alone combination phentermine prescribed part time fda advisory november subsequently regimen weight reduction requested voluntary judge denied renewed motion lawsuits early withdrawal fenfluramine dexfenfluramine market stages final determination whether reports cardiac valvular problems subsequent lawsuits filed state courts permitted proceed withdrawal products market spawned numerous class actions class certification denied california state product liability lawsuits filed manufacturers court appeal motion class certification still distributors fenfluramine dexfenfluramine phentermine pending pennsylvania state court one number manufacturers phentermine group august bayer ag withdrew baycolcerivastatin sodium defendant thousands lawsuits various state federal worldwide light reports adverse events including deaths district courts usa many filed class involving rhabdomyolosis glaxosmithkline participated actions lawsuits seek relief including combination marketing baycol usa pursuant copromotion compensatory punitive damages medical monitoring agreement bayer license holder refunds purchases drugs judicial panel manufacturer product following withdrawal bayer multidistrict litigation issued order consolidating transferring glaxosmithkline named defendants thousands federal actions district court eastern district lawsuits filed state federal courts usa behalf pennsylvania court approved global settlement proposed individuals putative classes former baycolusers defendant wyeth sold fenfluramine dexfenfluramine number suits allege plaintiffs suffered personal settlement subsequently confirmed third circuit court injuries including rhabdomyolosis use baycol others appeals include phentermine defendants claim persons took baycol although injured may including group individual plaintiffs may elect opt risk future injury may suffered economic damages class settlement pursue claims individually wyeth purchasing using baycol plaintiffs seek remedies including continues settle individual state court cases trial compensatory punitive statutory damages creation group continues dismissed lawsuits settled funds medical monitoring glaxosmithkline bayer wyeth corporation principal us subsidiary bayer ag signed glaxosmithkline received purported class action lawsuits filed allocation agreement bayer corporation agreed state federal courts usa alleging paroxetine pay per cent settlements compensatory damages active ingredient paxil addictive causes dependency judgements party retaining responsibility withdrawal reactions plaintiffs seek remedies including attorneys fees punitive damages federal cases compensatory punitive statutory damages cost consolidated multidistrict litigation proceeding us fund medical monitoring january federal district district court district minnesota lawsuits court judge california denied class action certification although early stages determination permitting counsel plaintiffs file one motion whether lawsuits group party certification remaining lawsuits early permitted proceed class actions stages determination whether glaxosmithkline along number pharmaceutical lawsuits pending state federal courts elsewhere companies named defendant number permitted proceed class actions purported class action numerous individual personal injury last decade litigation lawsuits state federal district courts usa alleging manufacturers prozac sustained serotonin reuptake thimerosal preservative used vaccines causes inhibitor ssri products paxil homicidal suicidal neurodevelopmental disorders injuries plaintiffs seek behaviour exhibited users products group remedies including compensatory punitive statutory damages received claims lawsuits respect paxil cost fund medical monitoring research none purport class actions lawsuits early stages determination whether purported class actions permitted proceed class actions glaxosmithkline notes financial statements legal proceedings continued antitrust november us federal trade commission ftc staff following voluntary withdrawal lotronex usa advised group staff conducting nonpublic november number lawsuits filed investigation determine whether group violating group state federal district courts including individual section federal trade commission act monopolizing personal injury actions purported class actions asserting attempting monopolize market paroxetine product liability consumer fraud claims plaintiffs seek remedies hydrochloride preventing generic competition paxil including compensatory punitive statutory damages requested group submit certain information connection number claims settled remaining actions investigation group cooperated staffs early stages although tentative trial dates investigation cases set early following public reference ftc investigation regarding paxil government investigations purported consumer class actions filed us district glaxosmithkline received subpoenas us attorneys court eastern district pennsylvania behalf putative office boston massachusetts requesting production classes indirect purchasers including consumers third party documents period present relating payers plaintiffs claim group monopolised repackaging relabelling private label arrangements market paxilby bringing allegedly sham patent litigation glaxosmithkline discussed thirdparty customers allegedly abusing regulatory procedures listing period issue whether prices charged patents fda orange book treble damages sought third parties glaxosmithkline products must counted alleged overcharges flowing conduct cases medicaid best price purposes group also received letters early stage determination whether centers medicare medicaid services cms stating permitted proceed class actions cmss position certain prices us pharmaceutical businesses smithkline included medicaid best price requesting beecham glaxo wellcome group party number glaxosmithkline retroactively adjust best price reports antitrust suits certain certified class actions quarters prior july include prices group instituted nations retail pharmacies consumers involved discussions us attorneys office resolve several states alleging conspiracies restraint trade issues challenging pricing practices group significant glaxosmithkline responding subpoenas number pharmaceutical companies wholesalers office inspector general us department health also sued similar litigation actions human services us department justice states except several actions brought state courts texas california connection allegations consolidated pretrial purposes district court pharmaceutical companies including glaxosmithkline northern district illinois federal class action component violated federal fraud abuse laws federal false includes pharmacies representing approximately twothirds claims act respect texas california comparable total us retail sales volume settled glaxo wellcome state laws result way certain drugs priced smithkline beecham since time group way medicare medicaid programmes reimburse entered settlements satisfactory terms group drugs nevada montana state attorneys general engaged conspiracy admission filed civil lawsuit state court glaxosmithkline wrongdoing made included final agreements several drug companies actions claim behalf august us district court district states payers behalf instate patients massachusetts ruled groups patent nabumetone relafen consumers damages restitution based defendants invalid anticipatory art unenforceable grounds pricing undefined set pharmaceutical products inequitable conduct group filed appeal decision first quarter county suffolk new york november august cafc issued decision filed action federal court also asserts claims affirming district courts judgement invalidity declining glaxosmithkline others relating reported average rule judgement inequitable conduct following wholesale price certain drugs covered states medicaid district court decision antitrust claims alleging competitive injury program new york state attorney general filed similar overcharges filed teva generic manufacturer complaint new york state court addition private payer class nabumetone purported classes direct purchasers action lawsuits filed glaxosmithkline several payers individual groups purported direct purchasers federal district state courts number federal cases plaintiffs claims based allegations fraudulent consolidated multidistrict litigation proceeding procurement patent wrongful listing patent fda us district court district massachusetts orange book prosecution sham patent infringement civil suits filed state attorneys general class action plaintiffs litigation cases originally filed us district removed federal court removed cases courts district massachusetts eastern district including nevada montana cases consolidated pennsylvania pending district massachusetts district massachusetts proceedings steps early stages determination taken consolidate removed cases nevada whether putative class actions permitted proceed montana private class action plaintiffs class actions originally filed state court seeking cases remanded respective state courts actions early stagesnotes financial statementsglaxosmithkline legal proceedings continued proceedings seek require operators hazardous waste facilities transporters waste sites generators us district court eastern district virginia hazardous waste disposed sites clean sites found various patents covering augmentin invalid group reimburse government cleanup costs instances filed appeal decision still pending glaxosmithkline involved alleged generator hazardous cafc immediately following adverse trial court decision waste although sites glaxosmithkline purported antitrust class actions filed behalf consumers involved current former operator facility although third party payers various federal courts superfund provides defendants jointly severally transferred consolidated us district court liable cleanup costs proceedings frequently resolved eastern district virginia plaintiffs allege group basis nature quantity waste disposed knowingly obtained invalid patents engaged site generator glaxosmithklines proportionate liability anticompetitive conduct prevent entry generic products cleanup costs substantially determined violation monopolization section us antitrust laws sites referred plaintiffs seek declaratory injunctive relief well treble damages alleged overcharges glaxosmithklines potential liability varies greatly site site determination whether putative class actions cost investigation study remediation sites early stages permitted proceed class actions could time substantial glaxosmithkline routinely accrues separately group prosecuting patent infringement suits amounts related share liability matters four companies filed andas seeking permission sell generic bupropion wellbutrin srzyban us three tax matters cases summary judgement entered pending tax matters described note group following adverse rulings patent litigation purported class action behalf purchasers third party payers filed us district court eastern district pennsylvania alleging group engaged anticompetitive conduct including prosecution sham patent infringement litigation prevent entry generic products plaintiffs seek declaratory injunctive relief well treble damages alleged overcharges commercial matters otsuka pharmaceutical co ltd initiated arbitration proceedings december concerning groups unilateral withdrawal grepafloxacin raxarvaxar october safety reasons otsuka alleges product withdrawal simultaneous public announcement constituted material breaches license supply agreements group believes underlying product withdrawal consistent terms agreements valid defences exist claims uk arbitration panel selected met hearing determine liability scheduled december smithkline beecham clinical laboratories indemnities connection sale smithkline beecham clinical laboratories sbcl quest diagnostics inc group agreed indemnify quest diagnostics aftertax basis respect certain liabilities arising conduct sbcl business prior closing including governmental private claims arising us governments investigation sbcls billing marketing practices environmental matters glaxosmithkline notified potential responsibility relating past operations past waste disposal practices certain sites primarily usa matters subject litigation including proceedings initiated us federal state governments waste disposal site remediation costs tort actions brought private parties glaxosmithkline advised may responsible party approximately sites appear national priority list created comprehensive environmental response compensation liability act superfund glaxosmithkline notes financial statements acquisitions disposals details acquisition disposal subsidiary associated undertakings joint ventures given book fair value net assets goodwill cost values adjustments acquired capitalised acquisition acquisitions iterfi sterilyo human kft iterfi sterilyo group acquired iterfisterilyo group initial cash consideration million payment payable maximum million depending financial performance acquired company net assets iterfisterilyo incorporated financial statements provisional fair values human kft group acquired vaccine related assets human kft manufacturing business located hungary cash consideration million disposals sb clinical laboratories cash refund million received respect indemnified liabilities arising sb clinical laboratories disposal occurred refund result successful case us court appeal sb clinical iterfi human laboratories sterilyo kft total cash flows cash consideration paid cash acquired net cash payment acquisitions net cash proceeds disposals book fair value net assets goodwill cost values adjustments acquired capitalised acquisition acquisitions block drug shionogi joint venture block drug company inc january group acquired block drug cash consideration million represented fair value assets acquired shionogi joint venture group established joint venture shionogi develop commercialise number compounds contributed parties group acquired per cent equity share capital cash consideration million committed make contributions certain development milestones achievednotes financial statementsglaxosmithkline acquisitions disposals continued disposals quest diagnostics inc may group disposed million shares investment quest diagnostics inc cash proceeds million reducing groups holding st december per cent recognising charge goodwill previously written reserves million profit million recognised affymax group completed sale affymax business affymax inc new holding company million nonvoting preference shares affymax inc representing value million million recognising charge goodwill previously written reserves million loss million made disposal costs million incurred completing sale tagamet february group sold tagamet japan sumitomo pharmaceutical co ltd cash consideration million recognising charge goodwill previously written reserves million loss million recognised quest diagnostics affymax tagamet block drug shionogi total cash flows cash consideration paid cash acquired net cash payment acquisitions net cash proceeds disposals book fair value net assets goodwill cost values adjustments acquired capitalised acquisition acquisitions glaxosmithkline pharmaceuticals sa acquisition minority interests glaxosmithkline pharmaceuticals sa group acquired per cent glaxosmithkline pharmaceuticals sa formerly polfa poznan sa poland cash consideration million goodwill million capitalised amortised line initial acquisition disposals affymetrix inc may group sold two million shares affymetrix inc cash proceeds million realising profit million sb clinical laboratories final cash settlement us million million paid october complete sale sb clinical laboratories sb clinical glaxosmithkline laboratories affymetrix pharmaceuticals sa total cash flows cash consideration paid cash acquired net cash payment acquisitions net cash proceeds disposals glaxosmithkline notes financial statements financial instruments related disclosures fair value financial assets liabilities table presents carrying amounts uk policies gaap fair values groups financial assets discussion groups objectives policies liabilities st december st december management offinancial instruments associated risks debtors creditors due within one year excluded included treasury policies operating financial review prospects fair values financial assets liabilities included atthe amount instrument could exchanged investments current transaction willing parties forced group holds number equity investments frequently liquidationsale following methods assumptions entities group entered research collaborations used estimate thefair values group seeks realise value investments equity investments market value based quoted market inpart research collaboration helps create therefore prices case listed investments market value certain investments regarded available sale reference quoted prices similar companies recent accounted foras current asset investments purposes financing information case material unlisted ofusgaap current asset investments classified investments available sale cash bank approximates carrying amount glaxosmithkline hedged part equity value liquid investments based quoted market prices similar holdings largest equity investment quest diagnostics inc companies recent financing information case series variable sale forward contracts contracts marketable securities approximates carrying amount equity collar structured five series one inthe case time deposits short maturity million quest shares mature shortterm loans overdrafts approximates carrying amount short maturity instruments group liquid investments representing funds surplus mediumterm loans market value based quoted market immediate operating requirements accounted prices case eurobonds fixed rate current asset investments purposes usgaap borrowings approximates carrying amount case investments classified available sale proceeds offloating rate bank loans loans sale investments classified available saleunder us gaap forward exchange contracts based market prices year ended stdecember weremillion exchange rates balance sheet date proceeds include rollover liquid funds shortterm deposit currency swaps based market valuations balance gross gains losses reflected consolidated profit sheetdate loss account respect investments classified available sale equity collar fair value determined based option us gaap million andmillionrespectively pricing model interest rate instruments based market valuations foreign exchange risk management balance sheet date group entered forward foreign exchange contracts debtors creditors approximates carrying amount inorder swap liquid assets borrowings currencies provisions approximates carrying amount required group purposes st december group auction rate preference stock approximates carrying outstanding contracts sell purchase foreign currency amount case floating rate instruments total notional principal amount million flexible auction market preferred stock based market million majority contracts periods valuations balance sheet date months less end year group number currency swaps fair value investments shares inplace respect mediumterm debt instruments group st december investments shares million million fair value borrowings denominated swapped foreign currencies million million difference match investments overseas group assets treated carrying amount fair value represents unrealised ahedge relevant net assets exchange gains loss million valuation shortfall considered losses recorded reserves represent permanent diminution value context length future period related share options interest rate risk management may exercised accordingly provision made manage fixedfloating interest rate profile debt group investments excluded financial instrument disclosure several interest rate swaps outstanding commercial banks fair value market value based quoted market price st december shares represent purchases employee share ownership concentrations credit risk credit exposures trusts satisfy future exercises options awards financialinstruments employee incentive schemes purchases matched group believe exposed major concentrations options predetermined exercise prices gain loss credit risk group exposed creditrelated losses recognised measured exercise price rather event nonperformance counterparties financial market value instruments expect counterparties fail meet obligations group applies boardapproved limits amount credit exposure one counterparty employs strict minimum credit worthiness criteria choice counterpartynotes financial statementsglaxosmithkline financial instruments related disclosures continued classification fair values financial assets liabilities following table sets classification financial assets liabilities provides reconciliation group net debt note shortterm debtors creditors excluded financial assets liabilities provisions included contractual obligation settle cash carrying fair carrying fair amount value amount value net debt liquid investments cash bank current asset financial instruments sterling notes bonds us dollar notes bonds private financing notes bonds swapped us dollars currency swaps interest rate swaps notes bonds swapped yen currency swaps mediumterm borrowings shortterm loans overdrafts total borrowings interest rate swaps total net debt fixed asset equity investments current asset equity investments debtors due year creditors due year provisions foreign exchange derivatives equity collar auction rate preference stock flexible auction market preferred stock total nonequity minority interests total financial assets liabilities total financial assets total financial liabilities appropriate currency interest rate swaps presented alongside underlying principal instrument carrying amounts instruments adjusted effect currency interest rate swaps acting hedges difference carrying amount fair value equity fixed current assets liquid investments represents gross unrealised gains million million respectively glaxosmithkline notes financial statements financial instruments related disclosures continued currency interest rate risk profile financial liabilities financial liabilities taking account currency interest rate swaps analysed total financial liabilities comprise total borrowings million million creditors due one year million million provisions million million nonequity minority interest preference shares million million exclude foreign exchange derivatives nil million creditors due within one year excluded benchmark rate determining interest payments floating rate financial liabilities tables libor fixed rate noninterest bearing weighted weighted average average weighted st december interest years floating average rate rate rate years total currency fixed maturity us dollars sterling euro japanese yen currencies fixed rate noninterest bearing weighted weighted average average weighted st december interest years floating average rate rate rate years total currency fixed maturity us dollars sterling euro japanese yen currencies currency interest rate risk profile financial assets total financial assets comprise fixed asset equity investments million million current asset equity investments million million liquid investments million million cash bank million million debtors due one year million million exclude foreign exchange derivatives million nil benchmark rate determining interest receipts floating rate assets table libor st december fixed floating noninterest rate rate bearing total currency us dollars sterling euro japanese yen currencies st december fixed floating noninterest rate rate bearing total currency us dollars sterling euro japanese yen currencies notes financial statementsglaxosmithkline financial instruments related disclosures continued currency exposure net monetary assetsliabilities groups currency exposures give rise net currency gains losses recognised profit loss account arise principally companies sterling functional currency monetary assets liabilities denominated overseas functional currency andborrowings designated hedge overseas net assets excluded table stdecember functional currency group operation net monetary assetsliabilities sterling us euro yen total held nonfunctional currency sterling us dollars euro japanese yen stdecember functional currency group operation net monetary assetsliabilities sterling us euro yen total held nonfunctional currency sterling us dollars euro japanese yen nonequity finance minority total total debt leases interests maturity financial liabilities within one year demand one two years two five years five years gains losses net hedges unrecognised gains losses beginning year gains losses arising previous years recognised year gains losses arising beginning year still unrecognised end year unrecognised gains losses arising year total unrecognised gains losses end year expected recognised within one year expected recognised one year total unrecognised gains losses end year unrecognised gains losses represent difference carrying amount fair value currency swaps interest rate swaps equity collar foreign exchange derivatives committed facilities group committed facilities back commercial paper programme million million days duration renewable annually st december undrawn committed facilities totalled million glaxosmithkline notes financial statements employee costs wages salaries social security costs pension postretirement costs cost sharebased incentive plans severance costs arising integration restructuring activities pension postretirement costs arising integration group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance information directors remuneration given remuneration report pages average number persons employed group including directors year number number number manufacturing selling general administration research development average number group employees excludes temporary contract staff numbers group employees end financial year given financial record pension postretirement costs uk pension schemes us pension schemes overseas pensions schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid schemes unfunded defined benefit schemes defined contribution schemes unfunded postretirement healthcare schemes postemployment costs pension postretirement costs arising integration included within ukpension costs exceptional charge million relating pension augmentation redundancies arising manufacturing restructuring plans uk pensions group undertakings operate pension arrangements cover groups material obligations provide pensions retired employees thesearrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length ofservice defined benefit schemes also include defined contribution sections aredescribed hybrid schemes table majority cases contributions defined benefit schemes determined accordance advice independent professionally qualified actuaries formal independent actuarial valuations groups main plans undertaken regularly normally least every three years theassets funded schemes generally held separately administered trusts insured pension costs accounting purposes assessed accordance independent actuarial advice generally using projected unit method spreading surpluses deficits average expected remaining service lives respective memberships certain countries pension benefits provided unfunded basis scheme administered trustee company whereassets held specific purpose matching liabilities unfunded schemes provision included within provisions pensions postretirement benefits charge profits respect benefits aggregate ofthe increase year intheassessed liabilities members still service net movement provisions set pensions inpayment liabilities generally assessed annually accordance advice independent actuariesnotes financial statementsglaxosmithkline employee costs continued throughout pension arrangements former glaxo wellcome companies former smithkline beecham companies continued operated separately however instances including usa pension arrangements merged following information deals set arrangements accordingly market value assets groups funded defined benefit pension funds dates latest actuarial valuations date back billion actuarial value assets sufficient cover approximately per cent benefits accrued members allowing future salary andpension increases uk defined benefit pension schemes account approximately per cent groups plans asset valuation projected benefit terms us defined benefit pension schemes account approximately per cent groups plans asset valuation projected benefit terms december group made special funding contributions uk us german pension schemes totalling million company review pension position annually make contributions appropriate pension costs expected higher new actuarial valuations ukand us schemes become available uk uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme relevant assumptions used calculating pension costs former glaxo wellcome former smithkline beecham uk defined benefit schemes accounting purposes follows pa pa rate increase future earnings discount rate expected longterm rate return investments expected pension increases uk equity dividend growth regular cost glaxo wellcome pension arrangements million became million credit financial statements allowance made spreading surplus disclosed level percentage salary expected future working lifetime existing members years recent triennial actuarial valuations glaxo wellcome schemes funding purposes carried stmarch date assets schemes represented per cent actuarial value benefits accrued members allowing future salary pension increases trustees uk pension schemes agreed companys request grant various benefit improvements included five per cent enhancement entitlement beneficiaries allowance made improvements funding level fell per cent following valuations normal company contributions schemes remain suspended least next formal valuation thetotal market value assets held schemes st march million regular cost smithkline beecham schemes million increased accounting cost million allowance made spreading deficit expected future working lifetime current employees scheme years latest valuation carried st december date actuarial value scheme assets represented per cent actuarial value accrued service liabilities based assumptions total market value assets held scheme st december million usa usa former glaxo wellcome smithkline beecham defined benefit hybrid schemes merged relevant assumptions used calculating pension costs accounting purposes follows pa pa rate increase future earnings discount rate expected longterm rate return investments cash balance creditconversion rate us equity dividend growth regular cost us scheme million increased accounting cost million allowance made spreading deficit expected future working lifetime current employees scheme latest valuation carried st january date actuarial value scheme assets represented per cent actuarial value theaccrued service liabilities total market value assets held scheme st january million glaxosmithkline notes financial statements employee costs continued frs disclosures group continues account pension arrangements accordance ssap accounting pension costs transitional provisions frs retirement benefits certain disclosures required basis valuation methodology adopted frs defined benefit schemes fair values pension scheme assets st december compared future pension liabilities calculated projected unit method applying following assumptions uk usa rest world pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na cash balance creditconversion rate na na na na inflation rate expected longterm rates return assets fair values assets liabilities uk us defined benefit schemes together aggregated data defined benefit schemes group follows uk usa rest world group average st december expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value scheme liabilities value schemes surplus deferred tax liability value schemes deficit deferred tax asset group total assets ukand us schemes include special contributions paid december allocated equities bonds uk usa rest world group average st december expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value scheme liabilities value schemes surplus deferred tax liability value schemes deficit deferred tax asset group total notes financial statementsglaxosmithkline employee costs continued uk defined benefit schemes also defined contribution sections account balances totalling million st december million defined benefit sections uk schemes closed new members projected unit method valuing pension scheme liabilities current service cost increase members schemes approach retirement deficits frs reflect different bases valuing assets liabilities compared ssap including immediate impact fair values assets st december group also operates number unfunded postretirement healthcare schemes principal one usa liability frs us scheme assessed using assumptions us pension scheme together assumption future medical inflation per cent reducing one per cent per year five per cent basis liability usscheme assessed million million reduced million million taking account deferred tax defined benefit pension postretirement benefit schemes accounted frs following amounts would recorded profit loss account statement total recognised gains losses year ended st december postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost curtailmentssettlements amounts creditedcharged net interest expected return pension scheme assets interest scheme liabilities amounts recorded statement total recognised gains losses actual return less expected return pension scheme assets experience gainslosses arising scheme liabilities changes assumptions relating present value scheme liabilities movements deficits year deficits schemes st january exchange adjustments charged operating profit employer contributions finance incomeexpense actuarial loss recognised statement total recognised gains losses deficits schemes st december history experience gains losses difference expected actual return scheme assets percentage scheme assets st december experience gainslosses scheme liabilities percentage present value scheme liabilities st december total amount recognised statement total recognised gains losses percentage present value scheme liabilities st december glaxosmithkline notes financial statements employee costs continued frs valuation basis applied financial statements instead ssap valuation basis effect profit loss account reserve taking account deferred tax would follows restated profit loss account reserve per balance sheet pension liability frs pension liability ssap per balance sheet postretirement healthcare schemes frs postretirement healthcare schemes provision per balance sheet profit loss account reserve including pension postretirement healthcare liability employee share schemes company operates share option schemes whereby options granted employees acquire shares adss glaxosmithkline plc grant price share award schemes whereby awards granted employees acquire shares adss glaxosmithkline plc cost subject tothe achievement performance targets details given relate schemes operated glaxosmithkline separately glaxo wellcome smithkline beecham date merger became schemes glaxosmithkline merger glaxo wellcome option outstanding date merger converted one glaxosmithkline option smithkline beecham share option wasconverted glaxosmithkline share option smithkline beecham ads option converted glaxosmithkline ads options corresponding adjustments grant price glaxosmithkline share option schemes company operates share option schemes savingsrelated share option schemes grants share option schemes normally exercisable three ten years date grant grants savingsrelated share option schemes normally exercisable three years saving options share option schemes normally granted market price ruling date grant accordance uk practice majority options savingsrelated share option schemes granted price per cent market price ruling date grant options outstanding share option share option savingsrelated schemes shares schemes adss share option schemes st december weighted weighted weighted number exercise number exercise number exercise price price price th december converted gw options converted sb options options exercised options cancelled st december options granted options exercised options cancelled st december options granted options exercised options cancelled st december range exercise prices order encourage employees convert options excluding savingsrelated share options held glaxo wellcome smithkline beecham shares adss glaxosmithkline shares adss programme established give additional cash benefit ten per cent exercise price original option provided employee voluntarily leave group two years date merger exercise option earlier six months expiry date original option two years date merger cash benefit also paid options expire unexercised market price exercise price date expirynotes financial statementsglaxosmithkline employee share schemes continued options outstanding share option share option savingsrelated schemes shares schemes adss share option schemes st december weighted latest weighted latest weighted latest number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total options exercisable except options shares granted options shares adss granted savingsrelated share options granted change effective exercise price outstanding options year options granted st december rdmarch options exercisable share option share option savingsrelated schemes shares schemes adss share option schemes weighted weighted weighted number exercise number exercise number exercise price price price st december st december st december glaxosmithkline share award schemes group operates performance share plan whereby awards granted directors senior staff cost percentage award vests based upon performance group three year measurement period performance conditions consist two parts applies per cent award first part condition compares glaxosmithklines total shareholder return tsr period tsr companies ukftse index period second part performance condition compares glaxosmithklines earnings per share growth increase ukretail prices index three year performance period shares adss number shares adss issuable number number th december converted glaxo wellcome awards converted smithkline beecham awards awards exercised st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards relating shares nil relating adss exercisable st december glaxosmithkline notes financial statements employee share schemes continued smithkline beecham share option schemes date merger smithkline beecham share options became exercisable shares adss weighted weighted exercise exercise number shares adss issuable outstanding options number price number price st december options granted options exercised options cancelled converted glaxosmithkline options st december smithkline beecham midterm incentive plan smithkline beecham adopted midterm incentive plan mtip participations mtip granted annually senior staff smithkline beecham designating target number shares participant based job grade following threeyear measurement period rn committee reviewed smithkline beechams total shareholder return relative companies comprising ftse index made final award proportion target number shares per cent depending performance first two measurement periods ended st december per cent per cent respectively target number shares awarded receipt award could deferred case shares remained mtip result merger outstanding awards became payable per cent target number shares end threeyear cycle shares adss number shares issuable midterm incentive plan number number st december awards granted awards exercised awards cancelled converted glaxosmithkline awards st december glaxo wellcome share option schemes date merger glaxo wellcome options except share options granted savingsrelated share options granted became exercisable performance conditions applicable lapsed savingsrelated share option schemes share option schemes total weighted weighted weighted exercise exercise exercise number shares issuable outstanding options number price number price number price st december options granted options exercised options cancelled converted glaxosmithkline options st december glaxo wellcome share award schemes glaxo wellcome operated long term incentive plan annual incentive plan long term incentive plan granted awards shares directors senior staff nominal cost percentage award vested based performance glaxo wellcome threeyear period annual incentive plan performance bonus consisting basic award ofshares matching award threeyear retention period result merger awards long term incentive plan became payable full retention period annual incentive plan lapsed number shares issuable share award schemes number st december awards granted awards exercised awards cancelled converted glaxosmithkline awards st december notes financial statementsglaxosmithkline employee share schemescontinued employee share ownership trusts group sponsors employee share ownership trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees employee share ownership trusts purchase shares onthe open market finance provided group way loan contributions expected cost obligations deliver shares schemes normally spread periods service respect awards options granted accelerated charge made respect outstanding cost providing shares awards options became exercisable solely result merger shares held share award schemes number shares nominal value cost less provision market value shares held share option schemes number shares nominal value cost less provision market value trusts also acquire hold shares meet notional dividends reinvested deferred awards smithkline beecham midterm incentive plan trustees waived rights dividends shares held employee share ownership trusts option pricing purposes valuing options arrive stockbased compensation adjustment reconciliation us accounting principles note blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected lives options granted share option schemes years years savings related share option schemes years years related party transactions glaxosmithkline held per cent interest quest diagnostics inc throughout holding reduced per cent february following quests acquisition unilab corporation december glaxosmithkline quest amended terms global trials agreement longterm contractual relationship quest primary provider clinical laboratory testing support groups clinical trials testing requirements worldwide february mr ingram member cet purchased portion land part residential property owned group adjacent mr ingrams residence total sale price based independent valuation land group subsequently determined retention residential property longer served business needs listed property sale independent valuation property rd june valued property offered sale estate agent mr ingram made highest offer property purchased group total consideration glaxosmithkline plc investment subsidiary companies glaxosmithkline plc initiated internal reorganisation result company acquired direct investments subsidiary companies previously held indirect investments glaxosmithkline notes financial statements reconciliation usaccounting principles summary material differences uk us gaap financial statements analyses reconciliations presented capitalised interest note represent financial information would uk gaap group capitalise interest usgaap required us generally accepted accounting principles usgaap requires interest incurred part cost constructing fixed applied instead ukgaap assets capitalised amortised life asset significant difference us uk gaap computer software ukgaap combination glaxo wellcome plc uk gaap group capitalises costs incurred acquiring smithkline beecham plc accounted merger developing computer software internal use pooling interest usgaap transaction software supports significant business system accounted purchase business combination glaxo expenditure leads creation durable asset us gaap wellcome acquiring smithkline beecham group applies sop accounting costs computer software developed obtained internal use glaxosmithkline plc formed give effect scheme restricts categories costs capitalised arrangement merger glaxo wellcome plc smithkline beecham plc effective thdecember glaxosmithkline plc goodwill intangible fixed assets acquired whole issued share capital glaxo wellcome plc ukgaap goodwill arising acquisitions smithkline beecham plc exchange shares accounted purchase method eliminated glaxosmithkline plcupon completion merger former shareholders funds additionally ukgaap requires shareholders glaxo wellcome held approximately per cent subsequent disposal closure business goodwill former shareholders smithkline beecham held previously taken directly shareholders funds charged approximately per cent issued share capital income beginning group changed glaxosmithkline plc accounting policy forgoodwill intangible assets uk gaap respect acquisitions ukgaap combination glaxo wellcome smithkline beecham goodwill arising acquisitions capitalised accounted merger ukgaap financial amortised period exceeding years statements glaxosmithkline ukgaap represent combined financial statements glaxo wellcome smithkline us gaap goodwill arising acquisitions prior beecham historical basis june capitalised amortised period exceeding years july fasb issued sfas us gaap business combination qualify goodwill intangible assets sfas requires pooling interests accounting glaxo wellcome goodwill longer amortised estimated useful life determined accounting acquirer purchase acquisition group must instead identify value reporting units dated thdecember us gaap financial purpose assessing least annually potential impairment statements glaxosmithkline prior merger therefore goodwill allocated reporting unit additionally group glaxo wellcome reassesses useful lives existing recognised intangible assets view proximity merger date financial year end intangible assets deemed indefinite lives longer date relative insignificance business activity amortised instead tested annually potential th december st december accounting impairment separate intangible assets finite lives continue date acquisition practical purposes taken amortised useful lives stdecember group adopted sfas st january reconciliation consolidated income statements implementation sfas resulted impairment consolidated statements comprehensive income changes groups goodwill initial impairment million shareholder equity year ended st december million net tax indefinitelived assets shown correspondingly reflect purchase method accounting cumulative effect accounting change theacquisition smithkline beecham glaxo wellcome ukgaap costs incurred integrating income statement presented us gaap format restructuring wellcome smithkline beecham block drug therefore certain exceptional items ukgaap product businesses following acquisitions divestments merger integration costs addition writeoff respectively charged profit loss account post inprocess research development classified within acquisition usgaap certain costs considered operating profit allocation purchase consideration thereby affecting consolidated balance sheet consolidated statement cash goodwill arising acquisition flows usgaap usgaapformat also presented ukgaap certain intangible assets related specific financial statements reflect purchase method compounds products purchased third party accounting combination glaxo wellcome smithkline developed commercial applications capitalised beecham also material adjustments would usgaap payments made compounds products required usgaap applied instead ukgaap still development yet received regulatory theperiods presented summary purchase accounting approval charged directly profit loss time adjustments usgaap adjustments provided receive regulatory approval reconciliations profit attributable shareholders equity shareholders funds uk usgaapnotes financial statementsglaxosmithkline reconciliation us accounting principles continued result merger certain groups options vested immediately requiring acceleration compensation expense merger transaction costs amount stockbased compensation expense related glaxo wellcome incurred total mergerrelated transaction costs accelerated vesting million disclosures million excluding integration restructuring costs uk required sfas included note gaap merger transaction costs expensed incurred usgaap direct acquisition costs additionally group entitled receive tax deduction acquiring company included portion purchase amount treated compensation us tax rules employee consideration stock options exercised usemployees year ukgaap treated reduction tax restructuring costs expense whereas usgaap portion amount requirements recording provision restructuring costs credited equity different certain aspects usgaap uk gaap accordingly adjustments made eliminate employee share ownership trust esot ukgaapprovisions restructuring costs notmeet us uk gaap shares groups stock held esot gaaprequirements arerecorded cost less provision representing difference cost option exercise price accounted marketable securities fixed asset investments projected losses exercise marketable securities consist primarily equity securities options covered shares recorded profit certain liquid investments ukgaap securities loss account life theoptions us gaap shares stated lower cost net realisable value us groups stock purchased esot accounted within gaap securities available sale statement shareholders equity cost gainsorlosses arising subsequent financial accounting standard sfas accounting issuance shares employees satisfy share options certain investments debt equity securities carried recorded adjustments toshareholders equity fair value unrealised gains losses net tax reported separate component shareholders equity derivative instruments statement financial accounting standard accounting pensions postretirement benefits derivative instruments hedging activities sfas key differences uk ssap usgaap relation amended sfas sfas interpreted defined benefit pension plans derivatives implementation group adopted group ukgaap effect variations cost effect st january sfas establishes accounting accumulated successive valuations amortised reporting standards derivative instruments including certain aggregate basis us gaap amortisation derivative instruments embedded contracts collectively transition asset costs past service benefit referred derivatives hedging activities uk improvements separately tracked experience gainslosses gaap derivative instruments used hedging dealt aggregate basis amortised recognised balance sheet matching principle outside per cent corridor used match gain loss hedging contracts foreign currency transaction profits relate uk gaap allows measurements plan assets liabilities sfas requires entity recognise derivatives either based result latest actuarial valuation usgaap assets liabilities consolidated balance sheet measure requires measurement plan assets liabilities made instruments fair value changes fair value date financial statements three months period recorded current earnings unless hedge accounting prior date obtained group designate derivatives pension adjustment also includes impact changes qualifying hedge instruments sfas sfas prescribes minimum pension liabilities included within accumulated requirements designation documentation hedging comprehensive income relationships ongoing assessments effectiveness order qualify hedge accounting group decided align measurement date pension plans st december certain group also evaluates contracts embedded derivatives groups plans measurement date pension assets considers whether embedded derivatives bifurcated liabilities th september separated host contracts accordance sfas requirements embedded derivatives exist clearly impact reflected cumulative effect accounting closely related host contract accounted change million credit net tax income separately host contract derivatives disclosures required sfas included note gains losses related fair value adjustments derivative instruments classified consolidated statement stockbased compensation income cash flows accordance nature uk gaap share options accounted equity derivative exercised valued issuance price usgaap group applies sfas accounting stockbased compensation fair value book value derivative instruments respect related accounting interpretations accounting option plans financial assets liabilities st december require options fair valued grant date disclosed classification fair value financial assets included profit loss vesting period options liabilities table note glaxosmithkline notes financial statements reconciliation us accounting principles continued comprehensive income statement requirement sfas reporting comprehensive income valuation derivative instruments provide comprehensive income statement met ukgaap fair value derivative instruments sensitive movements statement total recognised gains losses pages underlying market rates variables group monitors statement comprehensive income usgaap fair value derivative instruments periodic basis derivatives three years period ending st december presented including interest rate swaps cross currency swaps valued pages usgaap statement includes using standard valuation models counterparty valuations third net impact gains losses equity liquid investments party valuations standard valuation models used group translation adjustments consider relevant discount rates market yield curve valuation date forward currency exchange rates counterparty recent financial accounting standards board fasb risk significant rates variables obtained market pronouncements sources valuations based remaining term maturity june fasb approved sfas accounting instrument foreign exchange contracts valued using obligations associated retirement longlived assets forward rates observed quoted prices relevant markets requires fair values obligation associated possible group assumes parties longterm contracts retirement longlived assets capitalised part economically viable reserves right exercise early cost required implemented group termination rights economically beneficial rights exist effect st january group believe contract adoption standard material impact results dividends uk gaap dividends proposed provided year st january sfas accounting impairment respect recommended board ofdirectors disposal longlived assets adopted group approval shareholders usgaap suchdividends sfas develops one accounting model longlived assets provided declared board ofdirectors including discontinued operations disposed sale requires longlived assets measured lower deferred taxation carrying amount fair value less cost sell whether reported uk gaap group implemented frs continuing discontinued operations adoption sfas deferred tax requires deferred tax accounted material impact groups financial full provision basis similar requirement usgaap rather statements partial provision basis earlier years consequence profit attributable shareholders equity april sfas rescission fasbstatements shareholders funds ukgaap deferred tax amendment fasbstatement technical adjustments usgaap prior periods restated corrections issued statement updates clarifies impact net loss shareholders equity us simplifies existing accounting standards group gaap previously reported adoption frs believe adoption standard material impact eliminated differences deferred tax previously results existed ukgaap usgaap result sfas accounting costs associated exit disposal adjustment primarily relates deferred tax effect activities issued june sfas requires companies usgaap adjustments recognise costs associated exit disposal activities incurred rather date commitment exceptional items exit disposal plan applied prospectively exit items classified exceptional uk gaap meet disposal activities initiated st december group definition extraordinary us gaap therefore currently assessing impact standard classified operating expense november fasb published interpretation consolidated statement cash flows guarantors accounting disclosures requirements usgaap cash flow statement reports changes cash guarantees including indirect guarantees indebtedness cash equivalents includes shortterm highly liquid othersfin fin expands accounting guidance investments original maturities three months less sfass fins provisions initial recognition onlythree categories cash flows reported operating measurement applied guarantees issued modified activities including tax interest investing activities including st december disclosure requirements effective capital expenditure acquisitions disposals together financial years ending th december group cashflows available sale current asset investments believe adoption fin material andfinancing activities including dividends paid statement impact results ofcash flows presented january fasb published interpretation consolidation variable interest entities fin fin cash cash equivalents primary beneficiary entity must consolidate certain uk gaap cash balance includes cash bank entities known variable interest entities measurement cash balances usgaap cash cash equivalents principles apply groups financial statements include cash bank certain liquid investments original group believe adoption fin maturities three months less material impact resultsnotes financial statementsglaxosmithkline reconciliation us accounting principles continued consolidated balance sheet underus gaap assets current assets cash cash equivalents marketable securities accounts notes receivable inventories prepaid expenses deferred income taxes total current assets goodwill intangible assets property plant equipment investments affiliates assets deferred income taxes total assets liabilities shareholders equity current liabilities cash overdrafts accounts payable shortterm borrowings capital lease obligations income taxes dividends payable deferred income taxes accrued liabilities total current liabilities longterm borrowings capital lease obligations liabilities deferred income taxes total liabilities minority interest contingent liabilities commitments notes shareholders equity common stock per share par value shares authorised shares issued redeemable preference shares per share par value shares authorised nil nil shares outstanding additional paidin capital retained deficit cumulative comprehensive loss treasury stock total shareholders equity total liabilities shareholders equity certain items year ended st december reclassified comparative purposes glaxosmithkline notes financial statements reconciliation us accounting principles continued glaxo glaxo smithkline us gaap smithkline uk gaap adjustments us gaap reconciliation consolidated income statement revenues cost sales gross profit selling general administrative expenditure research development expenditure trading profit operating incomeexpense amortisation impairment goodwill intangible assets writeoff inprocess rd acquired product divestments merger transaction costs operating profit share profitslosses joint ventures associated undertakings profitloss disposal interest associate disposal businesses profit interest net interest expense profit ordinary activities taxation taxation profit ordinary activities taxation minority interests preference share dividends net incomeloss cumulative effect changes accounting principles cumulative effect changes accounting principles net incomeloss basic diluted net incomeloss per share cumulative effect changes accounting principles us gaap pence p cumulative effect changes accounting principles per share usgaappence p basic diluted net incomeloss per share cumulative effect changes accounting principles usgaap pence p basic diluted net incomeloss per ads cumulative effect changes accounting principles us gaap cumulative effect changes accounting principles per ads usgaap basic diluted net incomeloss per ads cumulative effect changes accounting principles usgaap consolidated statement comprehensive income changes shareholders equity usgaap shareholders equity beginning year net incomeloss exchange movements overseas net assets unrealised lossgain equity investments net tax unrealised gainloss liquid investments net tax unrealised gain derivatives minimum pension liability cumulative effect change accounting principle comprehensive lossincome dividends shares purchased cancelled shares issued employee share ownership plan shares issued purchase smithkline beecham shareholders equity end year certain items years ended st december reclassified comparative purposesnotes financial statementsglaxosmithkline less smithkline glaxo glaxo beecham smithkline us gaap glaxo smithkline preacquisition us gaap glaxo uk gaap adjustments smithkline uk gaap uk gaap adjustments smithkline restated restated usgaap restated restated restated usgaap p p p p glaxosmithkline notes financial statements reconciliation us accounting principles continued consolidated statement cash flows usgaap cash flows operating activities net incomeloss adjustments reconcile net income net cash provided operating activities depreciation amortisation intangible assets writeoff inprocess rd acquired impairment goodwill tangible intangible fixed assets gainloss sale fixed assets productive assets deferred taxes stock compensation tax benefit exercise stock options income associate loss sale associate investment derivatives changes operating assets liabilities net acquisitions increasedecrease inventory increase trade debtors increase trade creditors increasedecrease pension provisions net cash provided operating activities cash flows investing activities acquisition fixed assets acquisition intangible assets acquisition smithkline beecham cash received acquisition acquisition new businesses net cash acquired proceeds disposition fixed assets businesses proceeds sale intangible fixed assets increasedecrease equity investments net cash used inprovided investing activities cash flows financing activities increasedecrease liquid investments proceeds additional borrowings reduction debt purchase treasury stock dividends paid net repayment shortterm loans net repayment ofincrease cash overdrafts redemption preference shares issued subsidiary ordinary shares purchased cancellation issue share capital net cash used financing activities net increasedecrease cash cash equivalents exchange rate movements cash cash equivalents beginning year cash cash equivalents end year supplemental cash flow information cash paid year interest income taxes noncash investing financing activities purchase acquisition dated th december group acquired outstanding shares smithkline beecham exchange shares ofglaxosmithkline conjunction acquisition liabilities assumed follows fair value assets acquired fair value shares issued fair value liabilities assumed notes financial statementsglaxosmithkline reconciliation us accounting principles continued following summary material adjustments profit shareholders funds would required us gaap applied instead uk gaap adjustments reflected income statements balance sheets presented accordance usgaap restated restated profit profit attributable shareholders uk gaap less smithkline beechams preacquisition profit attributable shareholders uk gaap merger alignment adjustments usgaap adjustments writeoff smithkline beecham inprocess rd acquired capitalised interest computer software purchased intangibles reversalamortisation goodwill amortisation impairment intangible assets recognition cost sales fair value stepup inventory disposal purchased investment product divestments loss disposal subsidiary pensions postretirement benefits stockbased compensation provision esot shares derivative instruments restructuring tax benefits exercise us stock options merger transaction costs deferred taxation impairment equity investments net incomeloss us gaap cumulative effect changes accounting principles cumulative effect changes accounting principles net incomeloss cumulative effect changes accounting principles restated equity shareholders funds equity shareholders funds uk gaap usgaapadjustments tangible fixed assets investments product rights capitalised interest computer software goodwill intangible assets unrealised gains marketable securities pensions postretirement benefits employee share ownership trust restructuring costs derivative instruments dividends deferred taxation shareholders equity us gaap certain items years ended st december reclassified comparative purposes frs deferred tax implemented group ukgaap frs requires deferred tax accounted full provision basis rather partial provision basis earlier years change accounted prior year adjustment ukgaap purposes comparative adjustments arrive usgaap restated necessary change impact usgaap results glaxosmithkline notes financial statements reconciliation us accounting principles continued cthe market value investments included book value smithkline beechams net assets us gaap increase acquisition smithkline beecham investments related increases fair market value us gaap financial statements glaxosmithkline prior nonmarketable securities st december included merger glaxo wellcome us gaap accounting inthis amount increases equity investments equity acquirer acquisition smithkline beecham accounted investments measured fair value excess purchase method date merger fair value underlying tangible assets liabilities thdecember recognised goodwill within investments goodwill longer amortised reviewed annually impairment purchase accounting adjustments order determine proper allocation purchase price dthe fair value attributed pension obligations reflected related acquired assets smithkline beecham us recognition previously unrecognised actuarial gainslosses gaap purchase accounting cost acquisition calculated prior service costs transition amounts amounts recognised using market value shares issued fair value vested werebased actuarial assessments acquisitiondate options exchanged direct external acquisition costs ethe fair value attributed intangible assets related allocated fair value net assets acquired result primarily managements estimate value product fair value exercise increases values smithkline beechams rights inclusive respective patents trade marks inventory tangible fixed assets investments pension obligations onexisting products assembled workforce thefair recognised fair market values attributed value product rights determined based intangible assets mainly product rights inclusive patents discounted net future cash flow analysis smithkline beechams trade marks assembled workforce inprocess research approved product portfolio included existing approved development together appropriate deferred taxation effects products within pharmaceutical therapeutic areas difference cost acquisition fair value consumer healthcare product portfolios supplemental assets liabilities smithkline beecham products development process built upon existing recorded asgoodwill amount allocated inprocess research chemical entities within existing areas andwhich development required us gaap expensed subject separate us food drug administration approval immediately thefirst reporting period business also included management based estimates combination glaxosmithkline period ended weighted average useful life product rights future stdecember fair value adjustments recorded period substantial majority estimated net amount inventory expensed additional future cash flow value expected realised fair value amortisation depreciation berecorded respect assembled workforce reclassified togoodwill fair value adjustments tangible intangible assets sfas reviewed annually impairment resulting goodwill periods respective economic useful lives f amount total consideration allocated smithkline beechams inprocess research development projects iprd adjustments assets liabilities smithkline beecham wasestimated using current estimates status reflect fair values allocation excess purchase prospects rd portfolio iprd included consideration fair value net assets acquired based identified projects advanced stage development onmanagement best estimates fair value summarised management believed reasonable estimates projected thetable opposite discussed cash flows could prepared include basic athe total assumed purchase consideration calculated discovery portfolio gene patents reported iprd bymultiplying number glaxosmithkline shares issued value intended reflect present value tosmithkline beechams shareholders outstanding development activities way value allocated smithkline beecham shares average fair value glaxo iprd determined utilising risk adjusted income approach wellcome securities average fair value glaxo wellcome included earnings discounted appropriate cost securities calculated period four days prior capital investment estimates future cash flows related subsequent theannouncement merger individual iprd projects based existing estimates th january total assumed purchase consideration revenues contribution margin project also included fair value smithkline beecham vested gadditional liabilities related restructuring costs directly linked options exchanged vested options glaxosmithkline plans place date acquisition total number smithkline beecham vested options liabilities reflected costs close certain smithkline beecham multiplied bythe respective fair value ordinary manufacturing sites redundancy costs liabilities shares adr plans determined thjanuary related additional deferred tax liabilities previously bthe increase fair value inventory fixed assets recognised determined based difference carrying hdeferred taxes computed excess fair value value market value assets increase book value goodwill inprocess research inventory expensed inventory sold development using applicable weighted average statutory increase infixed assets allocated respective category tax rates depreciated remaining useful lives assets goodwill represents remainder unallocated purchase consideration includes value originally allocated workforce goodwill longer amortised sfas rather reviewed annually impairmentnotes financial statementsglaxosmithkline reconciliation us accounting principles continued purchase accounting adjustments total assumed purchase consideration outstanding shares costs fees transaction less book value smithkline beecham net assets us gaap less goodwill excess fair value inventory b excess fair value tangible fixed assets b excess fair value investments c excess fair value pension asset fair value attributed intangible assets e fair value attributed workforce considered goodwill e fair value attributed inprocess rd projects f additional liabilities assumed g deferred tax liabilities related purchase price adjustments h goodwill glaxosmithkline notes financial statements reconciliation us accounting principles continued following tables present details groups total purchased identifiable intangible assets subject amortisation accumulated st december gross amortisation impairment net product rights brands total following launch usa generic augmentinproduct carrying value product rights relating augmentinhas reviewed impairment million recorded carrying values certain product rights also reviewed impairment million recorded fair values determined using discounted cash flow model discussed note legal proceedings number distributors generic drugs filed applications market generic versions paxilin usa prior expiration groups patent carrying value paxilproduct rights usgaap billion st december group continue keep position review accumulated st december gross amortisation impairment net product rights brands total estimated future amortisation expense next five years purchased identifiable intangible assets subject amortisation st december follows year total carrying amount identifiable intangible assets subject amortisation brands following initial implementation sfas carrying values brands determined indefinite lives reviewed impairment million million net tax recognised recorded cumulative effect change accounting principle addition million charge recognised result changes market conditions management forecasts certain brand intangibles following table presents changes goodwill allocated groups reportable segments carrying value assembled workforce st december net tax reclassified opening balance goodwill accordance sfas acquired impairment exchange pharmaceuticals consumer healthcare total group accounted goodwill identifiable intangible assets indefinite lives sfas years ended st december impact reported usgaap results would follows net income usgaap amortisation net tax goodwill brands adjusted net income usgaap adjusted basic net income per share pence adjusted diluted net income per share pence notes financial statementsglaxosmithkline reconciliation us accounting principles continued earnings per share us gaap weighted average number shares issue millions millions millions basic adjustments share options diluted shares held employee share ownership trusts excluded shares issue taxation restated restated total tax expense uk gaap current tax expense deferred tax expense total tax expense us gaap current tax expense deferred tax expense total tax expense deferred taxation usgaap classification glaxosmithklines deferred taxation liabilities assets us gaap follows liabilities stock valuation adjustment current deferred taxation liabilities accelerated capital allowances product rights timing differences total deferred taxation liabilities assets intragroup profit timing differences current deferred taxation assets asset disposal pensions postretirement benefits tax losses manufacturing restructuring legal disputes timing differences total deferred taxation assets net deferred taxation us gaap difference uk effective taxation rate us effective taxation rate primarily related fair value adjustments goodwill intangibles related acquisitions wellcome smithkline beecham glaxosmithkline notes financial statements reconciliation us accounting principles continued segment information usgaap uk gaap segment information presented note includes results operations information historical combined glaxo wellcome smithkline beecham basis us gaap segment information results operations reflect merged operations glaxosmithkline relates glaxo wellcome period practical purposes regarded prior acquisition smithkline beecham glaxo wellcome operated one segment pharmaceuticals segment information respect assets relates glaxo wellcome smithkline beecham consolidated basis st december acquisition smithkline beecham glaxo wellcome occurred th december restated restated turnover location customer usa europe international external turnover turnover business sector pharmaceuticals consumer healthcare external turnover operating profitloss business sector pharmaceuticals consumer healthcare operating profitloss turnover location subsidiary undertaking usa europe international gross turnover usa europe international intersegment turnover usa europe international external turnover profit tax location subsidiary undertaking usa europe international operating profitloss share profits joint ventures associated undertakings profitloss disposal businesses andor interest associates net interest expense profitloss taxation profitloss taxation taxation minority interests preference share dividends net incomeloss cumulative effect changes accounting principles cumulative effect change accounting principle net incomeloss notes financial statementsglaxosmithkline reconciliation us accounting principles continued total assets business sector pharmaceuticals consumer healthcare total assets total assets location subsidiary undertaking usa europe international total operating assets cash cash equivalents marketable securities total assets total liabilities business sector pharmaceuticals consumer healthcare total liabilities total liabilities location subsidiary undertaking usa europe international total liabilities plant land equipment computer assets buildings vehicles software construction total total tangible fixed assets location subsidiary undertaking usa europe international total uk segment information given separately respect uk although included groups europe market region considered groups home segment purposes segmental reporting turnover location customer gross turnover intersegment turnover turnover location subsidiary operating profit total assets glaxosmithkline notes financial statements reconciliation us accounting principles continued pensions usgaap sfas disclosures year ended st december provided relation employees glaxosmithkline income statement disclosures provided relation employees glaxo wellcome group decided align measurement date pension plans certain groups pension plans measurement date pension assets liabilities th september group elected change measurement date plans th september st december result included net loss million credit income million net tax treated cumulative effect change accounting principle average number persons employed group including directors year number number number manufacturing selling general administration research development pension postretirement costs uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid schemes unfunded defined benefit schemes defined contribution schemes unfunded postretirement healthcare schemes postemployment costs disclosures include additional information required sfas pension costs uk us major overseas defined benefit pension plans restated following tables accordance us gaap pension costs million million million respect minor retirement plans recalculated accordance requirements sfas excluded net periodic pension costincome major retirement plans comprised service cost interest cost expected return plan assets amortisation prior service cost amortisation transition obligation recognised net actuarial gain net periodic pension costincome us gaap termination benefits curtailment costs adjustment change accounting principle major assumptions used computing pension costincome pa pa pa rates future pay increases discount rate expected longterm rates return plan assets aggregate average international plan assumptions vary significantly us assumptionsnotes financial statementsglaxosmithkline reconciliation us accounting principles continued change benefit obligation benefit obligation beginning year adjustment change accounting principle amendments service cost interest cost plan participants contributions actuarial loss benefits paid acquisition termination benefits curtailment costs exchange benefit obligation end year benefit obligation end year pension plans accumulated benefit obligations excess plan assets change plan assets fair value plan assets beginning year adjustment change accounting principle actual return plan assets employer contribution plan participants contributions benefits paid acquisition termination benefits curtailment costs exchange fair value plan assets end year fair value plan assets end year pension plans accumulated benefit obligations excess plan assets plan assets consist primarily investments uk overseas equities fixed interest securities securities linked uk retail price index property st december uk equities included million glaxosmithkline shares million shares market value million million funded status funded status unrecognised net actuarial loss unrecognised prior service cost unrecognised transition obligation net amount recognised amounts recognised statement financial position consist prepaid benefit cost accrued pension liability additional required liability intangible asset accumulated comprehensive income net amount recognised glaxosmithkline notes financial statements reconciliation us accounting principles continued postretirement healthcare usgaap disclosures provided relation employees glaxosmithkline income statement disclosures provided relation employees glaxo wellcome net healthcare cost service cost interest cost amortisation prior service cost net healthcare cost major assumptions used calculating net healthcare cost pa pa pa rate future healthcare inflation discount rate rate future healthcare inflation reflects fact benefits certain groups participants capped change benefit obligation benefit obligation beginning year adjustment change accounting principle amendments service cost interest cost plan participants contributions actuarial loss benefits paid acquisition curtailments exchange benefit obligation end year change plan assets fair value plan assets beginning year employer plan participants contributions benefits paid fair value plan assets end year funded status funded status unrecognised net actuarial loss unrecognised prior service cost accrued postretirement healthcare cost decrease increase impact per cent variation rate future healthcare inflation would effect total service interest cost effect provision postretirement benefits notes financial statementsglaxosmithkline principal group companies following represent principal subsidiary associated undertakings glaxosmithkline group stdecember details given principal country operation location headquarters business segment business activities equity share capital undertakings wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated europe location subsidiary undertaking segment activity england brentford glaxosmithkline services unlimited plc phch formerly glaxosmithkline services plc brentford smithkline beecham plc phch e h r p greenford glaxo group ltd ph h brentford smithkline beecham research ltd ph brentford smithkline beecham investments ltd phch f brentford glaxosmithkline research development ltd ph r brentford glaxosmithkline export ltd ph e brentford glaxosmithkline ukltd ph p greenford wellcome foundation ltd ph p brentford wellcome limited phch h brentford smithkline beecham swg ltd ch e brentford glaxo operations uk ltd ph p brentford glaxo wellcome international bv footnote iv phch h brentford glaxo wellcome investments bv footnote iv phch h stockley park glaxo wellcome uk ltd ph h p brentford staffordmiller ltd ch p austria vienna glaxosmithkline pharma gmbh ph belgium genval glaxosmithkline sa formerly glaxosmithkline belgium sa ph rixensart glaxosmithkline biologicals sa ph e r p rixensart glaxosmithkline biologicals manufacturing sa ph e p guernsey st peter port sb insurance ltd phch denmark ballerup glaxosmithkline consumer healthcare ch formerly smithkline beecham brndby glaxosmithkline pharma ph finland espoo glaxosmithkline oy ph france marly le roi glaxosmithkline sante grand publique sas ch marly le roi glaxo wellcome production sas ph p germany buehl glaxosmithkline consumer healthcare gmbh co kg ch p munich smithkline beecham gmbh ph greece athens glaxosmithkline aebe formerly glaxo wellcome aebe ph h p hungary budapest glaxosmithkline kft phch italy verona glaxosmithkline spa ph p r milan glaxosmithkline consumer healthcare spa ch h luxembourg mamer glaxosmithkline international luxembourg sa phch h mamer glaxosmithkline luxembourg sa phch h glaxosmithkline notes financial statements principal group companies continued europe location subsidiary undertaking segment activity netherlands zeist glaxosmithkline bv ph zeist glaxosmithkline consumer healthcare bv ch norway oslo glaxosmithkline ph poland poznan glaxosmithkline pharmaceuticals sa ph p warsaw glaxosmithkline consumer healthcare sp zoo ch portugal lisbon glaxosmithklineprodutos farmaceuticos lda ph formerly instituto lusofarmaco lda republic carrigaline smithkline beecham cork ltd footnote ph p ireland carrigaline smithkline beecham manufacturingltd footnote ph p spain madrid glaxo wellcome sa ph r p madrid smithkline beecham sa ph sweden mlndal glaxosmithkline ab ph switzerland muenchenbuchsee glaxosmithkline investments switzerland gmbh phch h muenchenbuchsee glaxosmithkline international switzerland gmbh phch h muenchenbuchsee glaxo wellcome international footnote iv phch h muenchenbuchsee glaxosmithkline agformerly glaxo wellcome ag ph zug adechsa gmbh ph e turkey istanbul glaxosmithkline ilaclari sanayi ticaret ph p formerly glaxo wellcome isas usa usa philadelphia smithkline beecham corporation phch e h r p pittsburgh glaxosmithkline consumer healthcare lp ch p jersey city block drug company inc ch h p wilmington glaxosmithkline financial inc phch f wilmington smithkline beecham holdings corporation phch h wilmington glaxosmithkline holdings americas inc phch h americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc phch p r asia pacific australia boronia glaxo wellcome australia ltd ph p dandenong smithkline beecham australia pty ltd phch china hong kong glaxosmithkline limited formerly glaxo wellcome china ltd ph tianjin sinoamerican tianjin smith kline french laboratories ltd ph india mumbai glaxosmithkline pharmaceuticals ltd footnote ii ph p nabha glaxosmithkline consumer healthcare ltd formerly smithkline ch p beecham consumer healthcare ltd footnote ii malaysia selangor glaxosmithkline pharmaceutical sdn bhd ph darul ehsan new zealand auckland glaxosmithkline nz limited ph ch pakistan karachi glaxo wellcome pakistan ltd ph ch p philippines manila glaxo wellcome philippines inc ph singapore singapore glaxo wellcome manufacturing pte ltd ph p singapore glaxosmithkline pte ltd formerly glaxo wellcome asia pacific pte ltd ph south korea seoul glaxosmithkline korea ph p taiwan taipei glaxo wellcome taiwan ltd ph pnotes financial statementsglaxosmithkline principal group companies continued japan location subsidiary undertaking segment activity japan tokyo glaxosmithkline kk ph p r kobe block drug company japan inc ch latin america argentina buenos aires glaxosmithkline argentina sa phch p brazil rio de janeiro glaxosmithkline brasil lda formerly smithkline beecham brasil lda phch p colombia bogota glaxosmithkline colombia sa phch mexico mexico city glaxosmithkline mexico sade cv phch p formerly glaxo wellcome mexico sa de cv puerto rico san juan glaxosmithkline puerto rico inc ph hato rey sb pharmco puerto rico inc ph p venezuela caracas glaxosmithkline venezuela ca formerly glaxo wellcome ca ph p middle east africa egypt cairo glaxo wellcome egypt sae ph p south africa midrand glaxosmithkline south africa pty ph p formerly glaxo wellcome south africa pty ltd johannesburg smithkline beecham consumer healthcare pty ltd ch p usa location associated undertaking usa teterboro quest diagnostics inc footnote iii new jersey footnotes exempt provisions section companies amendmentact ireland ii consolidated subsidiary undertaking accordance section companies act grounds significant influence iii holding reduced per cent february following quests acquisition unilab corporation iv incorporated netherlands v incorporated republic ireland directly held wholly owned subsidiary glaxosmithkline plc business segment phpharmaceuticals chconsumer healthcare business activity ddevelopment eexporting ffinance hholding company iinsurance mmarketing pproduction rresearch sservice full details group subsidiary associated undertakings attached companys annual return filed registrar ofcompanies glaxosmithkline financial record quarterly trend unaudited analysis provided quarter group results sterling financial year analysis comprises statutory results business performance results pharmaceutical sales therapeutic area profit loss account statutory months q cer cer sales pharmaceuticals consumer healthcare total sales cost sales selling general administrative expenditure research development expenditure operating costs trading profit pharmaceuticals consumer healthcare total trading profit operating incomeexpense operating profit share profitslosses joint ventures associated undertakings disposal businesses product divestments profit interest net interest payable profit ordinary activities taxation taxation profit ordinary activities taxation minority interests preference share dividends earnings profit attributable shareholders basic earnings per share p p profit loss account business performance sales pharmaceuticals consumer healthcare total sales cost sales selling general administrative expenditure research development expenditure operating costs trading profit pharmaceuticals consumer healthcare total trading profit operating incomeexpense operating profit share profitslosses joint ventures associated undertakings profit interest net interest payable profit ordinary activities taxation taxation profit ordinary activities taxation minority interests preference share dividends adjusted earnings profit attributable shareholders adjusted earnings per share p p financial recordglaxosmithkline months q months q q cer cer cer cer cer p p p p p p p p p p glaxosmithkline financial record pharmaceutical sales total group q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antivirals hiv combivir trizivir epivir retrovir ziagen agenerase herpes valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic gastrointestinal avandia zantac vaccines hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sales financial recordglaxosmithkline pharmaceutical sales usa q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antivirals hiv combivir trizivir epivir retrovir ziagen agenerase herpes valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic gastrointestinal avandia zantac vaccines hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sales glaxosmithkline financial record pharmaceutical sales europe q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antivirals hiv combivir trizivir epivir retrovir ziagen agenerase herpes valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic gastrointestinal avandia zantac vaccines hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sales financial recordglaxosmithkline pharmaceutical sales international q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antivirals hiv combivir trizivir epivir retrovir ziagen agenerase herpes valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic gastrointestinal avandia zantac vaccines hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sales glaxosmithkline financial record five year record record financial performance provided analysed accordance current reporting practice sales business segment pharmaceuticals consumer healthcare retained businesses healthcare services pharmaceutical sales therapeutic area central nervous system respiratory antibacterials antivirals metabolic gastrointestinal vaccines oncology emesis cardiovascular arthritis others continuing business divested products pharmaceutical sales geographic area usa europe international asia pacific japan latin america middle east africa canada international consumer healthcare sales otc medicines oral care nutritional healthcare continuing business divested products financial recordglaxosmithkline restated restated restated restated statutory results sales profit taxation earnings profit attributable shareholders dividends retained profit return capital employed per cent return capital employed calculated statutory profit taxation percentage average capital employed year merger restructuring disposal subsidiaries manufacturing restructuring merger costs product divestments items lossprofit taxation lossprofit attributable shareholders business performance results retained businesses sales rd expenditure per cent sales trading profit per cent sales net interest payable profit taxation adjusted earnings profit attributable shareholders business performance primary performance measure used management presented excluding merger items integration restructuring costs disposal businesses management believes exclusion nonrecurring items provides better comparison business performance periods presented accordingly information provided supplement included consolidated statement profit loss pages prepared accordance ukgaap statutory results include nonrecurring items share statistics earnings per share p dividends per glaxosmithkline share p glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividends per glaxosmithkline ads glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividends expressed terms glaxosmithkline shareads merger glaxo wellcome smithkline beecham thdecember shareholders adr holders received shares glaxosmithkline following ratios glaxo wellcome share glaxosmithkline share smithkline beecham share glaxosmithkline shares glaxo wellcome ads glaxosmithkline ads smithkline beecham ads glaxosmithkline adss glaxosmithkline ads represents glaxosmithkline shares glaxosmithkline financial record restated restated restated restated net assets fixed assets assets liabilities net operating assets net debt capital employed share capital share premium reserves equity shareholders funds minority interests capital expenditure tangible fixed assets number employees usa europe international asia pacific japan latin america middle east africa canada total international manufacturing selling administration research development number employees number permanent employed staff end financial period excludes employees employed managed glaxosmithkline contract basisglaxosmithkline investor information section discusses shareholder return return shareholders form dividends share price movements provides information shareholders shareholder return shareholder information share capital taxation information shareholders glaxosmithkline shareholder return merger glaxo wellcome smithkline beecham dividends merger implemented way scheme arrangement glaxosmithkline pays dividends quarterly present expected became effective th december new holding level dividend first three quarters company glaxosmithkline plc acquired glaxo wellcome higher dividend fourth quarter quarters dividend smithkline beecham accordance agreed merger announced time quarterly results announcement terms shareholders glaxo wellcome smithkline beecham board declared dividends follows received exchange existing shares shares glaxosmithkline follows dividends per share pence pence glaxo wellcome ordinary share glaxosmithkline first interim paid th july ordinary share second interim paid rd october smithkline beecham ordinary share third interim paid rd january glaxosmithkline ordinary shares fourth interim payable th april total case shares held american depositary shares adss holders glaxo wellcome adrs holders smithkline beecham adrs received dividends adss guide holders adrs tables set dividends glaxo wellcome ads glaxosmithkline ads paid per ads us dollars last five years dividends smithkline beecham ads glaxosmithkline adss adjusted uk tax credit less withholding tax applicable glaxosmithkline shares commenced trading london stock translated us dollars applicable exchange rates exchange glaxosmithkline adss commenced trading since th april claims refunds tax credits dividends new york stock exchange th december uk tax authorities negligible benefit us shareholders taxation year gsk gw sb general information concerning uk us tax effects share ownership set 'taxation information shareholders ' share price gsk gw sb st january dividends paid glaxo wellcome smithkline beecham adr high year holders expressed dividends per glaxosmithkline ads low year th december dividend calendar st december fourth quarter decreaseincrease exdividend date th february record date st february table sets middle market closing prices derived payable th april london stock exchange daily official list first quarter companys share price declined per cent exdividend date th may price st january st record date th may december compares decrease ftse payable rd july index per cent year two years since merger share price declined per cent second quarter st january line similar decrease exdividend date th july ftse index period record date st august payable nd october market capitalisation market capitalisation glaxosmithkline st december third quarter billion date glaxosmithkline third largest company market capitalisation ftse index exdividend date th october record date st october payable th january smithkline beecham plc floating rate unsecured loan stock loan stock listed exchange holders may require smithkline beecham plc redeem loan stock par ie every loan stock held first business day march june september december holders wishing redeem part loan stock complete notice back loan stock certificate return registrar arrive least days relevant redemption dateglaxosmithkline shareholder information ordinary shares annual general meeting company 's shares listed london stock exchange queen elizabeth ii conference centre th may broad sanctuary westminster registrar london swp ee company 's share register administered lloyds tsb registrars also provide following services annual general meeting company 's principal forum communication private shareholders addition formal glaxosmithkline investment plan resolutions put meeting presentation plan enables shareholders reinvest quarterly dividends chief executive officer performance business andor make monthly investments company 's ordinary future development opportunity questions shares using special dealing arrangement board chairmen board 's committees glaxosmithkline individual savings account take questions matters relating committees glaxosmithkline individual savings account isa investors holding shares company nominee service taxefficient way invest company 's ordinary shares arrange nominee service appointed glaxosmithkline corporate sponsored nominee corporate representative proxy respect shareholding corporate sponsored nominee provides facility order attend vote meeting shareholders hold shares without need share adr holders wishing attend meeting must obtain proxy certificates shareholders ' details held main bank new york enable attend share register remain confidential meeting vote business transacted adr holders shareview service may instruct bank new york shares shareview portfolio service provides shareholders represented adrs voted completing information investment company shareholders returning voting card provided bank new york may register service wwwshareviewcouk accordance instructions given share dealing facility financial reporting natwest stockbrokers limited offers sharedealing service financial reporting calendar behalf company shareholders wishing buy sell company 's shares announcement st quarter results th april announcement nd quarter results rd july share price information announcement rd quarter results nd october share price information available company 's website wwwgskcom information also available ceefax teletext preliminary announcement annual results th february ft cityline calling publication annual reportreview march calls charged p minute plus vat times results announcements american depositary shares results announcements issued london stock exchange lse made available lse news service company 's shares listed new york stock exchange time shortly afterwards issued media form american depositary shares adss made available website filed usa evidenced american depositary receipts adrs one securities exchange commission new york stock represents two ordinary shares exchange adr programme administrator financial reports adr programme administered bank new york company publishes annual report investor also provide following service needing full detail report annual review global buydirect available date publication glaxosmithkline global buydirect direct ads purchasesale dividend website reinvestment plan adr holders annual review sent shareholders date publication shareholders may elect receive also report publications writing companys registrars alternatively shareholders may year glaxosmithkline produced separate report elect receive notification email publication financial covering groups contribution society corporate reports registering wwwshareviewcouk social responsibility report covers issues copies previous financial reports available company 's primary interest stakeholders including contribution website printed copies obtained registrar society business ethics integrity access medicines rd uk customer response center usa community investment environment health safety report available secretariat companys head office website wwwgskcom glaxosmithkline share capital nature trading market glaxo wellcome pence per share ordinary shares company listed london fiscal periods th december high low stock exchange th december shares also listed new york stock exchange inthe form american depositary shares adss date following table sets periods indicated high us dollars per ads low middle market closing quotations pence shares fiscal periods th december high low london stock exchange derived daily official list high low last reported sales prices us dollars adss new york stock exchange derived new york stock exchange composite tape information relating share ads prices glaxo wellcome smithkline beecham prior date smithkline beecham pence per share merger also given fiscal periods th december high low glaxosmithkline pence per share fiscal periods th december high low quarter ended st march february us dollars per ads january december fiscal periods th december high low november october september quarter ended st december quarter ended th september quarter ended th june quarter ended st march quarter ended st december quarter ended th september quarter ended th june quarter ended st march th st december us dollars per ads fiscal periods th december high low quarter ended st march february january december november october september quarter ended st december quarter ended th september quarter ended th june quarter ended st march quarter ended st december quarter ended th september quarter ended th june quarter ended st march th st december rd march share capitalglaxosmithkline analysis shareholdings number total total number analysis shareholdings st december accounts accounts shares shares holding shares totals held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited totals bank new yorks holding held bny nominees limited represents companys adr programme whereby ads represents two ordinary shares p nominal value rd march number holders record shares usa holdings shares thenumberof registered holders adrs holdings adrs certain shares adrs held brokers nominees result number holders record registered holders usa representative number beneficial holders orofthe residence beneficial holders control company far known company directly indirectly owned controlled one corporations government thecompany know arrangements operation might result change control company substantial shareholdings rd march company received notification following interest three per cent shares bnynominees limited holds shares representing per cent shares held behalf holders american depositary receipts evidence american depositary shares legal general investment management limited holds shares representing per cent barclays plc holds shares representing per cent far known company person owner three per cent shares company directors officers interests directors officers company defined thecompanies act share options company given remuneration report pages exchange controls limitations affecting securityholders currently uk laws decrees regulations restricting import export capital affecting remittance dividends orother payments holders companys shares nonresidents uk limitations relating nonresidents uk english law companys memorandum articles association right tobe holder tovote respect companys shares glaxosmithkline taxation information shareholders information shareholders us shareholders summary principal tax consequences holders following summary certain united kingdom taxation shares adrs citizens residents united united states federal income tax considerations may kingdom united states set relevant usholder shares adrs summary complete analysis possible tax consequences applies shareholder holds shares adrs capital purchase ownership securities assets citizen resident united states domestic corporation otherwise subject united states federal shareholders subject special rules income taxation net income basis respect shares doubt taxation position consult adrs resident united kingdom uktax professional advisors purposes hold shares purposes trade new ukus income tax convention signed profession vocation carried united kingdom th july however date yet set ratification branch agency statements regarding united kingdom united states tax laws practices set based taxation dividends laws practices force date report gross amount dividends received including amounts respect associated tax credit uk withholding tax treated us holders adrs generally treated owners foreign source dividend income us tax purposes underlying shares purposes current united eligible dividend received deduction allowed us statesunited kingdom double taxation conventions relating corporations dividends adrs payable us dollars income gains income tax convention estate gift taxes dividends shares payable pounds sterling dividends estate gift tax convention purposes us paid pounds sterling included income us internal revenue code amended code dollar amount calculated reference exchange rate following analysis deals dividends paid day dividends received holder holders qualify th april advance corporation tax act abolished benefits current income tax convention dividends paid date united states united kingdom may eligible subject generally applicable limitations receive special us uk shareholders foreign tax credit equal oneninth amount cash dividends receive shares long make taxation dividends election include income additional notional th april rate tax credits reduced one dividend amount equal tax credit holder 's ninth result compensating reductions rate tax tax position determine whether effective use made dividend income increase tax borne uk special us foreign tax credits us tax liability resident individual shareholders tax credits however longer repayable shareholders tax liability less th april rate tax credits reduced one associated tax credit ninth act abolished consequently claims refunds tax credits dividends paid date taxation capital gains negligible benefit us shareholders uk shareholders may liable uk tax gains disposal shares adrs may also entitled taxation capital gains indexation relief taper relief sales indexation relief generally us holders subject uk capital gains tax calculated market value shares st march subject us tax capital gains realised sale cost subsequent purchases date disposal shares adrs purchase indexation relief individual shareholders ceased th april taper relief available individual shareholders estate gift taxes hold deemed hold shares least three years estate gift tax convention us shareholder sold generally subject uk inheritance tax inheritance tax stamp duty individual shareholders may liable inheritance tax uk stamp duty case may sdrt subject transfer shares adrs tax may charged certain exemptions payable issue transfer shares amount value shareholder 's estate reduced adr custodian depository rate per cent result transfer way gift disposal less price issued amount consideration provided full market value exceptionally gift disposal transferred sale value transferred subject uk inheritance tax us estate gift tax consideration estate gift tax convention would generally provide sdrt would payable transfer adr uk tax paid united states credited tax payable stamp duty payable transfer adr provided united kingdom instrument transfer executed remains times outside uk stamp duty transfer adr stamp duty would payable rate per cent consideration uk stamp duty case may stamp duty reserve tax transfer sale underlying shares would result sdrt subject certain exemptions payable liability uk stamp duty case may sdrt rate purchase shares rate per cent purchase price per cent minimum charge stamp minimum charge stamp duty liability duty liability arises arisesglaxosmithkline cross reference form f table provided cross reference information included annual report requirements form f item item identity directors senior management advisors na financial information consolidated statements financial information offer statistics expected timetable na financial statements see item key information legal proceedings selected financial data b significant changes na risk factors offer listing information company share price history history development company c markets b business overview additional information products b memorandum articles association footnote competition c material contracts na regulation exchange controls marketing distribution e taxation manufacture supply h documents display research development intellectual property quantitative qualitative disclosures market risk information technology treasury policies environment health safety note financial instruments related disclosures access medicines developing world description securities equity securities na global community partnerships defaults dividend arrearages delinquencies na c organisational structure property plant equipment material modifications rights security holders environmental responsibility use proceeds na note segment information controls procedures note tangible fixed assets reserved operating financial review prospects financial statements na operating results financial statements directors statements responsibility independent auditors report us accounting principles consolidated statement profit loss b liquidity capital resources consolidated statement total recognised gains losses c research development patents licenses etc consolidated statement cash flow trend information consolidated balance sheet directors senior management employees reconciliation movements equityshareholders funds directors senior management company balance sheet b compensation notesto financial statements remuneration report exhibits c board practices corporate governance employees footnote glaxosmithkline people information responsive item incorporated reference note employee costs memorandum articles association glaxosmithkline financial record pages groups annual report form f e share ownership year ended st december glaxosmithkline people note employee share schemes share options incentive plans directors interests major shareholders related party transactions major shareholders b related party transactions glaxosmithkline glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax us equivalent tax depreciation advance corporation tax act advance payment uk tax made dividends paid direct us equivalent american depositary receipt adr receipt evidencing title ads glaxosmithkline adr represents two ordinary shares american depositary shares adss ordinary shares registered new york stock exchange calledup share capital ordinary shares issued fully paid cer growth growth constant exchange rates combined code guidelines required listing rules financial services authority address principal aspects corporate governance company glaxosmithkline plc creditors accounts payable currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates debtors accounts receivable defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share dividend cover profit attributable shareholdersnet income divided dividends payable shareholders earnings per share basic income per share employee share ownership trusts trusts established group satisfy share based employee incentive plans equity shareholders funds aggregation shares reserves owned shareholders us equivalent shareholders equity finance lease capital lease free cash flow cash resources available payment dividends shareholders acquisitions freehold ownership absolute rights perpetuity gearing ratio net debt percentage shareholders funds net debt minority interests group glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements bymaking offsetting commitments intangible fixed assets assets without physical substance brands licences patents knowhow marketing rights purchased outside parties interest cover number times profit interest exceeds net interest payable interest payable interest expense interest receivable interest income nonequity minority interest preference shares issued subsidiary outside parties preference shares shares issued varying dividend rates treated outside interests profit income profit loss account reserve retained earnings profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue shares outstanding statement total recognised gains losses statement comprehensive income stocks inventories subsidiary undertaking affiliate glaxosmithkline holds majority shareholding andor exercises control tangible fixed assets property plant equipment turnover revenueglaxosmithkline index corporate executive team forwardlooking statements access healthcare accountability audit internal control corporate governance g accounting policies corporate social responsibility committee gearing accounting standards critical accounting policies global community partnerships acquisitions disposals cross reference form f global supply network adr programme administrator glossary terms inside back cover going concern basis american depositary shares derivative financial instruments goodwill animals research annual general meeting dermatologicals governmental investigations antitrust description business group companies dialogue shareholders antibacterials directtoconsumer advertising h antivirals directors senior management healthcare services associates hedging audit committee directors history development company auditors independent interests hiv aids b interests contracts balance sheet remuneration report impairment assets block drug responsibility share options independent auditors board executive share ownership guidelines information technology board committees terms conditions inlicensing business community diversity intangible assets business performance divested businesses divested products intellectual property business segments dividends interest cover interest rate risk management c e internal control capital employed earnings per share investments capital expenditure cardiovascular employees investor information cash flow costs j diversity joint ventures cautionary statement involvement associates centralnervoussystemcns numbers performance reward centres excellence drug discovery cedd share schemes l development leases chairman chief executive employee share ownership trusts esots legal proceedings officers statement liquid investments charitable donations environment health safety chlorofluorocarbons cfcs loans overdrafts combined code equity risk management lymphatic filariasis commitments exchange controls community investment exchange rates competition malaria consumer healthcare external suppliers manufacture supply business sectorsegment manufacturing restructuring f fair values competition market capitalisation manufacturing supply marketing distribution finanial results committee marketing distribution maturity counterparty risk financial assets liabilities products memorandum articles association financial instruments sales merger accounting adjustments financial period research development metabolic gastrointestinal financial position regulation financial record trade marks year record n constant exchange rate cer quarterly trend net debt financial reporting calendar net interest payable contact details inside back cover financial reporting standards frs contaminated land new products contingent liabilities financial statements nominations committee control company financial summary nonexecutive directors corporate administration financial trends ratios noon buying rate transactions committee fixed asset investments nutritional healthcare foreign exchange risk management glaxosmithkline index v oncology emesis sales vaccines consumer healthcare operating financial review prospects pharmaceuticals w oral care world economy operating incomeexpense sb clinical laboratories world market segment information outlook overthecounter otc medicines selected financial data senior management compensation interests p share buyback patents share capital payment policies share premium pension postretirement share price benefits share purchases share statistics pharmaceuticals shareholder information approvals submissions shareholder return business sector shareholders funds competition shareholdings analysis manufacturing supply statement total marketing distribution recognised gains losses products sales taxation research development taxation information shareholders tax rate regulation trade marks patents trade marks treasury operations pipeline treasury policies presentation financial statements tuberculosis price controls profit loss account u uk segment property plant equipment us gaap reconciliation us accounting provisions liabilities charges principles consolidated balance sheet r consolidated income statement reconciliation equity movements comprehensive income equity shareholders funds changes shareholders equity registrar consolidated statement cash flows regulation earnings per shareads remuneration committee material differences remuneration report uk us gaap report directors postretirement benefits research collaborations purchase accounting research development results usaccounting principles accounting policy segment information animals research selected financial data consumer healthcare taxation diseases developing world expenditure pharmaceuticals pipeline respiratory return capital employed revenue accounting policy risk factors risk oversight compliance council rocc contact details internet information investors company available glaxosmithklines corporate website wwwgskcom head office registered office glaxosmithkline plc great west road brentford middlesex tw gs tel united kingdom united states america investor relations investor relations great west road one franklin plaza brentford po box middlesex tw gs philadelphia tel pa fax tel toll free tel outside usa registrar fax lloyds tsb registrars causeway adr programme administrator worthing bank new york west sussex bn da shareholder relations wwwshareviewcouk po box church street station general enquiries annual report orderline new york ny corporate nominee service wwwadrbnycom tel inside uk tel toll free tel outside uk tel outside usa shareholder investment plans customer response center dividend reinvestment enquiries tel toll free tel inside uk tel outside uk monthly savings plan enquiries tel inside uk tel outside uk isa enquiries tel inside uk tel outside uk glaxo wellcome smithkline beecham corporate peps share centre limited oxford house oxford road aylesbury bucks hp sz tel corporate share dealing facility natwest stockbrokers corporate employee service mansell street london e tel inside uk tel outside uk email contactcesnatwestcom quoting gsk shareholders service printed st ives westerham press uk paper used production document made pulp harvested sustainable forests also using sawmill residues forest thinnings elemental chlorinefree